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Summary 
 
 CCR5 is a chemokine receptor together with CD4 used by HIV-1 as a primary 
gate of cell infection. For this reason CCR5 is of great interest for medicine as a target 
for the anti-HIV-1 therapies. Since the binding site of its endogenous ligand RANTES 
overlaps with the binding site of viral envelope glycoprotein gp120, a noninflamatory 
RANTES derivative 5P12-RANTES has been developed as an anti-HIV-1 infection 
microbicide. The primary aim of this thesis was to establish an NMR-amenable system 
to study CCR5 and to understand better the interaction with RANTES. 
 For this purpose CCR5 expressed in insect cells was characterized in detail with 
regards to its secondary structure, oligomeric state, particle size, stability, 
posttranslational modifications and functionality. In contrast to the previous results, 
carefully performed detergent screening revealed that FosCholine-12, a detergent which 
allows high yield purification, does not support CCR5 recognition by 2D7 and cannot 
be used for studying CCR5 interactions with ligands. Therefore for the functional 
studies the receptor was solubilized with a milder detergent mixture 
DDM/CHAPS/CHS, which was shown to support native CCR5 tertiary structure. 
 Using this setup it could be shown by SPR that 5P12-RANTES binds with 
higher affinity than another potent RANTES variant PSC-RANTES (Morin et al., 
manuscript in preparation). This explains why 5P12-RANTES, which unlike PSC-
RANTES does not cause CCR5 internalization, is an equally effective anti-HIV-1 
microbicide. On the other hand, the wild-type RANTES was shown to aggregate on the 
receptor micelle using a mechanism compatible with the linear oligomerization, a 
process that is proposed to serve local chemokine preconcentration. 
 To obtain an access to a cost-efficient source of isotope-labeled samples, an E. 
coli expression system was established for CCR5 (Wiktor et al., 2012, J Biomol NMR, 
in revision). The expression was facilitated by fusing the N-terminus of CCR5 to well 
expressing protein domains e.g. thioredoxin. The C-terminal CCR5 truncation and the 
mutation of cysteines increased the protein yield up to 10 mg/L and improved the 
sample stability. Due to the engineered thrombin proteolytic site the N-terminal fusion 
partner i.e. thioredoxin could be quantitatively cleaved and removed by size exclusion 
chromatography. The FC-12-purified receptor was abundant in α-helical secondary 
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structure but could bind RANTES, MIP-1β and conformation-dependent antibody 2D7 
only when solubilized by a DDM/CHAPS/CHS mixture. Using 15N,13C,2H-labeled 
CCR5 2D and 3D NMR experiments were recorded but only about 80 backbone 
resonances could be resolved. The spectral quality was jeopardized by large overlap 
and line-broadening and needs further improvements to allow the assignment and the 
structural investigation. 
 To study 5P12-RANTES by NMR the backbone assignment was completed. 
The HSQC spectrum revealed that, unlike wild-type RANTES and other chemokines, 
5P12-RANTES does not form dimers. The secondary chemical shift analysis suggest 
that the overall structure of 5P12-RANTES is similar to the wild-type RANTES, with 
the exception of the mutated N-terminus, which does not participate in the 
intermolecular β-sheet and was shown to be highly flexible. Another important 
observation was that RANTES secondary structure is perturbed by Fos-Choline 
detergents, whereas maltosides shift the RANTES monomer:dimmer equilibrium 
towards its monomeric form. 
 The last part of the thesis present an independent study, where using ubiquitin 
as an example the mechanism of protein unfolding is studied (Vajpai et al., 2012, Proc 
Natl Acad Sci USA, in revision) manuscript submitted for publication). The secondary 
chemical shift analysis showed that the alcohol-denatured ubiquitin structure closely 
resembles the cold- and pressure denatured structure. This suggests that alcohol, low 
temperature and pressure unfold proteins by reducing the hydrophobic effect, the cost 
of exposing hydrophobic residues. 
 
The data of this thesis will be presented in the following publications: 
1. Wiktor, M., Morin, S., Sass, H-J., Kebbel, F., Grzesiek, S. (2012) Biophysical 
and structural investigation of bacterially expressed and engineered CCR5, a G 
protein-coupled receptor. J Biomol NMR (2012, in revision). 
2. Vajpai, N., Nisius, L., Wiktor, M., Grzesiek, S. (2012) High pressure NMR 
reveals close similarity between cold and alcohol protein denaturation due to a 
reduction of the hydrophobic effect. Proc Natl Acad Sci USA (in revision). 
3. Morin, S., Wiktor, M., Sass, H-J., Hartley, O., Grzesiek, S. (2012) Modulation 
of RANTES binding to CCR5 by modifications in the N-terminus and C-
terminus (in preparation). 
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DMMAPS 3-(N,N-dimethylmyristylammonio)propanesulfonate 
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Fc  fragment crystallizable 
FC-12  Fos-Choline-12, n-dodecylphosphocholine 
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gp120  HIV envelope glycoprotein 120 kDa 
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GRK  G protein-coupled receptor kinase 
GTP  guanosine-5'-triphosphate 
HEGA-11 Undecanoyl-N-Hydroxyethylglucamide 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  human immunodeficiency virus 
HRP  horseradish peroxidase 
Hsc70  heat-shock cognate 70 kDa 
HSQC  heteronuclear single quantum coherence 
ICL  intracellular loop 
IEC  ion exchange chromatography 
IMAC  immobilized metal ion chromatography 
IP  immunoprecipitation 
IPTG  isopropyl β-D-1-thiogalactopyranoside 
ITC  isothermal titration calorimetry 
KD  dissociation constant 
LB  lysogeny broth (also Luria-Bertani broth) 
LDAO  N,N-dimethyl-1-dodecanamine-N-oxide 
MALDI matrix-assisted laser desorption/ionization 
MD  molecular dynamics 
Mega-9 nonanoyl-N-methylglucamide 
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MIP  macrophage inflammatory protein 
MOI  multiplicity of infection 
MP-12  n-dodecyl-β-D-matopyranoside (also DDM) 
MS  mass spectrometry 
MWCO molecular weight cutoff 
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Ni-NTA nickel-nitriloacetic acid 
NK  natural killer 
NP-40  Nonidet P-40 substitute, octylphenoxypolyethoxyethanol 
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OmpF  outer membrane protein F 
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PDZ  postsynaptic density 95-kDa protein (PSD-95), Drosophila discs large 
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PKC  protein kinase C 
PMSF  phenylmethanesulfonyl fluoride 
POPC  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
PTK  protein tyrosine kinase 
PTMs  posttranslational modifications 
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RANTES regulated on activation, normal T cell expressed and secreted 
RT  room temperature 
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SDDSAR sodium dodecanoyl sarcosine 
SD  standard deviation 
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SPR  surface plasmon resonance 
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TM  transmembrane 
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Organization of the thesis 
 
 The thesis starts with a general introduction (Chapter 1). Chapter 2 defines the 
goals. Chapter 3 contains the unpublished data obtained for the insect-expressed CCR5. 
Chapter 4: Biophysical and structural investigation of bacterially expressed and 
engineered CCR5, a G protein-coupled receptor is a complete manuscript submitted for 
publication (Wiktor et al., 2012, J Biomol NMR, in revision). Chapter 5 describes the 
unpublished results obtained for RANTES. Chapter 6: Modulation of RANTES binding 
to CCR5 by modifications in the N-terminus and C-terminus (Morin et al., manuscript 
in preparation) and Chapter 7: High pressure NMR reveals close similarity between 
cold and alcohol protein denaturation due to a reduction of the hydrophobic effect 
(Vajpai et al., 2012, Proc Natl Acad Sci USA, in revision) are complete manuscripts 
submitted for publication. Every manuscript has independent topic-specific 
introduction, materials and methods, references, figure/table numbering and formatting. 
Each chapter with results finishes with a separate discussion. The thesis ends with a 
brief common section Conclusions and perspectives (Chapter 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
1 Introduction 
 
1.1 Diversity of the GPCR superfamily 
 G protein-coupled receptors constitute a large protein superfamily found only in 
eukaryotes. About 4% of the protein-coding human genome codes for ~800 GPCRs (1). 
Based on phylogenetic analysis human GPCRs cluster into 5 main families: rhodopsin, 
adhesion, frizzled/taste2, glutamate and secretin which comprise 701, 24, 24, 15 and 15 
members, respectively (2). The diversity of the GPCR superfamily members is 
reflected in the variety of their ligand types. Photons, ions, odorants, nucleotides, fatty 
acids, amino acids, peptides and proteins are only some of the messages that GPCRs 
can transduce (3). As GPCRs regulate so many physiological processes such as vision, 
smell, behavior, mood, immune system, blood pressure, heart rate, digestion or 
homeostasis, they are the most commonly drugged protein family (4). About 40% of 
prescribed pharmaceuticals target GPCRs (5). 
 
1.2 GPCR function and turnover 
 The function of GPCRs is to transduce signals through the plasma membrane 
from the outside to the inside of a cell and trigger cellular response. On the intracellular 
side GPCRs are coupled to G-proteins, heterotrimeric molecular switches. Upon 
agonist binding, a cascade of conformation changes is induced in a GPCR and passed 
on to a Gα subunit of a G-protein resulting in the dissociation of GDP from Gα. As the 
cytoplasmic GTP/GDP ratio is about 9 (6), the empty nucleotide binding site is quickly 
re-occupied by GTP. This, however, renders Gα unable to interact with neither the 
GPCR nor the Gβ/γ subunit and the entire complex falls apart (7). Free Gα and Gβ/γ 
interact with various effector proteins like adenylate cyclase, phospholipase C or ion 
channels (8). The receptor is downregulated by phosphorylation and subsequent 
interaction with β-arrestin. This is usually followed by clathrin- and dynamin-
dependent endocytosis (9, 10). Subsequently, it can be either recognized by an adaptor 
protein (e.g. through its PDZ ligand or a dileucine-based motif) and recycled back to 
the plasma membrane or ubiquitinated and targeted for degradation (11). An alternative 
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pathway of clatrin-independent receptor internalization has also been reported (12). In 
the case of rhodopsin, however, the β-arrestin-mediated process of desensitization does 
not involve endocytosis. 
 
 
Figure 1.1 GPCR cycle: activation, signaling and downregulation adapted from Nisius (13). 
 
1.3 Known structures of GPCRs 
 The structure determination of membrane proteins and of GPCRs in particular 
is notoriously difficult due to the many obstacles impeding membrane protein sample 
preparation and subsequent structure determination. When this publication was written 
about 82000 entries appeared in the Protein Data Bank (14) but only as few as 335 
unique membrane protein 3D structures were known (15). GPCR structures are even 
sparser. The first, bovine rhodopsin, was solved in 2000 by Palczewski et al. (16), and 
until now 12 more unique GPCR structures were solved by X-ray crystallography: β2-
adrenergic (17, 18), β1-adrenergic (19), adenosine A2A (20, 21), dopamine D3 (22), 
CXCR4 (23), histamine H1 (24), M2 muscarinic acetylcholine (25), M3 muscarinic 
acetylcholine (26), S1P1 lipid (27), µ-opioid (28), κ-opioid (29) and δ-opioid (30) 
receptors. To obtain high-resolution structural data the replacement of the intracellular 
(IC) loop 3 with T4 lysozyme (17, 20, 22-30), thermostabilization (19, 21-23) or 
effector
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G protein
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α
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stabilization with anti- or nanobodies (17) proved to be successful strategies. 
Additionally, the majority of the crystallized GPCRs were bound to an agonist (21), an 
inverse agonist (17, 18, 26) or most often to an antagonist (19, 20, 22-25, 27-30). 
Although, not GPCRs, prokaryotic sensory rhodopsin II (31) and proteorhodopsin (32) 
are examples of a 7-TM domain proteins solved by NMR spectroscopy. 
 
 
Figure 1.2 Example of GPCR structure: homology model of CCR5 based on CXCR4 structure (23) 
(see Chapter 4). 
 
1.4 Biology of CCR5 and its involvement in disease 
 The C-C chemokine receptor 5 (CCR5) belongs to the γ-group of the rhodopsin 
family of GPCRs. It is found in the plasma membrane of Th1 lymphocytes, 
macrophages, NK cells and immature dentritic cells and is involved in various 
infectious and inflammatory diseases as well as cancer (33). Since humans carrying the 
Δ32 allele of the CCR5 gene, a 32-base pair deletion resulting in a premature stop 
codon in the extracellular (EC) loop 2 and a nonfunctional receptor, are healthy, the 
exact role of CCR5 is not completely understood. 
N
C
C224
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C324
Y10
Y14
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 The main interest in CCR5 is, however, a consequence of its involvement in 
AIDS. R5-tropic HIV-1 infection necessitates the sequential interaction of viral 
envelope glycoprotein gp120 with CD4 and CCR5 (34). Two copies of the CCR5-Δ32 
allele confer nearly complete resistance to HIV-1 infection (35, 36). Δ32 occurs at 5-
14% frequency in European Caucasians but not in African, Native American, and East 
Asian populations (37), which is a result of a selective pressure of the epidemics of 
plague, a viral haemorrhagic fever, that took place in Europe in medieval ages (38). 
Successful strategies to block HIV entry have been developed based on small-molecule 
inhibitors of CCR5 (39) as well as derivatives of its natural chemokine ligand RANTES 
(40-43). 
 
 
Figure 1.3 Mechanism of the HIV infection adapted from Doms et al. (44). HIV (yellow) using its 
envelope glycoprotein gp120 (light red) binds to CD4 (green) and to a chemokine coreceptor e.g. 
CCR5 (blue). This interaction triggers a conformational changes, upon which fusion peptide of gp41 
(dark red) is exposed and penetrates the plasma membrane to initiate membrane fusion. 
 
1.5 CCR5 structural features 
 The sequence of CCR5 is composed of 352 amino acids (40.6 kDa) folding into 
seven hydrophobic α-helical membrane-spanning segments (domains) with an 
extracellular N- and a cytoplasmic C-terminus. As a result of CCR5 membrane 
topology, three extracellular and four intracellular loops are formed with the last loop 
being closed up by the hydrocarbon chain of S-palmitoyl-L-cysteines 321, 323 and 324 
deeping into the membrane. 
 A characteristic feature of CCR5 shared with other chemokine receptors is the 
presence of four extracellular cysteines, one per each extracellular segment (N-terminus 
and three extracellular loops). The first pair Cys101 and Cys178 forms a disulphide 
bridge between 1st and 2nd ECLs, a structural hallmark of the entire GPCR superfamily 
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contributing to the GPCR stability. The second disulphide bridge between Cys20 and 
Cys269 connects the N-terminus with 3rd ECL and is conserved only among the 
chemokine receptor family (45). The second bridge is thought to impose an additional 
structural constraint and to stabilize the receptor in the conformation capable to bind 
ligands. 
 With CHO-K1 cells stably expressing CCR5 it was shown that alanine mutation 
of any of the extracellular cysteines completely abolishes MIP-1β binding (46). The 
situation was somewhat different for the conformation-sensitive antibodies. The 
interaction with CTC5, CTC8, 2D7, and mAbs 531, 501 and 549 was much more 
sensitive to the mutation of Cys101 and/or Cys178 than to the mutation of Cys20 
and/or Cys269 as shown in CCR5-transfected 293T cells (46). Similarly, the HIV 
coreceptor CCR5 function was more impaired by Cys101 and/or Cys178 mutation (14-
20% of the wild type CCR5 activity) than by Cys20 and/or Cys269 mutation (40-62% 
of the wild type CCR5 activity) as studied in human CD4-expressing U87 cells (46). 
 Another conserved features of CCR5 shared with other chemokine receptors are 
the DRYLAVHA motif in the 2nd ECL playing an important role in the coupling to the 
G-proteins and the unusually short positively charged 3rd ICL. CCR5 is also subject to 
many PTMs (posttranslational modifications). The previously mentioned 
palmitoylation of C-terminal cysteines 321, 323 and 324 facilitates CCR5 transport to 
the plasma membrane, ligand-stimulated endocytosis, coupling to the signaling 
pathways as well as GRK or PKC (protein kinase C)-mediated CCR5 phosphorylation 
(47-49). It was shown that N-terminal tyrosine residues are sulfated in Cf2Th canine 
thymocytes (50). This plays an important role in the interaction with chemokines and 
the HIV glycoprotein gp120, which are both known to bind heparin sulfate 
proteoglycans (51-55). It was also shown that CCR5 N-terminal peptides with 
minimum two sulfated tyrosines in positions 10 and 14 can efficiently block 
gp120/CD4 complex binding to CCR5 and therefore Tyr3 and Tyr15 sulfation is 
thought to be less important (56, 57). 
 CCR5 is also O-glycosylated, preferentially at Ser6, which also contributes to 
high affinity chemokine binding (50, 58). The 3rd ECL of CCR5 possesses a potential 
N-glycosylation site but as neither N-glycosidase endo F nor tunicamycin treatment 
changes CCR5 electrophoretic mobility (50) and as the elimation of this site by 
mutagenesis does not impair CCR5 cofactor functions (59), the N-link glycosylation 
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site is most likely not used. Serines 336, 337, 342 and 349 in the C-terminus of CCR5 
are subject to nonhierarchical phosphorylation (60). 
 
 
Figure 1.4 Two-dimensional topology of CCR5 derived from CCR5 homology model (see Chapter 
4). The position of the important structural features and PTMs were color-coded: N-terminal tyrosine 
sulfation (red), O-glycosylation (orange), DRYLAVVHA motif (green), C-terminal phosphorylation 
(cyan), PDZ substrate (pink), the cysteines including those forming disulphide bridges and those 
modified by palmitic acid (yellow). The position is plasma membrane is approximated with a grey 
box. 
 
1.6 Biology of RANTES as a chemokine 
 Chemokines (chemotactic cytokines) are small (8-10 kDa) soluble secreted 
proteins regulating the immune response. The chemokines act by attracting various cell 
types to sites of inflammation. Immune cells can localize inflammation site by a 
chemokine gradient established by signaling leukocytes. Based on the arrangement of 
two conserved N-terminal cysteines chemokines can be divided into four subclasses: C, 
CC, CXC, CX3C (61, 62). Two major chemokine subfamilies CC and CXC chemokines 
are primarily responsible for activation of monocytes, lymphocytes and basophils (CC 
chemokines) and neutrophiles (CXC chemokines). Chemokines signal via chemokine 
receptors, which belong to G protein–coupled receptors and which were named after 
the main chemokine they interact with e.g. CCR5, CXCR4, etc. 
 RANTES (regulated upon activation, normal T-cell expressed and secreted) 
known also as CCL5 quickly became interesting for both academia and pharmaceutical 
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industry, when in 1995 Cocchi et al. discovered that CC chemokines RANTES, MIP-
1α, MIP-1β can suppress HIV-1 infection with RANTES being the most potent natural 
chemokine (63). This discovery was followed by identification of the RANTES 
receptor, CCR5 (64). Interestingly, it was also shown that at high concentration, instead 
inhibiting, RANTES can also stimulate viral infection (65, 66). RANTES is known to 
signal via two distinct pathways (67). The first utilizes low RANTES concentrations 
(≤50 nM) and via Gαi-type GPCR pathway regulates chemotaxis and transient calcium 
mobilization. The second low affinity pathway requires higher RANTES concentrations 
(≥1 µM), and via PTKs (protein tyrosine kinases) causes general T cell activation, i.e., 
proliferation, interleukin-2 expression, etc. (67-69). 
 RANTES and other chemokines can form dimers, higher order oligomers as 
well as large molecular weight aggregates. Wild type RANTES is particularly 
aggregation-prone (70). Such properties affect the function of chemokines and may be 
important for the establishment of chemokine gradients (66, 71). To study the role of 
RANTES oligomerization and dissect the function of monomeric and aggregated 
RANTES, the key residues involved in RANTES oligomerization have been identified 
and the effect of their mutation studied (66, 71). It was shown that E26A and E66S 
mutations reduce RANTES aggregation tendency rendering predominantly tetrameric 
and dimeric RANTES, respectively. Although, disaggregated RANTES retained CCR5 
binding and Gαi-dependent signaling properties, it failed to activate the PTK pathway 
and did not activate T lymphocytes, neutrophils and monocytes (71). 
 
1.7 RANTES structural features 
 Structures of numerous chemokines including SDF-1α, vMIP-II, MIP-1β and 
RANTES have been solved by X-ray crystallography and NMR (72-77). Few structural 
features, that is a flexible N-terminus, three antiparallel β-strands and C-terminal α-
helix are highly conserved and constitute structural hallmarks of all chemokines (78). 
Chemokines share also the position of four cysteines residues: two at the N-terminus 
near each other, one in the center of the sequence and one in the C-terminal part (79). 
 At low pH and low protein concentration (conditions preventing precipitation) 
RANTES was studied in detail by NMR (80). RANTES monomer and dimer are in 
slow exchange regime and can be observed as separate sets of HSQC resonances. The 
dissociation constant of RANTES monomer-dimer equilibrium is 17.6 µM at pH 3.8 
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and only 2.9 µM at pH 6.0, which indicates that at higher pH the dimeric RANTES 
form is even more stabilized. Subsequently, using chemical shift difference between 
RANTES monomer and dimer, dimerization interfaced was mapped to residues: 10-16, 
19, 21, 31-35, 41, 42, 46-50, 54 and Q48 sidechain. These residues form a continuous 
patch at one side of RANTES molecule, which overlaps with the RANTES 
dimerization interface observed before in the crystal structure (81). According to the 
PDB entry 1EQT (81), residues 8-10 for an important intermolecular β-sheet stabilizing 
RANTES dimer. Based on the data obtained using various techniques (NMR, MS, 
SAXS) a rational for RANTES oligomerization was proposed (70). According to this 
model RANTES dimers can form a tetramer stabilized by the interactions between the 
second β-strand (residues 25-30) and C-terminal α-helix (residues 62 and 66) of one 
monomer and the corresponding residues of a monomer from another dimer. Since this 
interaction involves only one of the monomers forming each dimer, the other monomer 
can still interact with a monomer being part of a third dimer. In this way interaction can 
be propagated into long oligomers composed of even number of RANTES molecules. 
This model explains very well the reduced aggregation properties of RANTES E26 and 
E66 mutants (71). 
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Figure 1.5 Structures of RANTES. (A) Cartoon representation of the three dimensional RANTES 
crystal structure (one monomer of a dimer) based on the PDB entry 1EQT (81). Secondary structure 
elements were color-coded: β-strand and β-bridge (cyan), β-turn (orange), α-helix (green), 310-helix 
(purple), random coil (grey). Four cysteines forming disulphide bridges were colored yellow. Two 
glutamic acids important in RANTES aggregation were colored red. (B) Model of RANTES 
oligomerization based on the PDB entry 2L9H (70). As the interaction interface between two dimers 
(green and cyan) requires only one of the monomers forming each dimer, the oligomerization can be 
propagated into elongated polymers composed of even number of RANTES molecules. 
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2 Aims of the study 
 
 The goal of this dissertation thesis was to obtain an NMR-amenable system to 
study CCR5 and its interactions with ligands in particular with the chemokine 
RANTES. More specifically the work aimed at: (i) improving the yield and purity of 
the previously established expression system in insect cells, (ii) further biophysical 
characterization of the insect-produced material, (iii) optimizing solubilization 
conditions yielding stable and ligand-binding CCR5 as well as (iv) establishing a 
bacterial expression system to facilitate uniform isotope labeling, (v) biophysical 
characterization of the protein produced in E. coli, (vi) optimizing sample conditions 
and studying E. coli-expressed CCR5 by NMR and finally (vii) finding suitable 
conditions and studying CCR5 interaction with RANTES. The work should also help to 
understand and overcome the general bottlenecks hampering GPCR structure 
determination by NMR. The last part of the thesis aimed at the investigation of protein 
cold and alcohol denaturation. 
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3 Studies of CCR5 expressed in Sf21 
 
3.1 Materials and methods 
 
List of buffers 
Buffer 1A 20 mM Na2HPO4 pH 7.5, 300 mM NaCl, 10% (v/v) glycerol 
Buffer 1B 20 mM Tris-HCl pH 7.5, 100 mM (NH4)2SO4, 10% (v/v) glycerol 
Buffer 2  20 mM Na2HPO4 pH 7.5, 1 M NaCl, 10% (v/v) glycerol, 
  40 mM imidazole, 0.1% FC-12 
Buffer 3 20 mM Na2HPO4 pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 
  400 mM imidazole, 0.1% FC-12 
Buffer 4 10 mM HEPES pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.1% FC-12 
Buffer 5 10 mM HEPES pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.1% FC-12, 
  5 mM D-desthiobiotin 
Buffer 6 10 mM HEPES pH 7.4, 150 mM NaCl, 50 µM EDTA, 0.1% FC-12,  
  0.005% P20 (a surfactant, recommended by the sensor chip and SPR  
  instrument manufacturer,) 
 
Recombinant CCR5 expression 
 Recombinant CCR5 was produced using baculovirus-insect cell system 
essentially as described previously (82). High titer baculovirus stocks were obtained 
using Sf9 strain. CCR5 was overexpressed on a large scale (5-10 L) in Sf21 in all cases 
besides a single test expression performed in High Five for a comparison. Cells were 
grown in WAVE Bioreactor BASE2050EHT (GE Healthcare) in SF-4 Baculo Express 
Insect Culture Medium (BioConcept, Allschwil, Switzerland) at 27°C until a density of 
2.0-2.4×106/mL. About 40 h after infection at MOI=1 cells were harvested by 
centrifugation and stored at -70°C. 
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Preparation of membrane fraction 
 A frozen insect cell pellet (typically from 1 L of culture) was suspended in 100 
mL of buffer 1A or 1B and supplemented with EDTA-free complete protease inhibitor 
cocktail (Roche). Cells were broken using a dounce homogenizer (typically 40 strokes). 
Cell debris was removed by centrifugation at 300 g for 6 min. The supernatant was 
centrifuged at 100000 g for 30 min and the resulting pellet (from now on called 
membrane fraction) was washed twice with buffer 1A or 1B. Finally, membrane the 
fraction was suspended in buffer 1A or 1B and stored at -70°C. 
 
CCR5 purification 
 A frozen insect cell membrane fraction (typically from 1 L of culture) was 
thawed and supplemented with EDTA-free complete protease inhibitor cocktail 
(Roche) and 1.5-2.5% detergent. Protein solubilization was carried out at 4-8°C for 2 h. 
Unsolubilized material was removed by centrifugation at 100000 g for 30 min. The 
clarified supernatant was supplemented with 20 mM imidazole and bound to Ni-
charged Chelating Sepharose (GE Healthcare) beads for 1.5 h. The resin was washed 
with 50 CV of buffer 2. The protein was then eluted with buffer 3. Protein-rich 
fractions were pooled and bound to Strep-Tactin beads (IBA, Göttingen, Germany) for 
1.5 h. The resin was washed with 20 CV of buffer 4. The protein was eluted with buffer 
5. For the purification in DDM FC-12 was replaced with DDM for buffers 2-5. 
 
Gel electrophoresis and western blotting 
 Protein samples for SDS-PAGE were mixed with 5x SDS loading buffer (312.5 
mM Tris-HCl pH 6.8, 50% (v/v) glycerol, 25% β-mercaptoethanol, 10% SDS, 0.0125% 
bromophenol blue), incubated at 30°C for 15 min and centrifuged at 17000 g for 5 min 
prior to loading on a 4-20% gradient precast gel (Pierce). The electrophoresis was 
performed at 100 V constant voltage. Gels were stained using 0.25% solution of 
Coomassie Brilliant blue R-250 (AppliChem) in 25% isopropanol and 10% acetic acid 
and destained in 10% acetic acid. 
 For western blotting onto PVDF membrane (Bio-Rad), a Criterion Blotter (Bio-
Rad) was used. The transfer was performed at 0.5 A constant current for 1 h in the 
transfer buffer (48 mM Tris-HCl pH 9.2, 39 mM glycine, 0.375% SDS, 20% 
methanol). The membrane was blocked with 3% BSA in TBST buffer (10 mM Tris-
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HCl pH 8, 150 mM NaCl, 0.5% Tween-20). Subsequently the membrane was incubated 
with mouse monoclonal HIS-1 anti-polyhistidine-peroxidase antibody (Sigma-Aldrich) 
at 1:6000 dilution for 1 h. After washing 4 x 2 min with TBST buffer, the blot was 
developed using chemiluminescent HRP substrate (Roche). The signal was recorded 
using a BioMax XAR Film (Kodak) or using a LAS-4000 luminescent image analyzer 
(Fujifilm). The signal intensities were quantified using the ImageJ 1.43r (83). 
 
Circular dichroism spectroscopy 
 CD spectra were recorded on 3-13 µM monomeric CCR5 fractions. 
Measurements were performed on a Chirascan CD spectrometer (Applied 
Photophysics) at 20°C in 1 mm quartz Suprasil cuvettes (Hellma). Typically, spectra in 
a wavelength range of 195-260 nm spectra were recorded in triplicates and averaged. 
After baseline (buffer) subtraction, the mean residue molar ellipticity ΘMRM was 
calculated from the following equation ΘMRM=Θ/(C×n×l), where Θ is the ellipticity 
(deg), C is the concentration (mol/L), n is the number of residues and l is the optical 
path length (cm). The α-helical contents α% was calculated as follows α%=(-ΘMRM, 
222nm+3000)/39000 (84), where ΘMRM is given in units of deg×cm2×dmol-1. 
 
Mass spectrometry analysis 
 MS analysis was performed by the Functional Genomics Center Zurich. 
Purified ∼30 µM CCR5 50 µL solution samples (after Ni-NTA and after both Ni-NTA 
and Strep-tag purification) were shipped on ice. CCR5 samples (10 µL) were 
precipitated with 10 µL of 20% TCA and two times washed with cold acetone while 
centrifuged prior to the analysis. For the PTMs detection samples (also after 
precipitation as it was expected that samples in a detergent-containing solution cannot 
be efficiently digested) were subject to a proteolytic digestion with trypsin. 
 
Detergent exchange assay 
 IMAC and Strep-Tactin-purified CCR5 in buffer 5 (containing FC-12) was 
concentrated to ∼1.3 mg/mL. The protein was first supplemented with 2 M HEPES pH 
8 to final concentration of 90 mM and then diluted with ddH2O to adjust protein 
concentration to ∼0.92 mg/mL. Subsequently, the resulting protein solution was 
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aliquoted into 24 µL fractions followed by addition of 6 µL 10% detergents (all from 
Anatrace, DHPC from Avanti Polar Lipids). The resulting mixture (∼0.74 mg/mL 
CCR5 in 51 mM HEPES pH 8, 50 mM NaCl, 0.55 mM EDTA, 2.75 mM D-
desthiobiotin and ∼1.82x diluted FC-12) was incubated for 6 days at RT. The resulting 
precipitate was removed by centrifugation at 150000 g for 1h and the supernatant was 
analyzed for the protein contents on SDS-PAGE. 
 
Detergent solubilization assay 
 Frozen 20% (w/v) solutions of membrane fraction were thawed, diluted twice 
and supplemented with detergent to a final concentration of 2%. Solubilization was 
carried out at RT for 2 h with 1000 rpm shaking. Unsolubilized material was removed 
by centrifugation at 17000 g for 30 min. The clarified supernatant (2 µL) was loaded 
onto a Protran BA85 nitrocellulose membrane (Whatman) and dried at RT. Dot blots 
were blocked, labeled with anti-His-tag antibody, developed and quantified in the same 
way as western blots described below. Detergents were obtained from Anatrace, DHPC 
from Avanti Polar Lipids. 
 
Immunoprecipitation 
 0.5 mL aliquots of insect cell membrane fractions in buffer 1A or 1B were 
supplemented with detergents to 1% final concentration. Solubilization was carried out 
for 2 h followed by centrifugation at 17000 g for 15 min. 120 µL of the supernatant was 
transferred to a clean tube and incubated with 2.5 µL of 2D7 antibody (0.5 mg/mL) for 
1 h. Subsequently, after 15 min centrifugation at 17000 g, 100 µL of the supernatant 
was bound to 25 µL of Protein G Sepharose 4 Fast Flow (GE Healthcare) for 1 h. The 
resin was washed three times with buffer 1A or 1B supplemented with the tested 
detergent. To disrupt protein interactions 50 µL 2x SDS loading buffer was added. 
After 30 min incubation samples were analyzed by SDS-PAGE and western blotting. 
 
Dynamic light scattering 
 DLS measurements were performed on a Zetasizer Nano ZS instrument 
(Malvern Instruments) at RT. Samples (typically 80 µL) were placed in UV-transparent 
cuvettes UVette 220 – 1600 nm (Eppendorf), inserted into the instrument and 
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equilibrated for 5 min prior the measurement. Spectra were collected at least in 
triplicates and averaged. 
 
Surface Plasmon resonance 
 SPR was performed on a BIAlite instrument (Biacore) equipped with an NTA 
Sensor Chip (Biacore) at 12-20°C and 10-20 µL/min flow rate with buffer 6 as a typical 
running buffer. For the CCR5 immobilization the chip was functionalized with nickel 
ions (100 µL injection of 500 µM NiSO4) followed by 3-4 100 µL injections of purified 
200-266 nM CCR5. For the binding of RANTES-E66S to CCR5, 0.5 µM solution of 
RANTES-E66S was injected. To study RANTES-E66S unspecific adsorption to the Ni-
charged NTA chip, 10 µM RANTES-E66S solution in a suitable buffer (with adjusted 
NaCl concentration and pH) was injected. Before proceeding to the next tested 
condition the chip was stripped with 40 µL injection of 0.1 M HCl, running buffer was 
changed to another one (with higher NaCl concentration or pH) and the chip was re-
functionalized with NiSO4. 
 
3.2 Results 
 
CCR5 purification 
 
3.2.1.1 Introduction 
 The selection of the purification methods plays a key role in the final outcome 
and should be made carefully. One has to take into account not only the quality of the 
final product but also, very importantly, the cost, the time and the workload that need to 
be applied along the procedure. In the membrane protein field especially, where the 
system is complicated by the presence of detergents, the application of classical 
chromatography methods like SEC and IEC is usually more challenging. Therefore, for 
recombinant proteins, due to its robustness, IMAC, that relies on ∼1 µM affinity of 
polyhistidine to transition metal ions, is often a method of choice for the first 
purification step. This chapter demonstrates that, despite its limited specificity, upon 
fine-tuning, IMAC can yield good results. 
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3.2.1.2 IMAC chromatography 
 The prerequisite of applying IMAC is the presence of a polyhistidine tag, 
conventionally 6His-tag. Therefore, the wild type CCR5 construct which is used in this 
study contains one on its C-terminus (followed by Strep-tag). After membrane fraction 
preparation, which by depleting water-soluble proteins is a purification step by itself, 
CCR5 is solubilized in a detergent, clarified by centrifugation and bound to an IMAC 
resin. Subsequently the resin is washed with buffer containing imidazole (typically 20-
60 mM), salt (up to 2M) and glycerol (up to 50%) to remove unspecifically bound 
particles. Protein is usually eluted using high imidazole concentration (typically ≥250 
mM) or, less frequently, with low pH (4.5-5.3) or EDTA. 
 In order to ensure the optimal protein purity and yield, the washing 
concentration of imidazole was systematically optimized (Figure 3.1). The experiment 
aimed to determine the maximal concentration that does not yet lead to the elution of 
detectable amount of the protein. IMAC column with bound CCR5 was washed with 
stepwise increasing concentration of imidazole. The eluting protein was monitored by a 
UV absorption at 280 nm. First, 20 mM imidazole was applied until UV baseline 
stabilizes and then the concentration was raised with 20 mM increments until 100 mM, 
followed by 150, 200, 300 and 400 mM steps, 15 CV each. Eluted peaks were analyzed 
by anti-His-tag western blotting for the presence of CCR5 (Figure 3.2). 
 
 
Figure 3.1 Imidazole step gradient elution from IMAC column. UV absorption intensity (blue curve) 
is a sum of eluting protein (peaks) and increasing imidazole concentration (rectangular baseline 
shifts). 
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 The experiment showed that the fractions eluted with up to 40 mM imidazole 
did not contain detectable amount of CCR5 and therefore must have been entirely 
composed of the contaminants. 60-100 mM imidazole eluted CCR5 monomers, 
whereas from 150 mM imidazole on, dimers came along. To fully elute all CCR5 
oligomeric species minimum 300 mM imidazole was required. Similar experiment was 
performed earlier, with less resolution, in batch mode. CCR5 monomers eluted at 80 
but not at 50 mM imidazole, while 500 mM imidazole eluted all species. Both 
experiments are consistent with one another and suggest that up to 50 mM imidazole 
can be applied for washing and at least 300 is required for a complete elution. This 
experiment also shows that 15 CV is not sufficient for washing and the purity should 
benefit from larger washing volume. 
 
 
Figure 3.2 Western blotting of IMAC resin-eluted fractions. Two independent experiments 
(separated by a dashed line) of imidazole step gradient elution, first performed in batch (left) and 
second on a column with more resolution (right), yield overlapping result. 
 
 The concentration of imidazole at which the protein starts to elute depends also 
on the His-tag length and on a resin type. Intuitively, longer His-tag should need higher 
imidazole concentration to elute and indeed, a 10His-tagged CCR5 went off the resin at 
133 mM imidazole, dimers required 250 mM, whereas a complete elution 500 mM. 
Similarly, the minimum imidazole concentration required to elute protein from Ni-NTA 
(IMAC resin from Qiagen), which leaves only two unoccupied nickel coordination sites 
for polyhistidine binding (resin from GE Healthcare has three), should and is 
significantly lower. To elute 10His-tagged CCR5 monomers, dimers and all protein 80, 
167 and 400 mM imidazole respectively was necessary. A summary of all tested 
conditions can be found in Table 3.1. 
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Table 3.1 Imidazole concentration required for CCR5 elution from IMAC resin. Values are 
approximate and represent concentrations at which CCR5 monomer and dimer elution started to be 
observable on western blot and values necessary to complete the elution of all the oligomeric states. 
IMAC Resin Tag Monomer Dimer All 
GE Healthcare 6His-tag 60 mM 100 mM 300 mM 
GE Healthcare 10His-tag 133 mM 250 mM 500 mM 
Qiagen 10His-tag 80 mM 167 mM 400 mM 
 
3.2.1.3 Sf21, Sf9 and High Five insect cell lines 
 In structural biology there are three most frequently used insect cell lines: Sf21, 
Sf9 and High Five. Sf21 and Sf9 originate from IPLBSF-21 cell line (85), which was 
derived from the pupal ovarian tissue of the fall army worm, Spodoptera frugiperda, 
and doubles every 24 and 72 hours, respectively. High Five (BTI-TN-5B1-4) (Boyce 
Thompson Institute for Plant Research, Ithaca, New York, USA) originates from the 
ovarian cells of the cabbage looper, Trichoplusia ni, and doubles every 18 h. Due to 
smaller size and regular shape Sf9 are exceptional for the formation of monolayers and 
plaques, while High Five features fastest growth and for selected proteins provide 
highest secreted expression. However, the fact that most of crystallized GPCRs was 
expressed in Sf9 suggests that in terms of functional GPCR expression Sf9 proved its 
high usefulness. 
 In this section we have compared Sf21 and High Five in terms of the quality of 
the expressed CCR5. The protein from both cell lines was purified in parallel on Ni-
NTA and subsequently on Strep-Tactin resins using FC-12 as a detergent. After each 
purification step the eluate was analyzed on SDS-PAGE (Figure 3.3). His- and Strep-
tagged CCR5 construct (MW=42661.3 Da, for the complete sequence see Figure 3.10 
in section PTMs and sequence integrity) migrates on SDS-PAGE like a ~33 kDa 
protein, whereas CCR5 dimer like a ~55 kDa standard protein. Faster migration is 
common for membrane proteins and can be caused by the incomplete protein 
unfolding. The latter seems to be supported by the fact that CCR5 is able to form at 
least partially SDS-stable oligomers. 
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Figure 3.3 Two-step CCR5 purification in FC-12. Lane 1 (protein standards), lane 2 (IMAC-purified 
CCR5 from High Five), lane 3 (IMAC and Strep-Tactin-purified CCR5 from High Five), lane 4 
(IMAC-purified CCR5 from Sf21), lane 5 (IMAC and Strep-Tactin-purified CCR5 from Sf21). 
 
 In general, CCR5 expression in Sf21 and in High Five was similar in terms of 
the yield and the purity. A sharp band of a contaminant migrating at ~75 kDa, later 
identified as Hsc70 (heat-shock cognate 70 kDa), was somewhat more pronounced in 
Sf21. The monomer:dimer ratio was a bit higher for High Five but as on SDS-PAGE 
the oligomeric state of CCR5 might have been altered by the presence of SDS and/or 
BME, both purified CCR5 samples were additionally analyzed using SEC (Figure 3.4). 
The chromatogram confirmed that the monomer:dimer ratio of the CCR5 from High 
Five was indeed somewhat higher but as this difference is rather small and as the 
physiological oligomeric state of CCR5 is not known definitively, a minor difference in 
monomer:dimer ratio might not be a good criterion to prefer one cell line over the 
other. 
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Figure 3.4 Size exclusion chromatography of IMAC and Strep-Tactin-purified CCR5. For 
convenient monomer:dimer ratio comparison, chromatograms of CCR5 expressed in Sf21 (black 
curve) and in High Five (blue curve) were scaled in such a way that dimer peak height equals 1. 
 
3.2.1.4 Fos-Choline-12 versus DDM 
 Based on the research done previously in our group (82) FC-12 was selected as 
a main working detergent. The criteria that spoke for it at that time were: high CCR5 
yield and purity (as judged by SDS-PAGE), homogeneity (as judged by TEM negative 
stain) and ability to maintain its native conformation (as judged by IP and ITC). While 
a separate chapter is dedicated to the IP, here the example of the purification in an 
alternative detergent is presented. 
 However at the time when this research was performed only a few GPCR 
structures were solved it was already clear that the number of membrane protein 
structures (solved by crystallography) in detergents with sugar head groups largely 
exceeds the number of structures in any other detergent group. DDM is one of the most 
widely used and it was also tested for CCR5. The parallel purification involved 
solubilization with 1.5% FC-12 and 2.5% DDM followed by Ni-NTA and Strep-Tactin 
chromatography. The eluate collected after each purification step was subjected to 
SDS-PAGE (Figure 3.5). It was possible to purify CCR5 in DDM but despite larger 
DDM concentration used for solubilization, the purity of CCR5 was clearly lower after 
each step in comparison to the purification in FC-12 and the final yield was only ∼20-
40% of the yield achieved for FC-12. Importantly, the presented purification in FC-12 
is a representative example, whereas the purification in DDM is the best achieved 
outcome. Generally, purification in DDM (and other detergents with sugar head 
groups) resulted in unsatisfactory amounts of still impure protein. 
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Figure 3.5 CCR5 purification in FC-12 and in DDM. Lane 1 (protein standards), lane 2 (IMAC-
purified CCR5 in FC-12), lane 3 (IMAC and Strep-Tactin-purified CCR5 in FC-12), lane 4 (IMAC-
purified CCR5 in DDM), lane 5 (IMAC and Strep-Tactin-purified CCR5 in DDM). 
 
3.2.1.5 Removal of the persistent contaminant 
 Even though the imidazole concentration was carefully optimized and high salt 
(1M NaCl) and glycerol (10%) included in the washing buffer, there was always one 
strong contaminant band on SDS-PAGE which seemed completely resistant to the 
applied washing procedures on both IMAC and Strep-Tactin resins. This made us think 
(original idea of Sébastien Morin) that this contaminant is likely to interact directly 
with CCR5 and by this fail to wash out. The band was excised from a gel and send for 
MS analysis, which revealed that it is Hsc70. As Hsc70 binds substrates in ATP-
dependent manner, the presence of ATP could trigger its dissociation from CCR5. 
Following this hypothesis, IMAC washing buffer was supplemented with 10 mM ATP 
and 20 mM MgCl2, which resulted in almost complete removal of Hsc70 from CCR5 
samples (Figure 3.6). 
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Figure 3.6 Removal of the persistent contaminant. The inclusion of ATP and MgCl2 in the IMAC 
washing buffer removes Hsc70 from CCR5 samples. Lanes 1 (protein standards), Lanes 2-5 (various 
CCR5 samples purified with ATP and MgCl2), lanes 6-9 (various CCR5 samples purified without 
ATP and MgCl2). C-terminally truncated CCR5 constructs (lanes 3 and 5) migrate faster than the full 
length CCR5 (other lanes). 
 
Characterization of CCR5 secondary structure 
 Having purified CCR5 we have addressed the question of its quality using CD. 
As GPCRs are composed of as many as seven α-helical TM domains, it was expected 
to observe a strong CD signal exhibiting two pronounced minima at around 209 and 
222 nm. Approximately 2.5 µM CCR5 purified on IMAC and Strep-tag resins was 
subjected to the experiment and consistently with the expectation, characteristic double 
minima shape spectrum was observed (Figure 3.7). From the signal intensity at 222 nm 
it could be estimated that α-helical contents of CCR5 sample was ∼43%. This value is 
in a good range but may seem a little too low. The reduction in ellipticity may be 
attributed to the absorption flattening effect, which occurs when chromophores are 
closely packed and in the case of CCR5 sample may result from the presence of 
oligomers. It also cannot be excluded that FC-12 micelle does not favor as much α-
helical secondary structure as the lipid environment of a membrane. 
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Figure 3.7 Circular dichroism spectrum of CCR5. The spectrum recorded at 5°C exhibits a double 
minima shape (black curve), which is lost upon heating (green curve). Secondary structure 
denaturation is irreversible (blue curve). 
 
 CD is also a good method to examine thermal stability. The loss of ellipticity 
can be monitored as a function of temperature. In Figure 3.8 the mean residue molar 
ellipticity at 222 nm was plotted against increasing temperature from 5 to 95°C. The 
resulting curve represents a broad thermal transition, which starts already around 10°C. 
Heating the sample to 95°C causes not only a decrease of signal amplitude but also a 
loss of the characteristic double minima spectral shape. Cooling the sample down back 
to 5°C does not restore the initial amplitude of the signal, which suggests that thermal 
denaturation of CCR5 is irreversible.  
 
 
Figure 3.8 Mean residue molar ellipticity of CCR5 at 222 nm upon heating (black points) and 
cooling (blue points) shows a broad transition and the irreversibility of CCR5 secondary structure 
denaturation. 
 
-1.6
-1.3
-1.0
-0.7
-0.4
-0.1
200 210 220 230 240 250
5oC
95oC
5oC 
back
λ [nm]
Θ
M
R
M
×
10
-
4  
[de
g×
cm
2 ×
dm
ol
-
1 ]
5oC     95oC
95oC     5oC
Temperature [oC]
Θ
M
R
M
×
10
-
4  
[de
g×
cm
2 ×
dm
ol
-
1 ]
-1.5
-1.3
-1.1
-0.9
-0.7
0 10 20 30 40 50 60 70 80 90 100
 24 
PTMs and sequence integrity 
 The next step in the quality assessment aimed at the confirmation of CCR5 
integrity and the presence of the expected PTMs. Two solution CCR5 samples (eluted 
from IMAC and Strep-Tactin resins) were measured by MALDI-MS (Figure 3.9). 
Despite both samples were somewhat heterogeneous (contaminated by other proteins), 
CCR5 could be identified in each case. The pattern of the contamination peaks was 
similar in both cases, and not surprisingly, in sample 1 (after two purification steps) the 
CCR5 peak intensity was higher in relation to the intensity of the contamination peaks 
in comparison to sample 2 (after IMAC only). The measured m/z values 42621.3 and 
42633.9 are higher than the monoisotopic mass calculated for the unmodified CCR5 
(42359.1 Da), which suggests that the protein is indeed modified. 
 
 
Figure 3.9 Mass spectra of CCR5 samples after IMAC and Strep-Tactin (top panel) and after IMAC 
(bottom panel). Judging from the elevated m/z values CCR5 seems to be modified. 
 
 To enhance the resolution of the analysis, CCR5 sample was precipitated, 
digested with trypsin and analyzed by MALDI-MS. The following CCR5 peptides 
could be identified (Figure 3.10): 
- the N-terminal fragment MDYQVSSPIYDINYYTSEPCQK (acetylated), 
- the 2nd ECL fragment EGLHYTCSSHFPYSQYQFWK, 
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- the 7th TM domain fragment LDQAMQVTETLGMTHCCINPIIYAFVGEK, 
- the helix H8 fragment NYLLVFFQK and 
- three sequential C-terminal peptides: CCSIFQQEAPER, ASSVYTR and 
STGEQEISVGLHHHHHHWSHPQFEK. 
The identified sequences constitute only ∼1/3 of the CCR5 construct sequence and with 
the exception of 7th domain and potential helix 8 encompass weakly or unstructured 
regions of the protein (both termini and a long loop). Poor sequence coverage is not 
surprising as the tightly packed hydrophobic CCR5 core is likely to be resistant to the 
proteolysis. It was solely proven that N-terminus of CCR5 is acetylated (m/z increased 
by 42 Da). None of the expected PTMs, that is sulfation and glycosylation of N-
terminus and palmitoylation of C-terminus, could be detected despite the respective 
peptides were identified. After subtraction of acetyl (42 Da) and unmodified CCR5 
(42359.1 Da) masses from the bigger of the detected m/z values (42633.9), there is 
∼233 Da left for other modifications. This is too little for even one palmitoyl moiety 
(+238) but sulfation (+80) or glycosylation with a single N-acetylglucosamine (+203) 
could be accommodated. 
 
 
Figure 3.10 Sequence topology of the detected CCR5 peptides after trypsin digestion. Identified 
fragments (green filled circles) localize in N- and C-termini, 2nd ECL and TM domain 7, leaving TM 
domains 1-6 unrepresented. 
 
 These results taken together show that CCR5 expressed in Sf21 maintains its 
sequence integrity (both termini are not degraded) but it is not modified in a similar 
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way as it is in human cells. However, as the presence of PTMs may be dependent on 
the expression conditions, the latter conclusion holds only for this particular batch of 
CCR5. 
 
Detergent screening 
 
3.2.1.6 Introduction 
 Appropriate detergent system is the most important factor conditioning a 
successful preparation of a membrane protein. Wrong detergent can destabilize the 
protein, distort native structure, abolish activity or even denature protein completely. It 
can also lead to the formation of inhomogeneous in size and shape micelles, which will 
prevent crystal formation and decrease the quality of NMR signal. This chapter 
addresses the detergent screening issue from two different sides using two separate 
assays. The obtained readouts classify detergents according to two different parameters. 
 
3.2.1.7 Detergent exchange assay 
 The first detergent screening assay differentiates detergents according to the 
ability to keep CCR5 in solution over several days at RT. The advantage of this 
approach is that it uses purified detergent-solubilized CCR5 as an input and thereby 
does not require a detergent to be able to solubilize CCR5 from a membrane or any 
kind of insoluble state. In this way, detergents, which create an environment favoring 
CCR5 solubility but are too mild to actively solubilize (extract) it into solution, are not 
excluded from the analysis. On the other hand, as the initial detergent is still present, 
the requirement for a purified detergent-solubilized protein biases the screen towards 
potential detergent incompatibilities. In other words, the precipitation of CCR5 
resulting from its instability in a new detergent cannot be distinguished from a 
precipitation of an initial detergent by a new detergent, reasonably assuming that the 
forming precipitate can pull down CCR5 micelles. A similar complication involves the 
readout itself, that is SDS-PAGE, where ∼2% SDS is present in sample buffer. 
 As FC-12 efficiently solubilizes CCR5 from insect membrane fraction and 
gives good yields of purified protein, a detergent exchange assay was performed with 
the FC-12-solubilized purified protein. CCR5 aliquots were supplemented with the 
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screened detergents up to 2% final concentration. The precipitate that formed over 6 
days was removed by centrifugation. The supernatant was analyzed by SDS-PAGE 
(Figure 3.11) followed by a densitometric analysis of the monomeric and dimeric 
CCR5 bands. Subsequently, the obtained intensities were divided by the biggest value 
and plotted in Figure 3.12. 
 
 
Figure 3.11 Example of detergent exchange screen raw data. Incompatible surfactants precipitate 
CCR5, which results in decreased CCR5 band intensities. Lanes 1 and 12 (protein standards), lane 2 
(MP-8), lane 3 (C12E9), lane 4 (MP-11), lane 5 (Mega-9), lane 6 (DIFOS-12), lane 7 (FC-10), lane 8 
(C10E6), lane 9 (DHPC), lane 10 (FC-12), lane 11 (Tween-20). 
 
 The amount of CCR5 kept in the solution was very different for various 
detergents. The results, ranging from no to a complete precipitation demonstrate the 
applicability of the approach to diversify detergents for their ability to keep CCR5 in 
solution. In general, alkyl anionic (SDS and SDDSAR) and zwitterionic (Fos-Cholines) 
but not bile acid based (NaC, CHAPS, CHAPSO) detergents performed better than 
nonionic detergents. Not surprisingly, the entire group of Fos-Cholines was very good, 
keeping as much as ∼60-90% of CCR5 in a solution. Among nonionic detergents only 9 
out of ∼60 tested, including Tween-20, Brij-58, C12E9 and several representatives of 
maltoside family (TMP-12, TMP-10, TMP-8, MP-12, MP-6 and Cymal-7), kept more 
than half of CCR5 in the solution. Interestingly, detergents with glucose head groups 
precipitated nearly all CCR5. The only decent result of GP-6 with a CMC of ∼6.6% 
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(similarly as other detergents with very short alkyl chains) is likely due to the 
insufficient amount of detergent to perturb CCR5 in the remaining FC-12. 
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Figure 3.12 Detergent exchange screen with anionic (SDS to NaC), zwitterionic (DMMAPS to 
CHAPS) and nonionic (Tween-20 to Anameg-7) detergents. 
 As the solubility of CCR5 and detergent itself may depend on other factors such 
as pH and ionic strength, screening for optimal surfactants should take them into 
account. This would, however, add extra dimensions to already extensive analysis and 
normally requires high-throughput approach. Due to the technical limitation such 
multidimensional screen could not have been performed but the example of the pH and 
NaCl concentration effect on SDS-solubilized CCR5 is presented in Figure 3.13. In the 
case of anionic SDS a decrease of pH reduced CCR5 solubility. A decrease of salt 
concentration from 560 to 60 mM was however beneficial. 
 
 
Figure 3.13 Dependence of pH and salt on CCR5 solubility in SDS. 
 
3.2.1.8 Detergent solubilization assay 
 Another approach to detergent screening relies on the ability of a detergent to 
solubilize CCR5 from membrane fraction. The advantage of this approach is that it 
reveals candidates directly applicable for solubilization but in return it does not tell 
anything about protein stability in a longer timescale. In other words, it does require a 
detergent to efficiently solubilize CCR5 but does not require to keep it in a solution for 
more than few hours. Unlike the previous approach, this assay is also less biased 
because no other but tested detergent is present and the readout is SDS-free (SDS-
PAGE is not involved). 
 Based on the results of the previous screen, the set of tested detergents was 
modified in a way to contain a broader representation of zwitterionic detergent families 
(Fos-Cholines, Anzergents, dimethylamine oxides and dimethylglycines) and also a 
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
5.0 5.8 6.6 7.5 8.3
R
el
at
iv
e 
So
lu
bi
lity
 [R
U]
pH
560 mM NaCl 60 mM NaCl
 30 
new family of cationic detergents was included (trimethylammonium chlorides). The 
nonionic family was represented by maltosides. Each family consisted of detergents 
with few different lengths of the alkyl chain. 
 
 
Figure 3.14 Detergent solubilization screen - raw data. Solubilized and clarified insect cell 
membrane fraction was dried on a nitrocellulose membrane and developed in a form of dot blot. 
 
 Due to the presence of other proteins solubilized from the membrane fraction, a 
CCR5-specific readout was necessary. Hence, the solubilized CCR5 was detected by 
anti-His-tag western blotting (Figure 3.14). Clear differences between tested detergents 
were observed, ranging from a complete lack of signal to a saturated spot. After 
densitometric quantification, analogously as previously, numbers were normalized for 
the biggest value (Figure 3.15). Similarly as before anionic SDS and SDDSAR and 
zwitterionic Fos-Cholines performed very well solubilizing ∼60-100% of CCR5. Other 
zwitterionic detergents (with the exception of DMG-14 which solubilized ∼40%) 
solubilized <30% of CCR5, while the best of nonionic maltosides ∼30%. A clear trend, 
the longer the alkyl chain the more solubilized CCR5, can be observed in almost all of 
the tested detergent families.  
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Figure 3.15 Detergent solubilization screen presented as densitometrically-quantified dot blot signal 
reveals promising candidates for CCR5 solubilization. 
 
Immunoprecipitation with 2D7 
 
3.2.1.9 Introduction 
 So far the studies focused on the CCR5 yield, purity, integrity and gave some 
insight into the oligomeric state, secondary structure and its detergent preferences. All 
these experiments constitute indispensable starting points of structural and functional 
analysis but do not yet answer the question, whether the isolated CCR5 possesses its 
native properties. Desirable features would include: the ability to bind ligands, to 
interact with G proteins and trigger signaling cascade, to interact with drugs or any kind 
of readout that confirms that CCR5 maintains its native structure. 
 Some of these properties are very challenging to study because they require 
many other components (proteins, cellular environment, etc.) to be present and simply 
cannot be studied in a micellar system. Fortunately, many CCR5-specific antibodies 
have been already developed and some of them like for example 2D7 (CD195) are 
conformation-dependent, which means that they recognize a nonlinear structural motif 
on the 2nd ECL only when CCR5 maintains its native structure. Hence, 2D7 is widely 
used in the field as a CCR5 native conformation probe.  
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3.2.1.10 Detergent impact on 2D7 recognition 
 It has been reported using IP that 2D7 could recognize CCR5 solubilized in 
Cymal-5 but not in FC-14 or DHPC (86). Another group showed using SPR that CCR5 
solubilized in detergents with maltose head group maintain more 2D7 binding ability 
than CCR5 solubilized in any other detergent family (87). For our purpose, CCR5 
native conformation was probed using IP with 2D7 antibody. This assay does not 
require purified protein and can be performed directly on the clarified detergent-
solubilized membrane fractions. In brief, solubilized membrane fraction was 
centrifuged to remove insoluble material, supernatant was mixed with 2D7 (CCR5 
binding to Fab of 2D7) and transferred to a resin with immobilized protein G (binding 
of 2D7 Fc to protein G). The unbound material was removed by washing. An addition 
of SDS-PAGE sample buffer (containing SDS and BME) resulted in a dissociation of 
the proteins, which could be subsequently analyzed by western blotting. 
 Due to their harshness (SDS is used to disrupt CCR5 interaction with 2D7), 
SDS and other anionic detergents were not tested in this assay. Instead, the selection of 
detergents contained a broader representation of maltosides with alkyl or cyclic, shorter 
or longer chains connected with head groups by glyco- or thioglycosidic bonds. 2D7 
immunoprecipitated CCR5 solubilized in any of the tested maltoside detergents, 
regardless of chain length and type (Figure 3.16). Interestingly, it was not the case for 
other nonionic (C12E9) and zwitterionic (Fos-Cholines) detergents, which in the 
previous detergent screens showed to keep CCR5 in the solution (C12E9 and Fos-
Cholines) and to efficiently solubilize CCR5 from a membrane fraction (Fos-Cholines). 
These results clearly overlap with the findings of Mirzabekov (86) and Rich (87). 
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Figure 3.16 2D7 immunoprecipitation of CCR5 solubilized in various detergents. As both, 2D7 and 
anti-His-tag, antibodies were from mouse and as western blot development involved secondary anti-
mouse antibody, both CCR5 and IgG (not always) bands are present. Lane 1 (protein standards), lane 
2 (positive control), lane 3 (FC-10), lane 4 (FC-12), lane 5 (DDM), lane 6 (Cymal-5), lane 7 (Cymal-
7), lane 8 (TMP-8), lane 9 (TMP-10), lane 10 (C12E9). 
 
3.2.1.11 Effect of buffer conditions 
 To make sure the outcome of the IP assay is not dependent on other factors 
such as buffer and salt type as well as salt concentration or the stringency of membrane 
fraction washing before solubilization, 2D7 recognition was tested for membrane 
fractions washed either once or three times in two different buffers. Buffer 1A was 
composed of 20 mM negatively charged phosphate and 300 mM mono-charged NaCl 
ions. Buffer 1B contained 20 mM positively charged Tris and only 100 mM (NH4)2SO4 
dissociating into double-charged sulfate (VI) ions. Both buffers contained 10% (v/v) 
glycerol. Regardless of the conditions, 2D7 always immunoprecipitated CCR5 in 
Cymal-5 but never in FC-12 (Figure 3.17). This demonstrates that in the tested 
conditions, buffer conditions and the stringency of membrane fraction washing did not 
have an effect on 2D7 binding. 
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Figure 3.17 CCR5 immunoprecipitation with 2D7 antibody is not affected by buffer conditions and 
membrane washing. Lane 1 (protein standards), lane 2 (positive control), lane 3 (membranes washed 
1x in buffer 1B, solubilized in FC-12), lane 4 (3x, 1B, FC-12), lane 5 (1x, 1B, Cymal-5), lane 6 (3x, 
1B, Cymal-5), lane 7 (1x, 1A, FC-12), lane 8 (3x, 1A, FC-12), lane 9 (1x, 1A, Cymal-5), lane 10 
(3x, 1A, Cymal-5). 
 
3.2.1.12 Other observations 
 Following the concept of the IP experiment described above, the impact of 
several other factors on 2D7 recognition has been checked (Figure 3.18). A sample 
solubilized 4 days prior to the IP assay could not be immunoprecipitated. This could be 
a symptom of CCR5 losing its native conformation over time and/or a result of a 
proteolytic processing of the C-terminus, where His-tag (used for western blot 
development) is located. To verify the latter hypothesis, samples of solubilized 
membrane fraction were collected (and frozen) over several days of storage. Even 
though the samples were not subjected to any further processing (no IP), a decrease of 
western blot signal could be observed (data not shown). 
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Figure 3.18 Inhibition of 2D7 immunoprecipitation of Cymal-5-solubilized CCR5. After 
solubilization insect cell membrane fraction was clarified at 17000 g for 15 min (lane 2) or at 
100000 g for 20 min (lane 3) and purified on IMAC resin (lane 4). Immunoprecipitation was 
performed with: membranes solubilized 4 days before (lane 5), solubilized membranes clarified at 
17000 g for 15 min (lane 6) and at 100000 g for 20 min (lane 7), protein eluted from IMAC resin 
(lane 8). A decrease of CCR5 signal was observed when 3.33% Cymal-5 (lane 9), 1.67 M urea (lane 
10), 83.3 mM MES pH 5.5 (lane 11) or 1 M imidazole (lane 12) but not when 107 µM RANTES 
(lane 13) were added. 
 
 Secondly, the signal intensities of immunoprecipitated CCR5 after 
centrifugation at 17000 g for 15 min and at 100000 g for 20 min are very similar, which 
suggests that clarification using a tabletop centrifuge (17000 g, used for small volumes) 
and ultracentrifuge (100000 g, used for preparative scale) gives a comparable result. 
This conclusion holds upon making an assumption that in this assay 2D7 binding sites 
were in excess. 
 Thirdly, IMAC-purified CCR5 eluted with imidazole did not 
immunoprecipitated with 2D7, the same as unpurified CCR5 supplemented with 
imidazole, suggesting that imidazole inhibits CCR5 and 2D7 interaction. In a similar 
way CCR5:2D7 interaction was also inhibited by high concentrations of detergent, urea 
and by a pH decrease. Interestingly, inclusion of RANTES had only a moderate effect. 
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CCR5 size distribution and stability 
 Structural biology requires stable and homogenous samples. Although, 
monodispersity is an important and desirable parameter of a good sample for structural 
studies, many GPCRs are known to form dimers and higher oligomers. It is a matter of 
debate if, which and to what extent GPCR oligomers are physiological functional units 
or a result of biologically irrelevant interactions. The oligomerization behavior of 
GPCR may depend on the environment such as cell type, expression level, lipid 
composition, ligands, other proteins, etc. Artificial environment of detergent micelles 
may strongly affect (inhibit or promote) oligomerization. Sometimes chaotic 
oligomerization behavior may be a symptom of poor sample stability. 
 The size and oligomeric state of insect cell-expressed CCR5 was investigated 
by SEC (Figure 3.4) and DLS (Figure 3.19). Judging from the band pattern on SDS-
PAGE (Figure 3.3) or western blot (Figure 3.2), the CCR5 sample was composed of 
monomers, dimers (dominant) and higher oligomers (trimers and tetramers). SEC 
column was calibrated using standard globular proteins and from the calculated 
standard curve it could be estimated than CCR5 monomeric and dimeric micelles are 
~120 and 233 kDa, respectively. Values obtained form SLS measurement were 
somewhat smaller but in the same range, 94 kDa for monomer and 160 kDa for dimer. 
 
 
Figure 3.19 Dynamic light scattering with various CCR5 samples. 
 
 As for SEC sample usually needs to be concentrated enough to be detectable by 
UV and is subsequently heavily diluted during the run, conclusions about the initial 
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oligomeric state have to be drawn with care. In other words, if oligomerization is a 
concentration derivative of a sample being in an equilibrium, it is difficult to state what 
protein (and detergent) concentration does a certain elution profile represent. Hence, 
being more interested in detecting than in the absolute particle sizes, we have turned to 
DLS, which is a noninvasive technique enabling particle sizing directly in a sample 
volume. Figure 3.19 shows that it is possible to differentiate between empty micelles, 
CCR5 monomers, dimers and oligomers and that upon concentration the average 
particle size increases. It could also be indirectly shown that, at least to some extent, 
CCR5 oligomerization/aggregation is a result of disulphide bridge formation by 
reactive cysteines. Average particle size of CCR5 sample increased upon concentration 
and over time (Figure 3.20A). This effect was much less pronounced when reduced Cys 
were overreacted with tetramethylrhodamine (Figure 3.20B). 
 
 
Figure 3.20 Average CCR5 particle size increases upon sample concentration and storage (A) and to 
much extent after blocking cysteines (B). 
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Construction of C-terminally truncated CCR5 
 The observation that CCR5 aggregates in a cysteine-dependent manner led us to 
the conclusion that CCR5 sample stability may benefit from removing some of the 
cysteine residues from the CCR5 sequence. After learning from MS analysis that C-
terminal cysteines most likely are not palmitoylated, their removal became a logical 
first step. The C-terminal truncation appeared a better solution than mutagenesis as it 
also removes a large stretch of the unstructured C-terminus, which would have to be 
removed anyway, when crystallization trials were considered. 
 Based on the available CCR5 membrane topology prediction presented by 
Oppermann (88) two versions of C-terminal CCR5 truncation were designed (Figure 
3.21). As according to the proposed topology helix 7 ends at Trp300 and helix 8 is not 
predicted, in the first version of the C-terminus truncation CCR5 sequence ends at 
Asn306. In the second version the sequence continues for another 13 amino acids 
passing hydrophobic stretch YLLVFF and ending on Arg319, which is the last polar 
residue before a cysteine cluster. In order to improve the purification on Ni-NTA resin 
(enhance purity by more rigorous washing) the His-tag was extended from 6 to 10 
histidines. These two truncation constructs we subsequently expressed in both insect 
cells, where they were used to study CCR5 oligomerization (Sébastien Morin, 
unpublished data) and E. coli (see Chapter 4). For the expression in insect cells, an 
eight residue Strep-tag sequence WSHPQFEK was included at the very end to allow for 
an additional optional Strep-Tactin affinity purification. A list of the new CCR5 
constructs for insect cell expression can be found in Table 3.2. 
 After the CXCR4 structure was published, we have made a CCR5 homology 
model, from which a topology prediction could be derived (see Chapter 4). Our model 
predicts also a potential helix 8. This would mean that the position of the Asn306 
truncation unfortunately lies in the middle of the α-helical stretch. However, as helix 8 
was not always present in the crystallized GPCRs including CXCR4, it is unlikely that 
such truncation would affect the overall structure of the receptor.  
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Figure 3.21 Two versions of the C-terminally truncated CCR5 construct designed based on 
Oppermann’s CCR5 topology (88) but depicted on the topology derived from our homology model, 
which is based on the CXCR4 X-ray structure (23). The potential helix 8 was marked by dashed 
lines. 
 
Table 3.2 List of CCR5 constructs cloned for insect cell expression. Constructs 2 and 3 are new. The 
constructs were used to study CCR5 oligomerization (Sébastien Morin, unpublished data). 
No. Name Length Mutations C-terminal Tags 
1 CCR5 1-352 wild type His6-tag, Strep-tag 
2 m2CCR5306 1-306 C58S, C224S His10-tag, Strep-tag 
3 m2CCR5319 1-319 C58S, C224S His10-tag, Strep-tag 
 
Preliminary SPR studies 
 SPR is a very robust and sensitive method to study protein interactions. 
Remarkably low sample requirements (picograms), no necessity of extensive 
purification or isotope labeling make SPR a widely applicable tool in the GPCR field, 
where obtaining large amounts of pure labeled material is often challenging. Studying 
protein-protein or even protein-drug interactions, screening for solubilization and 
crystallization conditions are only some of the wide variety of SPR applications (89-
91). 
 For our purposes SPR was used to check CCR5 sample quality (interaction with 
2D7) and to study its interaction with RANTES. Due to the high aggregation tendency 
of the wild type RANTES, less aggregating RANTES-E66S was chosen. First, the 
purified CCR5 was immobilized on Ni-charged NTA chip via its C-terminal His-tag 
(Figure 3.22). Each CCR5 injection resulted in an increase of SPR signal caused by the 
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presence of the immobilized receptor. The amplitude of each consequent increase was 
smaller than the previous one, which is a symptom of saturating the binding sites. 
 
 
Figure 3.22 Immobilization of the FC-12-solubilized purified CCR5 (266 nM) on Ni-charged NTA 
chip. Each of the three injections cause a baseline increase, first ∼690 RU, second ∼340, third ∼170 
(green lines). The sudden signal jumps in the beginning and in the end of the injections are caused 
by a buffer mismatch (red lines). 
 
 No 2D7 binding could be observed for CCR5 in FC-12, which overlaps with 
the results of the IP assays. Subsequently, 500 nM RANTES-E66 solution was injected. 
An increased of SPR signal was observed in both reference (Ni-NTA) and sample (Ni-
NTA with immobilizaed CCR5) channels (Figure 3.23A). As the reference and the 
sample channels are aligned sequentially (sample channel after reference channel), the 
sample channel experiences a decreased initial RANTES-E66 concentration and 
initially the net signal (sample channel – reference channel) is negative (Figure 3.23B). 
When the reference channel saturates, the net signal becomes positive because the 
RANTES-E66S dissociation rate from the sample channel (with CCR5) is slower than 
from the reference channel. Unspecific RANTES-E66S adsorption to the reference 
channel results in the fact that the binding curve is a sum of two separate interaction 
events (RANTES-E66S to the Ni-charged NTA chip and RANTES-E66S to the Ni-
charged NTA chip with immobilized CCR5) and cannot be fitted and interpreted as a 
single RANTES-CCR5 binding event. 
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Figure 3.23 Binding of 0.5 µM RANTES-E66S to FC-solubilized purified CCR5 immobilized on 
Ni-charged NTA chip. (A) Separate signals from the reference (black curve) and the sample (red 
curve) channels. (B) Net signal (blue curve) signals is a result of subtraction of the reference channel 
signal from the sample channel signal. 
 
 To investigate the unspecific RANTES-E66S binding to the the Ni-charged 
NTA chip, several difference salt and pH conditions were tested (Figure 3.24). As 
before, a strong RANTES-E66S adsorption was observed at 150 mM NaCl pH 7.4. An 
increase of NaCl concentration fro 150 to 300 mM resulted in significant reduction of 
the unspecific binding. The increase of pH from 7.4 to 8.6 had a similar but much 
smaller effect. Further increase of NaCl concentration further decreased unspecific 
interaction up to bearly detectable level at 800 mM pH 7.4 or even at 500 mM pH 8.6. 
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Figure 3.24 Unspecific RANTES-E66S (10 µM) interaction with Ni-charged NTA chip is salt- and 
pH-dependent. 
 
3.3 Discussion 
 Due to its direct involvement in HIV infection and other diseases CCR5 is a 
natural drug target. However, as CCR5 is also involved in immune system regulation, 
targeting it with drugs requires high precision and selectivity. For this reason a three 
dimensional CCR5 structure is highly desirable, since it would reveal atomic details of 
the CCR5 molecular architecture and the mechanism of the interaction with ligands. 
 To study CCR5, an insect cell-based expression system was previously 
established in our laboratory (82). It typically provided ∼1 mg of CCR5 after two step 
purification per 1L of insect cell culture. FC-12 was selected for CCR5 solubilization as 
it gave the most homogenous population of particles as judged by EM negative staining 
and supported 2D7 recognition as judged by IP assay. In this work we sought to 
characterize our CCR5 production platform in more detail, polish the protocols towards 
the higher yield and purity and study CCR5 interactions with ligands. 
 First, the concentrations of imidazole used for Ni-NTA purification were 
optimized in a way such that maximum amount of CCR5 and minimum amount of 
contamination are bound, that no CCR5 is lost during washing and that elution is 
efficient and complete. For the Ni-charged Chelating Sepharose resin from GE 
Healthcare and 6His-tag CCR5 these conditions translate to about 20 mM imidazole for 
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binding, 40 mM for washing and 400 mM for elution. For the Strep-Tactin purification 
the D-desthiobiotin concentration used for elution was doubled to 5 mM as 2.5 mM 
was not sufficient to fully and efficiently elute all bound CCR5. It was also noticed that 
plenty of CCR5 remains unsolubilized and an increase of detergent:protein ratio during 
solubilization (from 1% to 1.5-2.5%) boosts the yield. All these modifications together 
doubled or even tripled the final yield of purified CCR5 (maximum 3.2 mg/L) and 
enabled us to fully take adventage of the established CCR5 insect expression system. 
 To increase the purity, the biggest CCR5 contamination observed on SDS-
PAGE gels was analyzed by mass spectroscopy and identified as Hsc70, which is a 
ubiquitously expressed heat shock protein, a chaperone that constitutes an important 
element of protein folding machinery. As Hsc70 binds hydrophobic sequences (e.g. 
CCR5) in an ATP-modulated manner (binding is reversible in ATP-bound state), it 
could be successfully depleted by the inclusion of magnesium ions and ATP in the Ni-
NTA washing buffer. However, the fact that it interacts with CCR5 may indicate that 
the receptor is recognized by insect cell as misfolded protein and/or it experiences some 
folding problems. Perhaps it is also one of the reasons that CCR5 cannot be efficiently 
and stably solubilized by maltoside detergents (described later). 
 The expression in an alternative insect cells strain High Five was explored and 
compared to the expression in Sf21. Both the yield and the purity of the CCR5 purified 
from each strain were comparable, with a little bit lower Hsc70 contamination of High-
Five expressed receptor. The monomer:dimer ratio was a bit higher for High Five but 
within a batch to batch variability. 
 Based on the calibration of the size exclusion column with standard proteins it 
could be calculated that CCR5 dimer and monomer migrate as spherical particles of 
∼233 and ∼120 kDa, respectively. The values obtained by SLS are a bit smaller but 
within the same range, ∼160 for dimer and ∼94 kDa for monomer. The sizes obtained 
previously by Nisius are smaller: 130 and 75 kDa (82), which after careful inspection is 
likely to be a result of the incorrect SLS device setup (wrongly typed UV extinction 
coefficient of CCR5, that is 7.110e+2 instead of 1.420e+3 mL/[g×cm]). This seems to 
be confirmed by the fact that the retention volumes of CCR5 dimer and monomer peaks 
in Figure 3.25 overlap with the CCR5 chromatogram by Nisius (82), which suggest that 
the CCR5 particle sizes must have been very similar indeed. 
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Figure 3.25 Overlay of the CCR5 chromatogram from Figure 3.4 with the chromatogram presented 
by Nisius (82). The proportions of the chromatogram has been modified to match both scales. 
 
 The function of CCR5 in native tissues requires several PTMs. Eukaryotic 
systems such as insect cells are much closer to human than E. coli and are expected to 
process proteins in a similar way. To investigate the quality of PTMs of the CCR5 
expressed in our Sf21 system MS analysis was performed. The measured whole 
construct mass of 42633.9 kDa is however only slightly (∼275 Da) higher than the 
monoisotopic mass of the CCR5 construct (42359.1 Da), which is by far not sufficient 
to accommodate the C-terminal palmitoylations. To enhance the resolution of the MS 
analysis the peptides resulting from CCR5 trypsinolysis were analyzed and also no 
modifications could be found on the identified N- and C-terminal CCR5 peptides. In 
addition, it could be solely proven that the N-terminus is acetylated, which was a 
unexpected modification. However it cannot be completely excluded that some of the 
more fragile modifications e.g. sulfation may be removed during sample processing and 
the presence and amount of PTMs is probably to some extent batch to batch dependent, 
in general, the results were a bit disappointing. This shows that even eukaryotic 
systems such as insect cells have to be carefully inspected for their ability to perform 
the expected human-like PTMs. 
 Based on the CD analysis, the spectrum of FC-12-purified CCR5 exhibited a 
characteristic double minima shape, which means that the sample is abundant in α-
helical secondary structure. Based on the mean residue molar ellipticity at 222 nm it 
could be estimated that α-helical contents of purified CCR5 is 43%. This value is close 
to ∼50% expected from a typical GPCR (92, 93) and confirms that the FC-12-purified 
CCR5 is, at least based on CD, reasonably well folded. The subsequent thermal 
denaturation showed that during heating both features of the CCR5 spectrum: the shape 
and the amplitude are irreversibly lost. CCR5 undergoes a broad transition, which starts 
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already around 10°C, which suggests that at the tested conditions the receptor is 
unstable. As melting temperature of CCR5 has not been reported in the literature to 
compare with, such low thermal stability may be either a natural property of the 
receptor or a symptom of nonoptimal solubilization conditions. 
 To search for better surfactants large-scale detergent screening was performed. 
The selection of a suitable detergent is an important and often a challenging issue in 
membrane protein research. A suitable detergent: 
- should solubilize (destroy) the membrane but should not affect (denature) 
the protein (its structure and function), 
- should keep the protein soluble and prevent aggregation but should not 
interfere with crystallization, 
- should provide enough of hydrophobic environment such that protein 
function is maintained but should produce small, homogenous, well 
tumbling micelles for NMR, etc. 
In practice, fulfilling all these criteria at the same time is often difficult, especially 
when it comes to more complex and fragile systems like for example mammalian 
membrane proteins. 
 In the case of CCR5 it turns out particularly challenging to find one universal 
detergent that would fulfill all the expectations. Performed detergent screening revealed 
several promising candidates able to solubilize CCR5 from the membrane fraction and 
keep the receptor in solution. As shown by two independent assays anionic (SDS, 
SDDSAR) and zwitterionic detergents (especially Fos-Cholines) are effective at CCR5 
solubilization and keeping in solution to facilitate efficient purification. Unfortunately, 
as shown by IP, in these detergents CCR5 cannot be recognized by 2D7 antibody. 
Although it cannot be completely excluded that these detergents perturb the structure of 
2D7 itself or that they specifically block the CCR5-2D7 interaction site, it is a certain 
hint that the native tertiary CCR5 structure may not be maintained in FC-12. This does 
not contradict the α-helical secondary structure of the FC-12-purified receptor observed 
by CD, because in the case of the latter the relative orientation of the helices cannot be 
assessed. 
 On the other hand, when CCR5 is solubilized in detergents with a maltose head 
group, CCR5-2D7 interaction takes place. As shown in Figure 3.16 and Figure 3.17 the 
type (aliphatic or cyclic) and the length of the hydrocarbon chain and the type of buffer 
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do not affect the outcome in a major way. These results coincide with the work of 
Mirzabekov, who with IP reported CCR5 recognition by 2D7 in Cymal-5 but not in 
FC-14 (86) and with the work of Navratilova (91) and Rich (87), who studied CCR5-
2D7 interaction using SPR but not with the work of Nisius (82), where using IP 2D7 
recognition was reported in FC-12. In the case of the latter, in turned out that detergent 
was erroneously omitted during washing, which resulted in a false positive. This shows 
that for IP assays, where precipitation is virtually indistinguishable from pull-down 
effect, ensuring conditions favoring good protein solubility (also enough detergent in 
case of membrane proteins) throughout the entire procedure is a key issue. 
 Having observed that FC-12 may in some way affect CCR5 native 
conformation we have extensively explored the possibility to solubilize and purify 
CCR5 in maltoside detergents. The emphasis was put on DDM as it is the most popular 
and successful detergent in three dimensional structure determination of membrane 
proteins. Unfortunately, DDM failed to efficiently solubilized CCR5 from the insect 
membrane fraction, yielding only 20-40% of the amount purified in FC-12. In addition, 
the receptor stability and purity were not satisfactory for further biophysical 
experiments. Similar results (low yield and purity, poor stability) were achieved when 
FC-12 to DDM exchange was performed on the column (Ni-NTA or Strep-Tactin) as 
well as when other members of maltoside family were used (TMP-8, TMP-9, TMP-10, 
TMP-12, MP-6, MP-11, MP-13). 
 Last but not least it could be observed that CCR5 aggregates over time and 
upon concentration in a cysteine-dependent manner. This means that some of the 
cysteines are reactive and persuaded us to eliminate the most likely not palmitoylated 
cysteines 321, 323 and 324 by a C-terminal truncation. For this purpose, based on the 
CCR5 topology available at that time (88), two C-terminal CCR truncation variants 
were designed with Asn306 and Arg319 being the last CCR5 residues (Figure 3.21). 
These constructs were later used both in insect cell and E. coli expression systems. 
However, it could be shown that even the C-terminally truncated CCR5 with 
additionally mutated C58S and C224 were still prone to aggregation (Sébastien Morin, 
unpublished data), which may indicate that, at least to some extent, the extracellular 
cysteines may not be fully oxidized into disulphide bridges. Perhaps this CCR5 
population is the same as the one, which co-purifies with the cytoplasmic Hsc70. 
 To check the quality of CCR5 samples and to study its interaction with ligands 
we turned to SPR. Using nickel-charged NTA chip CCR5 could be efficiently 
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immobilized via its C-terminal His-tag. No 2D7 binding could be observed for the FC-
12-purified CCR5, which confirms the outcome of the IP assay. Interaction with 
RANTES-E66S was observed for both: the reference and the sample channel and 
subsequently using a single channel it was shown that RANTES-E66S exhibits a strong 
electrostatic affinity to Ni-NTA sensor chip. This observation was a clear indication 
that functionalized with negatively charged groups NTA chip is not suitable to study 
interaction with positively charged RANTES and became a starting point for an 
antibody-based immobilization system, which was established and successfully used by 
Sébastien Morin to understand the details of CCR5 interaction with various RANTES 
variants (see Chapter 6). 
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Abstract The CC chemokine receptor 5 (CCR5) is an 
integral membrane protein belonging to the class of G 
protein-coupled receptors (GPCRs). It plays a crucial role 
in the regulation of leukocyte trafficking and effector 
function. Furthermore, it is the major HIV-1 coreceptor 
and therefore a target for virus entry inhibitors. Here, we 
report E. coli expression and a broad range of biophysical 
studies on E. coli-produced CCR5. After systematic 
screening and optimization, we obtained 10 mg of 
purified, detergent-solubilized, well folded CCR5 from 1 
L culture in a triple isotope-labeled (2H, 15N, 13C) minimal 
medium. Thus the material is suitable for NMR 
spectroscopic studies. The expected α-helical secondary 
structure content is confirmed by CD spectroscopy. The 
solubilized CCR5 is monodisperse and homogeneous as 
judged by transmission electron microscopy (TEM). 
Interactions of CCR5 with its ligands, RANTES and MIP-
1β were assessed by surface plasmon resonance (SPR) 
yielding a KD in the nanomolar range. Using size 
exclusion chromatography, stable monomeric CCR5 could 
be isolated. We showed that cysteine residues affect both 
the yield and the oligomeric distribution of CCR5. HSQC 
spectra suggest that the transmembrane (TM) domains of 
CCR5 are in equilibrium between several conformations. 
Our robust and efficient E. coli expression system 
overcomes numerous technical bottlenecks and can be 
used for a wide range of biophysical and structural studies 
on GPCRs. We also present a model of CCR5 based on the 
crystal structure of CXCR4 as a useful starting point for 
CCR5 engineering. 
 
Keywords CCR5; G protein-coupled receptor; Expression 
in E. coli; NMR; homology modeling 
 
Introduction 
 
G protein-coupled receptors constitute a large protein 
superfamily found only in eukaryotes. About 4% of the 
protein-coding human genome codes for ~800 GPCRs (1). 
Based on phylogenetic analysis human GPCRs cluster into 
5 main families: rhodopsin, adhesion, frizzled/taste2, 
glutamate and secretin which comprise 701, 24, 24, 15 and 
15 members, respectively (2). The diversity of the GPCR 
superfamily members is reflected in the variety of their 
ligand types. Photons, ions, odorants, nucleotides, fatty 
acids, amino acids, peptides and proteins are only some of 
the messages that GPCRs can transduce (3). As GPCRs 
regulate so many physiological processes such as vision, 
smell, behavior, mood, immune system, blood pressure, 
heart rate, digestion or homeostasis, they remain the most 
commonly drugged protein family (4). About 40% of 
prescribed pharmaceuticals target GPCRs (5). 
The structure determination of membrane proteins is 
notoriously difficult due to the many obstacles impeding 
membrane protein sample preparation and subsequent 
structure determination. When this publication was written 
about 82000 entries appeared in the Protein Data Bank (6) 
but only as few as 335 unique membrane protein 3D 
structures were known (7). GPCR structures are even 
sparser. The first, bovine rhodopsin, was solved in 2000 by 
Palczewski et al. (8), and until now 12 more unique GPCR 
structures were solved by X-ray crystallography: β2-
adrenergic (9, 10), β1-adrenergic (11), adenosine A2A (12, 
13), dopamine D3 (14), CXCR4 (15), histamine H1 (16), 
M2 muscarinic acetylcholine (17), M3 muscarinic 
acetylcholine (18), S1P1 lipid (19), µ-opioid (20), κ-opioid 
(21) and δ-opioid (22) receptors. To obtain high-resolution 
structural data the replacement of the intracellular (IC) 
loop 3 with T4 lysozyme (9, 12, 14-22), 
thermostabilization (11, 13-15) or stabilization with anti- 
or nanobodies (9) proved to be successful strategies. 
Additionally, all crystallized GPCRs were bound to an 
agonist (13), an inverse agonist (9, 10, 18) or most often to 
an antagonist (11, 12, 14-17, 19-22). Although, not 
GPCRs, prokaryotic sensory rhodopsin II (23) and 
proteorhodopsin (24) are examples of a 7-TM domain 
proteins solved by NMR spectroscopy. 
The CC chemokine receptor 5 (CCR5) belongs to the 
γ-group of the rhodopsin family of GPCRs. It is found in 
the plasma membrane of Th1 lymphocytes, macrophages, 
NK cells and immature dentritic cells and is involved in 
various infectious and inflammatory diseases as well as 
cancer (25). Since humans carrying the Δ32 allele of the 
CCR5 gene, a 32-base pair deletion resulting in a 
premature stop codon in the extracellular (EC) loop 2 and 
a nonfunctional receptor, are healthy, the exact role of 
CCR5 is not completely understood. 
The main interest in CCR5 is, however, a consequence 
of its involvement in AIDS. R5-tropic HIV-1 infection 
necessitates the sequential interaction of viral envelope 
glycoprotein gp120 with CD4 and CCR5 (26). Two copies 
of the CCR5-Δ32 allele confer nearly complete resistance 
to HIV-1 infection (27, 28). Δ32 occurs at 5-14% 
frequency in European Caucasians but not in African, 
Native American, and East Asian populations (29), which 
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is a result of a selective pressure of the epidemics of 
plague, a viral haemorrhagic fever, that took place in 
Europe in medieval ages (30). Successful strategies to 
block HIV entry have been developed based on small-
molecule inhibitors of CCR5 (31) as well as derivatives of 
its natural chemokine ligand RANTES (32-35). 
High-resolution structural data would greatly improve 
the understanding of CCR5 function and the nature of its 
interaction with the chemokine ligands RANTES, MIP-
1α, and MIP-1β, as well as substantially enhance 
possibilities for anti-HIV drug discovery. So far it has 
been very challenging to obtain sufficient amounts of this 
protein suitable for structural studies. Large-scale CCR5 
expression at the yield of 1 mg/L was reported in insect 
cells (36) where screening for mutants is time-consuming 
and isotope labeling is very costly and has not been 
achieved for deuterium. 
Alternatively, 1-3 mg/L of CCR3 but only 0.1-0.3 
mg/L of CCR5 was obtained from E. coli after fusing the 
N-terminus of the chemokine receptor to the C-terminus of 
thioredoxin (37). However, the described expression 
system required the usage of rich TB medium, where the 
yields are usually higher than in minimal media necessary 
for the isotope labeling. Furthermore, ligand binding of the 
expressed chemokine receptors was not shown. However, 
there is a growing number of GPCRs expressed in E. coli 
(38-44), for which ligand binding could be shown as a test 
for functionality. Petrovskaya et al. recently compared 
direct expression of 17 diverse GPCRs in E. coli to hybrid 
expression with the N-terminal fusion partners OmpF or 
Mistic (45). Interestingly, almost all GPCRs expressed in 
the presence of a fusion partner at >5 mg/L yield, but for 
most the expression was severely reduced in its absence. 
Here we report a CCR5 production platform that yields 
up to 10 mg of purified protein per 1 L of bacterial culture. 
CCR5 is solubilized from E. coli without the requirement 
of refolding. As the expression conditions were optimized 
in minimal medium, triple isotope (2H/13C/15N) labeling 
does not compromise the yield. In order to boost the 
expression, we fused the N-terminus of CCR5 to well 
expressing small proteins or signal sequences. A C-
terminal 10His-tag and rigorous washing conditions yield 
over 90% purity after a single IMAC purification step. The 
fusion partner can be readily and quantitatively cleaved off 
by thrombin and separated on a size exclusion column, 
where CCR5 monomers and dimers migrate as separate 
symmetric peaks. Both monomers and dimers are 
monodisperse and homogeneous as judged from electron 
micrographs. The expected α-helical secondary structure 
content is confirmed by circular dichroism (CD) 
spectroscopy. Purified CCR5 interacts with RANTES and 
MIP-1β with nanomolar affinities. Recorded 1H-15N 
HSQC spectra suggest that the TM domains of CCR5 are 
in equilibrium between several conformations. Our system 
establishes a robust platform for biophysical and structural 
studies on CCR5. Due to the high yield and the possibility 
of isotope labeling it is suitable for both X-ray 
crystallography and NMR. We also show that the number 
of cysteine residues has a severe impact on both protein 
yield and oligomeric state. Following Hernanz-Falcón et 
al. (46) two point mutations I52V and V150A were 
introduced to reduce the tendency of dimer formation, but 
no reduction was observed. 
 
 
Material and methods 
 
Generation of expression constructs 
 
Plasmids pET28F10 and pMT10H10 containing the 
CCR2b sequence fused to OmpF and Mistic were a 
generous gift from Prof. A. Arseniev (Russian Academy of 
Sciences, Moscow, Russia). Plasmid pCA528 was kindly 
provided by Prof. A. Spang (Biozentrum, Basel, 
Switzerland). pET vectors were obtained from Novagen. 
The E. coli-optimized CCR5 DNA sequence in the pQE-
T7 vector was generated by GeneArt. The CCR5 gene was 
cloned using standard molecular biology techniques. 
Plasmid DNA was amplified with the QIAprep Spin 
Miniprep Kit (Qiagen). Point mutations were carried out 
using the QuikChange II XL Site-Directed Mutagenesis 
Kit (Agilent Technologies). 
 
Protein expression 
 
Freshly transformed Rosetta 2(DE3) Competent Cells 
(Novagen) were transferred to 1-2 L of M9 medium after 
overnight growth on LB agar plates. The cultures were 
shaken in 5 L baffled flasks at 100 rpm at 37°C until 
OD600=2.6-2.8. The culture was cooled down on ice with 
occasional shaking until the temperature dropped to 20-
25°C. Bacteria were induced with 1 mM IPTG and were 
shaken at 100 rpm at 20°C. After harvesting, cells were 
pelleted and stored at -70°C. 
For expression in D2O transformed cells were grown 
on LB agar plates prepared in 50% D2O. 1-2 L cultures 
were preceded by 100 mL precultures grown until 
OD600=1. All compounds used in the preparation of M9 
medium in D2O (including trace elements, vitamins, 
antibiotics) were prepared in D2O. Uniform 15N- and 13C-
labeling was carried out using 15NH4Cl (1 g/L), and 13C6-
glucose (4 g/L) as the sole nitrogen and carbon sources, 
respectively. Details of the M9 medium composition can 
be found in Text S1. 
 
Membrane fraction preparation 
 
Frozen E. coli cell pellet (1 g) was suspended in 6-8 mL of 
buffer A (20 mM HEPES pH 7, 150 mM NaCl, 10% (v/v) 
glycerol) supplemented with 0.5 mM PMSF, 5 mM 
benzamidine and EDTA-free complete protease inhibitor 
cocktail (Roche). Cells were broken using a French press 
at 31600 psi. Cell debris was removed by centrifugation at 
6600 g for 15 min. The supernatant was centrifuged at 
126000 g for 15 min, and the resulting pellet (from now on 
called membrane fraction) collected. After suspending in 
buffer A, a 20% (w/v) solution of the membrane fraction 
was stored at -70°C. 
 
Detergent screening 
 
Frozen 20% (w/v) solutions of membrane fraction were 
thawed, diluted twice and supplemented with detergent to 
the final concentration of 2%. Solubilization was carried 
out at RT for 2 h with 1000 rpm shaking. Unsolubilized 
material was removed by centrifugation at 100000 g for 30 
min. The clarified supernatant (2 µL) was loaded onto a 
Protran BA85 nitrocellulose membrane (Whatman) and 
dried at RT. Dot blots were blocked, labeled with anti-His-
tag antibody, developed and quantified in the same way as 
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western blots described below. Detergents were obtained 
from Anatrace with the exception of DHPC (1,2-
Diheptanoyl-sn-Glycero-3-Phosphocholine, Avanti Polar 
Lipids). 
 
Protein purification 
 
A frozen 20% (w/v) solution of membrane fraction was 
thawed and supplemented to a final concentration of 0.5 M 
NaCl, 20 mM KCl, 10 mM MgCl2 and 2.5% FC-12. 
Protein solubilization was carried out at 4-8°C for 1-2 h. 
Unsolubilized material was removed by centrifugation at 
126000 g for 30 min. The clarified supernatant was 
supplemented with 35 mM imidazole and bound to Ni-
NTA beads (Qiagen) for 2 h. The resin was washed with 
100 column volumes of buffer B (20m M HEPES pH 7, 1 
M NaCl, 60 mM imidazole, 10% (v/v) glycerol, 0.1% FC-
12). The protein was then eluted with buffer C (20 mM 
HEPES pH 7, 150 mM NaCl, 0.4 M imidazole, 0.15% FC-
12). Protein-rich fractions were pooled and dialyzed 
against buffer D (20 mM Tris pH 8, 150 mM NaCl, 0.5 
mM EDTA, 0.1% FC-12). To cleave the fusion partner, 2 
U of thrombin per 1 mg of purified protein was sufficient 
to complete the cleavage over 16 h at RT. The protein was 
concentrated using 30 kDa molecular weight cut off 
(MWCO) concentrator and injected onto Superdex 200 
10/300 GL (analytical run) or Superdex 200 26/60 HiLoad 
(preparative run) columns equilibrated in buffer E (20 
Na2HPO4 pH 7.4, 180 mM NaCl, 0.1% FC-12). 
 
Gel electrophoresis and western blotting 
 
Protein samples for SDS-PAGE were mixed with 5x SDS 
loading buffer (312.5 mM Tris-HCl pH 6.8, 50% (v/v) 
glycerol, 25% β-mercaptoethanol, 10% SDS, 0.0125% 
bromophenol blue), incubated at 30°C for 15 min and 
centrifuged at 17000 g for 5 min prior to loading on a 4-
20% gradient precast gel (Pierce). The electrophoresis was 
performed at 100 V constant voltage. Gels were stained 
using 0.25% solution of Coomassie Brilliant blue R-250 
(AppliChem) in 25% isopropanol and 10% acetic acid and 
destained in 10% acetic acid. 
For western blotting onto PVDF membrane (Bio-Rad), 
a Criterion Blotter (Bio-Rad) was used. The transfer was 
performed at 0.5 A constant current for 1 h in the transfer 
buffer (48 mM Tris-HCl pH 9.2, 39 mM glycine, 0.375% 
SDS, 20% methanol). The membrane was blocked with 
3% BSA in TBST buffer (10 mM Tris-HCl pH 8, 150 mM 
NaCl, 0.5% Tween-20). Subsequently the membrane was 
incubated with mouse monoclonal HIS-1 anti-
polyhistidine-peroxidase antibody (Sigma-Aldrich) at 
1:6000 dilution for 1 h. After washing 4 x 2 min with 
TBST buffer, the blot was developed using 
chemiluminescent HRP substrate (Roche). The signal was 
recorded using a BioMax XAR Film (Kodak) or using a 
LAS-4000 luminescent image analyzer (Fujifilm). The 
signal intensities were quantified using the ImageJ 1.43r 
(62). 
 
Transmission electron microscopy (TEM) 
 
For TEM analysis 5 µL of 10 µg/mL protein solution was 
adsorbed on carbon-coated copper 200 mesh grids 
rendered hydrophilic by glow discharge in air during 20 s. 
The grids were washed in five drops of double distilled 
water and negatively stained with two drops of 2% uranyl 
acetate. Electron micrographs were recorded on a Philips 
CM10 instrument equipped with a LaB6 filament 
operating at an accelerating voltage of 80 kV. Images were 
recorded at nominal defocus values of 0.5 µm on a Veleta 
CCD camera at a nominal magnification of 130000x, 
corresponding to a pixel size of 3.7 Å at the sample level. 
 
Circular dichroism spectroscopy 
 
CD spectra were recorded on 3-13 µM monomeric CCR5 
fractions. Measurements were performed on a Chirascan 
CD spectrometer (Applied Photophysics) at 20°C in 1 mm 
quartz Suprasil cuvettes (Hellma). Typically, spectra in a 
wavelength range of 195-260 nm spectra were recorded in 
triplicates and averaged. After baseline (buffer) 
subtraction, the mean residue molar ellipticity ΘMRM was 
calculated from the following equation ΘMRM=Θ/(C×n×l), 
where Θ is the ellipticity (deg), C is the concentration 
(mol/L), n is the number of residues and l is the optical 
path length (cm). The α-helical contents α% was 
calculated as follows α%=(-ΘMRM, 222nm+3000)/39000 (63), 
where ΘMRM is given in units of deg×cm2×dmol-1. 
 
Surface Plasmon resonance (SPR) 
 
Interaction assays were performed using a T100 Biacore 
instrument (GE Healthcare). The setup consisted of a CM5 
chip on which an antibody against the His-tag (Qiagen) 
was immobilized, using amine coupling chemistry. The 
antibody (4000-10000 RU) could capture ~2000-5000 RU 
of recombinant His-tagged CCR5, solubilized from 
membranes using a detergent mixture of 1% DDM, 1% 
CHAPS, 0.2% CHS, and 1 mM DOPC at pH 7. 
Thioredoxin removal was performed on the chip using 5 U 
of thrombin injected in 300 µL over 60 min (5 µl/min) at 
20°C. Experiments were performed in the buffer F (20 
mM HEPES pH 7.0, 150 mM NaCl, 0.1% DDM, 0.1% 
CHAPS, 0.02% CHS, 50 nM DOPC, 0.1 mg/mL BSA) 
with a flow rate of 50 µl/min. Signals were processed with 
the Biacore T100 Evaluation Software using double 
referencing with both a reference channel and blank 
injections. 
 
Nuclear magnetic resonance (NMR) 
 
CCR5 (monomeric fraction) produced in isotope 
labeled M9 medium was concentrated in 30 kDa MWCO 
Ultracel-30K Amicon Ultra Centrifugal Filter (Millipore) 
to ∼100 µM concentration. The sample was supplemented 
with 5% D2O for locking and transferred to a Shigemi 
tube. HSQC spectra were recorded at 15-35°C on a Bruker 
DRX800 spectrometer equipped with a triple resonance Z-
gradient TCI cryoprobe. For indirect (nitrogen) dimension 
63 increments for a total time of 25.2 ms and for direct 
(proton) dimension 512 points for a total time of 40 ms 
were collected. Spectra were processed using NMRPipe 
3.0 (64). 
 
CCR5 model building 
 
The core of CCR5 (residues 19–298) was built using the 
SWISS-MODEL server 
(http://swissmodel.expasy.org/workspace) with the crystal 
structure of CXCR4 (3ODU(15), 32% sequence identity) 
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as a template. At the C-terminus of CCR5, helix H8 
modeled based on the rhodopsin structure 3C9L (49) was 
added using VMD 1.9 (65). In addition, the N-terminus of 
CCR5 (residues 1–18) and another part of the C-terminus 
including palmitoylated cysteines (residues 312–331) were 
added as an extended amino acid chain. Residues 332-352 
were not included to reduce computational time for energy 
minimization. Finally, sulfate groups were added to Tyr10 
and Tyr14 as well as palmitoyl groups to Cys321, Cys323 
and Cys324. 
After each manipulation step the structure was energy-
minimized and relaxed by a short molecular dynamic 
simulation (MD) run using NAMD 2.7 (66). For these MD 
runs the protein was embedded in a lipid bilayer of 137 
POPC molecules, hydrated with 10774 TIP3 water 
molecules and neutralized by adding Na+ and Cl- ions. The 
final structure was embedded in a bilayer of 188 POPC 
molecules, hydrated with 20781 TIP3 water molecules, 
neutralized with several short (≤1 ns) equilibration steps 
and finally equilibrated with a 10 ns MD run. 
 
Results 
 
Protein expression 
 
Even though many approaches are described in the 
literature, there is no universally applicable strategy to 
obtain a high yield GPCR expression system. The 
selection of expression vector, bacterial strain, culturing 
conditions, etc. remains largely empirical. To increase the 
chance of achieving high yield, we tested the expression of 
CCR5 cloned into several different T7-inducible vectors 
containing various N- and C-terminal fusion partners/tags. 
The summary of tested constructs can be found in Table 1. 
As we intended to use our expression system also for 
isotope labeling, expression was carried out in M9 
minimal medium supplemented with Hutner’s trace 
elements (47). To neutralize the codon bias in some of our 
constructs we used Rosetta 2(DE3) cells carrying the 
pRARE plasmid encoding for rare tRNAs. 
GPCR overexpression was assayed by western blot for 
each of the cloned constructs. The expression in pET-22b 
and pQE-T7 vectors, which provide no or only a very 
small fusion partner, was clearly lower than in others. This 
suggests that CCR5 expression yield benefits from the N-
terminal fusion partner. However, the type of the fusion 
partner seems of much less importance than expected. For 
every tested fusion construct, the yield was significantly 
higher at 20°C than at 37°C (Fig. 1a,b). A further decrease 
of the temperature to 12°C or a decrease of IPTG 
concentration from 1 mM to 0.1 mM resulted in a lower 
yield. The highest yield was achieved at 20°C after 24-48 
h after induction (Fig. 1a-d). 
For further optimization of the protein construct, it was 
important to anticipate the sequence-specific position of 
the secondary elements. Initially constructs were based on 
the two-dimensional topology predicted by Oppermann et 
al. (48). However, after the crystal structure of CXCR4 
(15) became available, we generated a homology model 
based on the latter structure and the C-terminal helix H8 of 
rhodopsin (49) using state-of-the-art molecular dynamics 
energy minimization in explicit solvent of CCR5 
embedded in a lipid bilayer. The result of the simulation is 
shown as a full structural model in Figs. 2 & S1 and the 
subsequently derived secondary structure topology in Fig. 
3a. 
Anticipating problems with the formation of 
intermolecular disulphide bridges we have systematically 
tested the role of all 12 cysteines by the truncation of the 
cysteine-containing C-terminus (after N306 or R319) and 
site-directed mutagenesis of the remaining 9 cysteines in 
other regions. In those regions, solvent-exposed cysteines 
were mutated to serines, whereas cysteines in the TM 
domains were replaced by alanines. The locations of the 
respective residues are highlighted in Figs. 2 and 3A, and 
the naming convention of the various mutants is listed in 
Fig. 3b. 
The expression of these cloned constructs was again 
monitored by western blotting against the C-terminal His-
tag. The signal from the shorter (1-306) CCR5 constructs 
was stronger than from the longer (1-319) constructs (Fig. 
1a,b). From this observation, we conclude that the shorter 
constructs were either expressing better or more resistant 
to C-terminal degradation. Therefore further work was 
limited to the shorter (1-306) CCR5 constructs (CCR5306). 
Within the latter, a negative correlation exists between the 
expression yield and the number of cysteine residues (Fig. 
1c). Thus the m2CCR5306 construct containing 7 cysteines 
(Fig. 3b) expressed worse than m7CCR5306 (4 Cys) or 
m6CCR5306 (3 Cys), and much worse than m9CCR5306 (0 
Cys). 
 
Detergent screening 
 
Detergent selection is a crucial step in the preparation of a 
membrane protein sample. A suitable detergent should be 
able to solubilize the protein, keep it stable and functional 
in solution as well as allow structural studies. 
Unfortunately, it is often very difficult to find a detergent 
system that fulfills all these criteria. To address this 
challenge we performed a systematic screen by 
solubilizing E. coli membrane fractions in various 
detergents at 2% (w/v) concentration. After removal of the 
unsolubilized material, the clarified solutions were dried 
on a nitrocellulose membrane and analyzed by dot blot 
using an anti-His antibody. The chemiluminescent signal 
was quantified densitometrically and normalized to the 
maximum value (Fig. 4). 
The results indicate that CCR5 is efficiently solubilized 
by anionic (sodium dodecanoyl sarcosine and SDS) and 
zwitterionic detergents (FosCholines and dimethyl 
glycines) with aliphatic chains. The cationic 
trimethylammonium chlorides and the zwitterionic 
Anzergents are intermediate to moderate in their 
solubilization efficiency. Nonionic detergents (maltosides 
and Anapoes) turned out to solubilize CCR5 extremely 
poorly with the single exception of tetradecylmaltoside, 
which solubilized about a third as much as FosCholines. 
Due to its relatively mild character and lipid-like 
headgroup we picked FosCholine-12 (FC-12) as the main 
working detergent. Even though FosCholines with longer 
hydrocarbon tails performed better, they are much less 
suitable for NMR due to their high aggregation number 
and lower solubility. 
 
Protein purification and identity confirmation 
 
Considering a broad scope of applications we sought to 
establish a simple, robust and efficient purification 
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scheme. CCR5 expressed in E. coli was only found in the 
insoluble fraction after cell disruption (Fig. 1d). 
Subsequently, this insoluble fraction was separated by 
centrifugation (see Materials and Methods section) into a 
heavier (cell debris) and a lighter (membrane) fraction 
with CCR5 being present in both of them. The isolated 
membrane fraction was readily solubilizable by a number 
of detergents (see Detergent Screening section). Similarly, 
the CCR5 could also be solubilized from the heavier 
fraction. However, for most applications only the 
preparation from the lighter fraction was used. 
The solubilized CCR5 was purified using Ni-NTA 
chromatography resulting in up to 10 mg of ∼90% pure (as 
estimated from SDS-PAGE) CCR5 (in FC-12) per 1 L of 
E. coli culture (Fig. 1d,e). Interestingly, purification by Ni-
NTA triggered CCR5 oligomerization on SDS-PAGE, 
which was reversible by dialysis (Fig. 1e). The fusion 
partner was cleavable with thrombin (Fig. 1e). Other 
proteases were also tested including TEV, PreScission (GE 
Healthcare) and 3C proteases with no (TEV) or partial 
success (Fig. S2). 
Trials to solubilize CCR5 in dodecylmaltoside and 
shorter chain maltosides failed. Some protein could be 
purified in tetradecylmaltoside but precipitated within few 
hours after elution from the Ni-NTA column. CCR5 
solubilized in FC-12 followed by a detergent exchange to 
dodecylmaltoside on Ni-NTA also resulted in nearly 
complete protein precipitation. 
The purified CCR5 migrated as a mixture of partially 
stable dimers at apparent MW of ∼50 kDa and monomers 
at ∼30 kDa on an SDS-PAGE (Fig. 1e). Both MW values 
are smaller than expected. This phenomenon is common 
for membrane proteins and can be caused by incomplete 
protein unfolding by SDS and/or by binding more SDS 
molecules than soluble proteins. Besides monomers and 
dimers also higher order oligomers were often observed 
(Fig. 1e), especially after protein concentration. 
Discrete and sharp bands of CCR5 monomer and 
oligomers on the SDS-PAGE suggest that the primary 
structure of the protein is maintained. The identity and 
integrity of the C-terminus of the expressed constructs 
were confirmed by anti-His antibody western blotting (Fig. 
1a-d). To further confirm the protein identity, trypsinized 
FC-12-solubilized CCR5 was analyzed by mass 
spectrometry. We were able to identify large stretches of 
fusion partners and the N-terminal fragment of CCR5 in 
both CCR5 monomer and oligomer bands (Fig. S3). 
Peptides from TM domains of CCR5 were not detectable, 
which suggests that the CCR5 core was resistant to 
proteolysis. 
 
Characterization of CCR5 size distribution, stability and 
homogeneity 
 
It is commonly observed that GPCRs form homo- and 
heterodimers as well as higher oligomeric structures. For 
both E. coli (Fig. 1) and insect cell expressed CCR5 (36), 
besides monomers also oligomers are detected on SDS 
gels. The biological relevance of GPCR oligomerization is 
not clear. Thus heterogeneity also presents a problem for 
structural studies. For this reason, the question of 
oligomerization was further investigated under non-
denaturing conditions using size exclusion 
chromatography (SEC). 
After Ni-NTA purification and digestion by thrombin, 
cleaved TrxA-m11CCR5306 was concentrated and injected 
onto a Superdex 200 column. CCR5 migrated as a mixture 
of monomers, dimers and higher order oligomers (Fig. 5a). 
This observation is consistent with the results of the SDS-
PAGE (Fig. 1e). Good protein separation was achieved on 
a 60 cm long size exclusion column. According to a 
column calibration with standard soluble proteins, the 
monomer and dimer peaks migrated similarly to particles 
of about 95±3 (SD) kDa and 184±9 kDa MW, respectively 
(N=7). This suggests that the monomeric (dimeric) CCR5 
micelle contains ∼165 (∼313) FC-12 molecules. The ratio 
of monomer and dimer micelles depended on the 
stringency of Ni-NTA washing conditions, since higher 
imidazole concentrations depleted the monomeric fraction. 
Apparently, this is due to the weaker binding of monomers 
to Ni-NTA. Relative to the monomers and dimers, the 
fraction of higher order oligomers was much smaller. 
In order to assay the influence of disulphide formation 
on the quality of the preparation, the cysteine-containing 
CCR5 mutants were compared to the cysteine-free mutants 
under non-reducing conditions by SEC (Fig. 6). The 
number of cysteines clearly correlates with enhanced 
oligomerization. The m2CCR5306 mutant (7 Cys) formed 
the most oligomers, whereas m6CCR5306 (3 Cys) and 
m7CCR5306 (4 Cys) mutants were less oligomerized. 
Interestingly, the effect of EC Cys mutations (m6CCR5306) 
seems similar to the effect of TM Cys mutations 
(m7CCR5306), which suggests that both EC and TM Cys 
may mediate disulphide bond formation. The higher 
oligomer formation of the cysteine-containing mutants 
could be suppressed by the addition of a reducing agent 
(Fig. S4). Mutation of all Cys residues (m9CCR5306 and 
m11CCR5306) resulted in a significant reduction of 
oligomerization, essentially rendering most of the protein 
in monomeric and dimeric form. Hence, it is likely that the 
remaining dimers and the residual higher oligomers are 
stabilized by non-disulphide interactions, presumably 
between the TM domains. 
As non-dimerizing CCR5 would be of advantage for 
structural studies, following the findings by Hernanz-
Falcón et al. that point mutations I52V and V150A 
strongly reduce dimer formation in HEK-293 cells (46), 
we tested these mutations in the m9CCR5306 mutant, 
which does not contain cysteines that could lead to 
intermolecular disulphide bridges. In contrast to the in 
vivo findings (46), these mutations did not reduce the 
CCR5 dimerization propensity (Fig. 6). 
To assess the stability of CCR5 monomer and dimer 
preparations, both fractions were concentrated to ∼40 µM 
and incubated for 5 days at RT. After 2 days of incubation, 
almost no change in the size distribution was detected, 
whereas after 5 days only a small fraction of monomers 
interconverted to dimers and some of dimers fell apart to 
monomers or formed higher order oligomers (Fig. 5b). We 
tested a maximum monomer CCR5 concentration of 137 
µM, which also did not show any significant 
oligomerization after 4 days of incubation. Thus on the 
time scale of several days, both CCR5 monomer and dimer 
preparations are very stable. The homogeneity of the 
monomeric and dimeric CCR5 preparations was confirmed 
by negative stain TEM. Monomeric CCR5 particles were 
on average ∼6.6 nm in diameter (Fig. 5c) and dimeric ∼8.3 
nm (Fig. 5d). 
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Characterization of CCR5 secondary structure 
 
The secondary structure content of the CCR5 monomer 
preparations was assessed by CD. For all studied 
constructs we observed double minima at about 208 and 
222 nm characteristic for α-helical proteins (Fig. 7). The 
absolute mean residue molar ellipticity ΘMRM for Mistic-
m7CCR5306 (46%) was slightly larger than for OmpF34-
m7CCR5306 (43%) and TrxA-m7CCR5306 (42%). This can 
be explained by the fact that Mistic is a purely helical 
bundle and increases the ΘMRM of the whole fusion 
construct. This is not the case for the other fusion 
constructs, where the fusion partners contribute much less 
to ΘMRM due to their mixed α/β (TrxA-m7CCR5306) or 
likely β secondary structure (OmpF34-m7CCR5306). The 
42% α-helical content of TrxA-m7CCR5306 is similar to 
the value of ∼40% obtained by Ren et al. for the 
thioredoxin-CCR3 fusion construct (37). For the 
m7CCR5306 monomer, that is after removal of the fusion 
partner from CCR5, the CD signal was the strongest and 
indicated an α-helical content of 52%. This is in a good 
agreement with the ∼50% helical content of a typical 
GPCR (39, 50). 
To assess the thermal stability of the CCR5 
preparation, the CD spectrum of TrxA-m7CCR5306 was 
followed over the range from 5 to 95°C in 5°C increments 
(Fig. S5a). With increasing temperature the spectrum lost 
amplitude and its characteristic double minima. 
Decreasing the temperature from 95˚C back to 5°C did not 
restore the initial shape and intensity, which indicates that 
denaturation was irreversible. The plot of the ellipticity at 
222 nm against temperature (Fig. S5b) shows that a very 
broad thermal transition between 20 and 80˚C. Low 
thermal stability is common within the GPCR family, 
however in the case of our preparation it may further 
reduced by a non-optimal detergent system that lacks 
important lipids of the native membrane, as well as the 
absence of stabilizing ligands. 
 
Functional studies of CCR5 
 
Due to the numerous differences in the expression 
machinery and the cellular environment, the production of 
functional GPCRs in heterologous systems is very 
challenging. To prove the proper folding and the 
functionality of our CCR5 preparation, we tested binding 
of several ligands to CCR5 using SPR. High sensitivity, 
automatization and high-throughput makes this method 
widely used in the GPCR field for screening ligands (51), 
solubilization (52) and crystallization (53) conditions. 
For the SPR experiments, CCR5 was solubilized in a 
mixture of DDM/CHS/CHAPS and DOPC as a similar 
detergent/lipid composition was demonstrated to give best 
receptor activity for CCR5 and CXCR4 (52) as opposed to 
FC-12 where little binding could be detected. The protein 
was immobilized on the sensor chip via the anti-His-tag 
antibody. Binding was assayed for the CCR5 natural 
chemokine ligands RANTES and MIP-1β as well as for 
the conformation-dependent antibody 2D7 (Fig. 8), which 
recognizes several residues from the second EC loop (54). 
Each of the studied analytes showed fast binding and slow 
dissociation reactions. KD values obtained from fitted kon 
and koff rates were all in the nanomolar range. m7CCR5306 
bound RANTES with KD=1.6 nM. m11CCR5306 for which 
cysteines involved in disulphide bridge formation were 
mutated showed a decreased binding ability manifested in 
2-fold increase of KD (3 nM) and 3-fold decrease of the 
response amplitude. 2D7 and MIP-1β bound with 3 nM 
and 70 nM affinity, respectively. 
 
NMR studies of CCR5 
 
As opposed to crystal structures, which provide frozen 
snapshots of GPCR structures, NMR in principle can give 
simultaneous access to protein structure, dynamics and 
interactions. Thus it emerges as a promising method to 
rationalize GPCRs’ function. However, due to the 
numerous challenges in the sample preparation, the 
success of NMR studies on GPCRs has been very limited 
so far. 
To make our system suitable for NMR, the expression 
optimization was carried out directly in minimal medium. 
In this way isotope labeling does not compromise the final 
yield, which for detergent-solubilized, cleaved, monomeric 
CCR5 was 2 mg per 1L of cell culture in triply isotope-
labeled (2H, 15N, 13C) minimal medium. For NMR 
measurements, samples were prepared from monomeric 
CCR5 fractions of the m11CCR5306 mutant. To estimate 
the quality of the preparation 1H-15N correlation spectra 
were recorded (Figs. 9 & S6). To optimize spectral quality, 
a variation of salt (0-180 mM NaCl), pH (4.2-7.4) and 
temperature (5-35˚C) was carried out. Optimal conditions 
were found at 20°C, 0 mM NaCl and pH 4.2. Under these 
conditions, the spectra did not change over a period of few 
months. An increase in temperature to 35°C gave only 
marginal improvement. However, it had a destabilizing 
effect on the protein and caused a decrease of the NMR 
signal over time. The spectrum of m11CCR5306 under 
optimal conditions (Fig. 9) has a narrow dispersion, 
characteristic for an α-helical protein. It contains on the 
order of 60-80 intense and narrow resonances that 
presumably correspond to flexible backbone amides in the 
N- and C-terminal tails and the interhelical loops. 
Furthermore, a background of many more broad 
resonances is observed that most likely correspond to 
protein core residues. The line broadening in this region 
may be related to intermediate conformational exchange 
and/or to the large size of the protein micelle. 
 
Discussion 
 
Due to its involvement in HIV infection, CCR5 is a major 
target for structural biology and the pharmaceutical 
industry. Despite that expression and purification schemes 
have been described for numerous GPCRs, there is a lack 
of an efficient isotope labeling platform for CCR5. 1 mg/L 
expression of CCR5 was reported in insect cells (36) 
where screening for mutants is time-consuming and 
isotope labeling very costly. On the other hand, so far no 
high-yield expression in isotope-labeled form has been 
reported for CCR5 in E.coli where these limitations are not 
present (37). Our goal is to develop methods that allow 
structural and biophysical characterization in particular by 
NMR for CCR5 and potentially other GPCRs. Here, we 
have achieved large overexpression of CCR5 by fusing 
small stable protein domains or signal sequences to its N-
terminus.  
As the induction of CCR5 expression essentially 
arrested E. coli growth, increasing cell density proved to 
be a successful strategy to maximize the CCR5 yield. The 
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highest CCR5 overexpression was observed 24-48 h post 
induction at OD600 ∼3. The induction at earlier or later 
phase of growth resulted in lower yields. Temperature had 
a dramatic effect on the expression level with the optimum 
∼20°C. Variation of the CCR5 sequence also influenced 
the final yield. Thus the expression of the longer CCR5 
constructs (1-319) seemed much lower than the expression 
of the shorter ones (1-306). The number of cysteines in the 
CCR5 sequence correlated negatively with the expression 
level. When all 9 Cys residues were mutated (m9CCR5306 
and m11CCR5306), the yield was highest. Intermediate 
expression, ∼60% of m11CCR5306, was observed for 
m6CCR5306 (2 IC Cys and 4 EC Cys mutated) and 
m7CCR5306 (2 IC Cys and 3 TM Cys mutated), while the 
yield of m2CCR5306 (2 IC Cys mutated) was lowest, i.e. 
∼1/3 of m11CCR5306. 
As a suitable detergent is a crucial element of a 
successful membrane protein preparation, we have 
performed a systematic detergent screening. Charged 
detergents, especially anionic and zwitterionic were very 
efficient in CCR5 solubilization. Nonionic detergents, with 
the exception of tetradecylmaltoside, which solubilized 
about ∼1/3 of available CCR5, worked very poorly. 
Generally, the results are in agreement with previously 
obtained data (37) strongly proposing FosCholines as 
promising candidates. Unfortunately, a good surfactant for 
solubilization is not always also well suited for other 
purposes. For some applications, like the SPR functional 
assay, other detergents or detergent/lipid mixtures were 
reported to provide better receptor activity (51). Therefore, 
the optimal detergent system as well as efficient detergent 
exchange protocols are currently being developed in our 
laboratory. 
Protein oligomerization can severely decrease 
homogeneity of a sample and in this way compromise the 
quality of a sample for structural studies. In the case of 
CCR5 expressed in E. coli, the Cys residues, besides 
affecting the yield, also mediate oligomerization. Using 
SEC we have shown that the number of cysteines in TrxA-
CCR5306 constructs correlates with the amount of 
oligomerized protein (Fig. 6). The fact that Cys-mediated 
oligomerization was also observed in the case of 
m7CCR5306, for which all but the EC Cys were mutated, 
may suggest that in our system, at least to some extent, EC 
disulphide bridges are not properly formed. On the other 
hand, the oligomerization of m6CCR5306, for which all but 
the TM cysteines C213, C290, C291 were mutated, 
implies that also TM Cys residues are reactive. This 
observation is consistent with our model, where C213 and 
C291 are present on the surface of the CCR5 core (Fig. 2) 
and where they are accessible for intermolecular 
disulphide formation. 
When not jeopardized by intermolecular disulphide 
bridge formation, CCR5 exists as a mixture of monomers, 
dimers and higher order oligomers. Due to their high 
stability, dimers and oligomers can be also visible on SDS-
PAGE. Both monomeric and dimeric species can be 
separated, concentrated and studied separately. The 
interconversion between monomers and dimers occurs 
after few days and goes both possible directions. As 
judged by TEM, both fractions are homogenous and 
monodispersed with a clear difference in size. Based on 
the retention volume, the size of monomers and dimers 
was estimated to be 95±3 (SD) kDa and 184±9kDa, 
respectively (N=7). 
Based on computer modeling followed by the cross-
linking of CCR5-transfected cells it was proposed that two 
point mutations together I52V and V150A yield a 
nonsignaling, nondimerizing mutant of CCR5 (46). Even 
though these findings were later contradicted by another 
group with co-immunoprecipitation and BRET 
experiments (55), a nondimerizing CCR5 mutant would be 
so desirable for NMR studies, that we decided to test these 
findings again in our laboratory. Unfortunately, in our 
hands none of the I52V + V150A mutants (m7CCR5306 or 
m11CCR5306) had significantly smaller propensity for 
dimerization in comparison to the wild type CCR5 with 
regards to these two residues (Fig. 6), however, due to the 
low resolution and limitations of our methodology (Ni-
NTA chromatography and SEC), a subtle effect cannot be 
excluded. The hypothesis of the involvement of these two 
residues in dimerization is further challenged by the 
recently published CXCR4 structure, a chemokine 
receptor family member, which crystallized as dimer with 
the interaction surface created by helices V and VI 
(CXCR4 bound to IT1t) or by the IC ends of helices III 
and IV for the CXCR4 bound to CVX15 (16). 
Due to its robustness, polyhistidine-tag 
chromatography is widely used as a first purification step. 
Using a 10His-tag we achieved strong binding and could 
apply more rigorous washing conditions without 
compromising the final yield. This resulted in ∼10 mg of 
purified TrxA-m11CCR5306 from 1 L of E. coli culture. 
This is a vast improvement over the previously described 
system, where ∼0.3 mg of CCR5 per L was reported (37). 
Importantly, this yield is not compromised when isotope 
labeling including D2O is applied, which makes our 
system fully suitable for NMR studies. Out of 10 mg of 
CCR5 oligomeric mixture it is possible to isolate 2 mg of 
cleaved monomeric CCR5. 
The quality of our preparations was assessed by CD, 
where all CCR5 constructs showed the characteristic 
features of an α-helical secondary structure. NMR 
supports this observation as the HSQC spectrum of CCR5 
exhibits, typical for α-helical proteins, rather narrow peak 
dispersion (~2 ppm). Based on the circular dichroism data, 
we estimate that α-helices constitute ∼52% of the 
sequence of m7CCR5306 monomer which suggests that 
CCR5 produced with our method has a correct secondary 
structure. The CD data indicate that the thermal stability of 
CCR5 is not very high. Some secondary structure is 
already lost at 5°C but, as the amplitude of these changes 
is relatively small, it is difficult to judge their consequence 
on CCR5 structure and activity. Low thermal stability can 
be explained by several factors, most importantly 
suboptimal detergent system, lack of important lipids, 
absence of a ligand, nano/antibody or a small molecule 
drugs, that would stabilize CCR5. 
Besides the CD-confirmed secondary structure, the 
quality of the protein preparation was further validated 
using an interaction assay. Using SPR we observed high-
affinity binding of RANTES to m7CCR5306 (KD = 1.6 nM) 
and m11CCR5306 (3 nM). The observed affinity is close to 
the 0.38 nM obtained in a cellular binding assay (56). The 
remaining difference can be understood by the lack of 
posttranslational modifications (Tyr sulfation), which 
strongly contribute to the affinity of CCR5 for chemokines 
(57). The drop in affinity of m11CCR5306 relative to 
m7CCR5306 may be related to the lack of cysteines 
involved in disulphide bridges important for chemokine 
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binding (58). High-affinity (3 nM) binding of 
m11CCR5306 was also observed for the antibody 2D7 
antibody, which is commonly used as a native 
conformation probe. For MIP-1β a 70 nM affinity was 
detected, which again is only about one order of 
magnitude lower than the 7.2 nM measured for CCR5 
stably expressed in Cf2Th cells (56). All these 
observations confirm that the E.coli-expressed, detergent-
solubilized CCR5 has the ability to bind ligands. 
Due to the substantial challenges in the preparation of 
isotope labeled samples, NMR spectra of GPCRs are very 
sparse in the literature. Therefore, only few HSQC spectra 
of 15N labeled GPCRs have been reported, including the 
vasopressin V2 receptor (59), bovine rhodopsin (60), and 
the chemokine CXCR1 receptor (61).  
Here, we present a spectrum of uniformly 15N-labeled 
CCR5. Our initial HSQC spectrum of CCR5 had low 
dispersion and very broad lines besides for a number of 
apparently mobile terminal or loop residues. Similar 
observations have been made for other GPCRs (59-61). 
However, the quality of the CCR5 spectrum could be 
improved substantially by a decrease of the pH from 7.4 to 
4.2 and the removal of salt, which reduced hydrogen 
exchange and increased the sensitivity of the 
measurement. Unfortunately, even with these 
improvements the quality of the spectra is still not 
sufficient for structural analysis and needs further 
improvement but presents a starting point in the NMR 
investigation of CCR5. Obviously, the key bottleneck is 
the severe line broadening, which may be the result of 
conformational heterogeneity of the TM domains and/or 
chemical exchange on an intermediate time scale in the 
microsecond to millisecond range. Therefore CCR5 
stabilization, locking in a single conformation, may be an 
important step towards the improvement of the NMR 
spectra. 
Due to major difficulties in sample preparation for 
structural studies, protein engineering is very common in 
the GPCR field. This process alters the protein sequence 
and may modify its native properties, but so far has been 
indispensible for gaining insights into the structure and 
function of this important class of proteins. As all solved 
GPCR structures were obtained by crystallography, not 
surprisingly, alterations comprised stabilization 
(rigidification, fixation in selected conformations), 
removal of unstructured regions, introduction a soluble 
domain into a loop, etc. 
NMR spectroscopy on the other hand requires isotope 
labeling. However, so far efficient isotope labeling has not 
been possible for insect cells or natural tissues from which 
all solved GPCRs were derived. Thus simple prokaryotic 
organisms, like E. coli are often the system of choice for 
an NMR spectroscopist, as they allow cost-effective 
isotope labeling in addition to fast access to protein 
engineering. Due the size limitations of NMR, the 
preparation of stable, monomeric and non-aggregating 
GPCRs is vital. Taking advantage of E. coli, we developed 
a highly efficient and robust CCR5 expression platform, 
which may find applications in broad biophysical, 
functional as well as structural characterization of CCR5. 
We also believe that many of our observations have more 
general character and may be useful and applicable for 
other GPCRs. 
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Figure legends 
 
Fig. 1 Summary of the expression and purification of CCR5 in E. coli monitored by western blot and SDS-PAGE. (a-b) 
Comparison of the expression of longer (319) and shorter (306) constructs of OmpF34-CCR5 (a) and Mistic-CCR5 (b) at 
20°C and 37°C. CCR2b constructs are used as a positive control. (c) Comparison of the expression of various Cys 
mutants of TrxA-CCR5306. (d) Expression, membrane preparation and binding to Ni-NTA of TrxA-m11CCR5306. Broken 
E. coli cells expressing CCR5 were centrifuged to remove cell debris. Decanted suspension (tot) was subsequently 
separated into insoluble membrane (ins) and soluble cytoplasmic (sol) fractions. CCR5 was found in the membrane 
fraction (ins) but not in the cytoplasmic fraction (sol). Solubilized membranes (inp) were loaded on Ni-NTA. (e) 
Purification of TrxA-CCR5306. After elution from Ni-NTA oligomerized TrxA-CCR5306 was dialyzed and digested with 
thrombin 
 
Fig. 2 Modeled 3D structure of CCR5 (residues 1-331) based on the CXCR4 structure (15). Sulfation of Tyr10 and Tyr14 
as well as palmitoylated Cys321, Cys323 and Cys324 are depicted as spheres 
 
Fig. 3 CCR5 topology and engineered mutations. (a) Membrane topology prediction of the human CCR5 according to the 
CXCR4 homology model (Fig. 2). The grey rectangle approximates the position of the membrane. EC (IC) space is at the 
top (bottom). The potential posttranslational modifications include sulfation of Y3, Y10, Y14 and Y15, phosphorylation 
of S336, S337, S342 and S349 (both marked as black circles), palmitoylation of C321, C323 and C324 as well as 
glycosylation of S6. The positions of mutated residues are highlighted (C in blue, other in green). C-terminal truncations 
are marked with red circles and potential helix H8 with dashed lines. Disulphide bridges form between C20 and C269 and 
between C101 and C178. (b) Table summarizing the introduced point mutations of the listed CCR5 mutants 
 
Fig. 4 Detergent screening for solubilization of OmpF34-m7CCR5306. Values were normalized against FC-16. 
Abbreviations: DHPC, DiMetPhOx-10: n-decyl-N,N-dimethylamine-N-oxide, TriMetAmm-10: N-
dodecyltrimethylammonium chloride, Sarcosine-12: sodium dodecanoyl sarcosine, DiMetPhOx-8: 
dimethyloctylphosphine oxide, HESO-8: N-octyl-2-hydroxyethyl sulfoxide, Maltoside-6: n-hexyl-β-D-maltopyranoside 
 
Fig. 5 Monomers and dimers of CCR5. (a) Size exclusion chromatography of m11CCR5306 on a Superdex 200 HiLoad 
26/60 column. The 60 cm long column enables isolation of monomers and dimers. (b) Stability test of m7CCR5306 
monomers and dimers. To prevent Cys oxidation 1 mM TCEP was included. Purified monomers and dimers were 
concentrated separately to ∼40 µM and re-run on a Superdex 200 10/300 GL column. For easier comparison all 6 
chromatograms were scaled to 1. Negative stain pictures of m7CCR5306 monomers (c) and dimers (d) 
 
Fig. 6 Size exclusion chromatography of various CCR5306 mutants demonstrates the impact of Cys residues on the 
oligomeric state of the purified CCR5. No observable difference between m9CCR5306 and m11CCR5306 suggests that 
I52V and V150A mutations are not involved in CCR5 dimerization 
 
Fig. 7 CD spectra of several CCR5306 constructs show characteristic features of α-helical secondary structure 
 
Fig. 8 SPR functional assay of m7CCR5306 (cyan) and m11CCR5306 (other colors). The graph contains 4 overlaid 
independent runs, normalized for the amount of immobilized receptor and plotted to the same scale. Each run is composed 
of 3 phases separated by the dashed lines: equilibration, binding and dissociation. Fitted curves are in red 
 
Fig. 9 TROSY spectrum of ∼100 µM 2H,-15N-labeled m11CCR5306 monomers recorded at 20°C 
 
Table 1 Summary of GPCR constructs tested for expression. *(residues 1 to 34 from 362 total) 
Vector N-term. tag Fusion partner Cleavage site GPCR cDNA C-term. tag Expression 
pET28F10 - OmpF (1-34/362)* - CCR2b H. sapiens 6His +++ 
pMT10H10 - Mistic (1-110/110) thrombin CCR2b H. sapiens 10His +++ 
pET-22b - pelB (1-22/374) pelB CCR5 H. sapiens 8His + 
pGEV2 - GB1 (1-56/56) thrombin/3C CCR5 H. sapiens/E. coli 6/8His +++ 
pQE-T7 6His - TAGZyme CCR5 E. coli - + 
pET28F10 - OmpF (1-34/362) - CCR5 E. coli 6/10His +++ 
pMT10H10 - Mistic (1-110/110) - CCR5 E. coli 10His +++ 
pET-41a - GST (1-218/218) - CCR5 E. coli 6/10His +++ 
pCA528 6His SUMO (1-98/101) Ulp1/3C CCR5 E. coli 0/10His +++ 
pET-32b - TrxA (1-109/109) -/3C/TEV/thrombin CCR5 E. coli 6/10His +++ 
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Text S1 The exact composition of M9 medium used in this study 
 
To make 1L of M9 medium mix: 
- 851 mL autoclaved ddH2O, 
- 0.1 mL 0.22 µm-filtered 1 M CaCl2, 
- 2mL 0.22 µm-filtered 1 M MgSO4, 
- 10 mL 0.22 µm-filtered Hutner’s trace elements, 
- 3 mL 0.22 µm-filtered 10 mg/mL thiamine hydrochloride, 
- 4 mL 0.22 µm-filtered 0.25 mg/mL biotin, 
- 20 mL 0.22 µm-filtered 20% glucose, 
- 10 mL 0.22 µm-filtered 10% NH4Cl pH 7.4, 
- 100 mL 0.22 µm-filtered 10 x M9 salts (67.8 g Na2HPO4, 30 g KH2PO4, 5 g NaCl pH 7.4). 
 
To prepare 200 mL of 100 x Hutner’s trace elements use the procedure below: 
1. Dissolve 1 g FeSO4 and 10 g EDTA in 80 mL of ddH2O. Adjust pH. A golden yellow solution results above around pH 
5.5 and this is sufficient to proceed. 
2. Dissolve the listed salts in 80 mL of ddH2O: 
- 4.4 g ZnSO4 · 7H2O, 
- 2.2 g H3BO3, 
- 1 g MnCl2 · 4H2O, 
- 0.32 g CoCl2 · 6H2O, 
- 0.235 g CuCl2 · 2 H2O, 
- 0.22 g (NH4)6Mo7O24 · 4H2O. 
3. Combine solutions 1 and 2 and adjust pH to 6.9 using KOH and bring volume to 200 mL. Solution is bright green. 
4. Filter through 0.22 µm and store at 4°C. Solution turns purple. 
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Fig. S1 Modeled 3D structure of CCR5. Model was rotated by 180° in relation to Fig. 2 
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Fig. S2 TrxA-m7CCR5306 cleavage with 3C protease. Protein eluted from Ni-NTA with buffer F (20 mM HEPES pH 7, 
300 mM NaCl, 0.4 M imidazole, 0.1% FC-12, 10 mM β-mercaptoethanol) is cleaved very poorly. Certain improvement is 
achieved upon adding 1 mM DDT and 1 mM EDTA (*). Cleavage in buffer G (50 mM Tris-HCl pH 8, 150 mM NaCl, 
0.1% FC-12, 1 mM DDT and 1 mM EDTA) is more efficient but still not complete after 140 h even when large amounts 
of 3C protease are used. Increase of temperature from 6°C to 22°C does not make a significant difference 
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Fig. S3 Identity confirmation of TrxA-m7CCR5306 and Mistic-m7CCR5306. (a) Monomer and dimer (TrxA-m7CCR5306) 
or monomer and trimer (Mistic-m7CCR5306) CCR5 bands (red rounded rectangles) were excised from SDS-PAGE gel 
stained with Colloidal Blue Stain Kit (Novex) and digested with trypsin prior to mass spectrometry analysis. (b) Identified 
peptide fragments of the analysed fusion constructs were marked in bold. Individual components of the fusion constructs 
(fusion partner, linker, cleavage site, CCR5 sequence, His-tag) were marked with colors 
  
TrxA-m7CCR5306 monomer 
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLLFKNGEVAA
TKVGALSKGQLKEFLDANLAGSGSGHMDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVVLILINSKRLKSMTDI
YLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSAITWVVAVFAS
LPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVIAYSGILKTLLRSRNEKKRHRAVRLIFTIMIVYFLFWAPYNIVL
LLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHAAINPIIYAFVGEKFRNLEHHHHHH 
TrxA-m7CCR5306 dimer 
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLLFKNGEVA
ATKVGALSKGQLKEFLDANLAGSGSGHMDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVVLILINSKRLKSMT
DIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSAITWVVAVF
ASLPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVIAYSGILKTLLRSRNEKKRHRAVRLIFTIMIVYFLFWAPYNI
VLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHAAINPIIYAFVGEKFRNLEHHHHHH 
Mistic-m7CCR5306 monomer 
MGFCTFFEKHHRKWDILLEKSTGVMEAMKVTSEEKEQLSTAIDRMNEGLDAFIQLYNESEIDEPLIQLDDDTAELMKQARDMYGQEKL
NEKLNTIIKQILSISVSEEGEKEGSGSGLVPRGSHMDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVVLILINS
KRLKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSAIT
WVVAVFASLPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVIAYSGILKTLLRSRNEKKRHRAVRLIFTIMIVYFL
FWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHAAINPIIYAFVGEKFRNLEHHHHHHHHHH 
Mistic-m7CCR5306 trimer 
MGFCTFFEKHHRKWDILLEKSTGVMEAMKVTSEEKEQLSTAIDRMNEGLDAFIQLYNESEIDEPLIQLDDDTAELMKQARDMYGQEKL
NEKLNTIIKQILSISVSEEGEKEGSGSGLVPRGSHMDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVVLILINS
KRLKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSAIT
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Fig. S4 Effect of β-mercaptoethanol (BME) on the oligomeric state of TrxA-m7CCR5306 
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Fig. S5 Heat denaturation of TrxA-m7CCR5306 measured using CD. (a) 200-250 nm CD spectra of TrxA-m7CCR5306 at 
series of temperatures in the range of 5-95°C. Heat irreversibly changes the shape and the amplitude of the spectrum. (b) 
Plot of mean residue molar ellipticiy at 222 nm versus temperature shows a broad transition 
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Fig. S6 Normalized HSQC spectra of ∼100 µM 2H,-15N-labeled m11CCR5306 at various conditions. Upon pH change from 
7.4 (a) to 5.8 (b) and 4.2 (c) new resonances become visible. Upon removal of 180 mM NaCl an increase of sensitivity is 
observed (d) 
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5 Studies of RANTES 
 
5.1 Materials and methods 
 
Cloning, expression and purification 
 The DNA sequence of 5P12-RANTES-E66S DNA was obtained by mutating 
the RANTES-E66S gene inside the pGEV2 plasmid containing the enterokinase-
cleavable GB1-RANTES-E66S fusion construct under the T7 promoter (plasmid from 
our laboratory collection). The cloning strategy omitted gene amplification and ligation 
using the fact that the mutated nucleotides formed three clusters. The procedure 
involved three sequential site-directed mutagenesis PCR steps, each mutating 3-7 
nucleotides and resulting in a mutation of 2-4 amino acids. After each PCR step 
plasmid was amplified in self-prepared TOP10 cells and sequenced to screen for the 
correctly mutated clones. To check the expression, pGEV2-transformed self-prepared 
BL21 cells were grown in 500 mL M9 medium at 37°C in baffled flasks with 130 rpm 
shaking. When OD600 reached 2, protein expression was induced with 1 mM IPTG. 
Collected culture samples were analyzed on SDS-PAGE followed by Coomassie 
staining. Isotope labeled RANTES was expressed and purified essentially as described 
previously (80). 
 
Nuclear magnetic resonance 
 Isotope labeled RANTES samples were in 50 mM KH2PO4 pH 3.8, 0.02% 
NaN3 (RANTES-E66S and 5P12-RANTES-E66S samples in Figures 5.3-5.7 and Table 
5.1) or in 50 mM DCOONa pH 3.8 (RANTES-E66S and 5P12-RANTES-E66S 
samples in Figures 5.8-5.11 and Table 5.2). NMR samples were supplemented with 5% 
D2O for locking and transferred to a Shigemi tube (5P12-RANTES-E66S in Figures 
5.3-5.7 and Table 5.1, 250 µL) or glass tubes (all other samples, 400 µL). NMR 
experiments were recorded on a Bruker DRX600 spectrometer (5P12-RANTES-E66S 
in Figures 5.3-5.7 and Table 5.1) or on a Bruker DRX800 spectrometer equipped with a 
triple resonance Z-gradient TCI cryoprobe (all other spectra). 15N,13C-labeled 5P12-
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RANTES-E66S and 15N,13C,2H-labeled RANTES-E66S in FC-12 resonances were 
assigned using CBCANH (600 MHz, 37°C) and HNCACB (800 Mhz, 25°C) spectra, 
respectively. NMR spectra were processed using NMRPipe (94) and Sparky (95). Cβ, 
Cα chemical shifts were obtained from CBCANH (HNCACB) experiment, whereas 
HN, N and C’ from HNCO. Proton dimension was referenced for the water chemical 
shift according to pressure and temperature, while the heteronuclei according to the 
IUPAC-IUBMB-IUPAB recommendations (96). Random coil shifts, that were 
subtracted from the experimental shifts in order to calculate secondary chemical shifts, 
were obtained from the web server of the University of Kopenhagen 
(http://www1.bio.ku.dk/english/research/pv/sbin_lab/staff/MAK/randomcoil/script), 
which uses protein sequence, pH and temperature corrections (97-99). Standard 15N 
relaxation measurements (T1/T2, {1H}-15N NOE) were recorded on uniformly 15N,13C-
labeled 5P12-RANTES-E66S at 600 MHz at 37°C. T1/T2 decay curves were fitted by 
an in-house written routine implemented in MATLAB (MathWorks, Inc.) using a 
simplex search minimization and Monte Carlo estimation of errors. 
 
Circular dichroism 
 CD spectra of 50 µM 15N,13C,2H-labeled RANTES-E66S in 50 mM DCOONa 
pH 3.8, 5% D2O were recorded at 20°C in 1 mm quartz Suprasil cuvettes (Hellma) 
using a Chirascan CD spectrometer (Applied Photophysics). Data points in a 
wavelength range of 200-260 nm were collected in triplicates and averaged followed by 
buffer subtraction (buffer + 0.5% FC-12 for RANTES-E66S spectrum in 0.5% FC-12). 
 
5.2 Results 
 
Cloning and expression testing 
 As a natural consequence of being a potent HIV-entry inhibitor and CCR5 
ligand, 5P12-RANTES became an important subject of our studies. Although a very 
efficient and well characterized 5P12-RANTES expression platform was established in 
yeast, to obtain isotope labeled samples for NMR studies, we turned to our E. coli-
based production system, which by that time was well established in our laboratory and 
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for many years has been successfully used to obtain milligram quantities of isotope 
labeled wild type RANTES and RANTES-E66S samples. 
 From the previous research performed in our laboratory and by others (71, 80) 
it was known that the wild type RANTES is very prone to aggregation and easily 
precipitates, especially at high concentration and high pH, which makes it quite 
challenging to study. Mutation E66S turns out to be a remedy as it significantly reduces 
aggregation tendency leaving molecular structure, dimerization property and other 
RANTES characteristics intact. For those reasons E66S mutations was included to the 
5P12-RANTES sequence. 
 
 
Figure 5.1 Generation of 5P12-RANTES-E66S DNA. Fragment of pGEV2 plasmid with the N-
terminus of RANTES-E66S (top) and three primer pairs designed for site-directed mutagenesis PCR 
(bottom). Differing nucleotides and amino acids were marked with green (RANTES-E66S) and red 
(5P12-RANTES-E66S). 
 
 pGEV2 plasmid bearing enterokinase-cleavable GB1-RANTES-E66S fusion 
was used as a starting point for constructing 5P12-RANTES-E66S. The wild type 
RANTES and 5P12-RANTES differ in their N-termini and to go from one to the other 
the insertion of the very N-terminal glutamine and the mutation of seven more residues 
are necessary. This 8 amino acid difference translates to 15 nucleotides and after 
sequence alignment it becomes visible that differing nucleotides cluster in three groups 
(Figure 5.1). This feature made it possible to conveniently use site directed mutagenesis 
and avoid often problem-prone re-ligation of the new insert and empty plasmid. Three 
sequential site-directed mutagenesis PCR reactions intertwined with plasmid 
-3’5’-
5’- -3’
5P12-RANTES-E66S
RANTES-E66S
gga tcc gac gac gac gac aag         tcc cca tat tcc tcg gac acc aca ccc tgc tgc ttt gcc tac att gcc
  G   S    D    D    D     D    K           S     P   Y   S   S    D     T    T    P    C   C   F   A   Y    I    A
 -7   -6   -5   -4    -3    -2    -1    0     1     2    3   4   5     6     7    8    9   10  11  12 13  14  15 16 
  G   S    D    D    D     D    K    Q    G     P   P   L   M    A     T    Q   S    C   C   F   A   Y    I    A
gga tcc gac gac gac gac aag cag ggc cca cct tta atg gcc acc caa  tcc tgc tgc ttt gcc tac att gcc
0Q-S1G-RANTES-E66S primer pair
5’- ga tcc gac gac gac gac aag cag ggc cca tat tcc tcg gac acc -3’
5’- ggt gtc cga gga ata tgg gcc ctg ctt gtc gtc gtc gtc gga tc -3’
T8Q-P9S-RANTES-E66S primer pair
5’- c cca tat tcc tcg gac acc caa tcc tgc tgc ttt gcc tac att g -3’
5’- c aat gta ggc aaa gca gca gga ttg ggt gtc cga gga ata tgg g -3’
Y3P-S4L-S5M-D6A-RANTES-E66S primer pair
5’- gac gac aag cag ggc cca cct tta atg gcc acc caa tcc tgc tgc -3’
5’- gca gca gga ttg ggt ggc cat taa agg tgg gcc ctg ctt gtc gtc -3’
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amplification and sequencing resulted in expression-ready 5P12-RANTES-E66S 
sequence. Subsequently, the test showed large overexpression of 5P12-RANTES-E66S 
proving that the construct is ready for the isotope labeling for NMR studies (Figure 
5.2). 
 
 
Figure 5.2 Expression test of GB1-5P12-RANTES-E66S fusion (lanes 5-7) with T7E-RANTES-
E66S as control (lanes 2-4). Whole E. coli cells were analyzed on SDS-PAGE after 0 (lanes 2 and 
5), 2 (lanes 3 and 6) and 4 h after induction (lanes 4 and 7). 
 
5P12-RANTES-E66S heteronuclear fingerprint 
 15N-1H HSQC experiment enables observation of NH groups. Resonances in the 
spectrum represent a fingerprint of amino acids making up the protein. Most of the 
resonances come from the backbone amide groups but side chain HN groups of Asn, 
Gln, His, Trp, and sometimes Lys can also be observed. For these reasons and due to its 
sensitivity HSQC experiment is widely used as a sample quality check and at the same 
time constitutes the first chapter of NMR analysis. 
 HSQC spectrum of 15N,13C-labeled 5P12-RANTES-E66S is composed of 63 
well-resolved backbone amide peaks, which correspond to 63 nonproline residues of 
5P12-RANTES-E66S (Figure 5.3). This means that 100% of the observable residues is 
visible in the spectrum. Apart from the backbone amides a number of side chain 
resonances from Trp, Asn and Gln is also present. The backbone resonances span over 
4 ppm in hydrogen dimension. Such wide peak dispersion is a characteristic feature of a 
well-folded protein, where each amino acid experiences a unique, well-defined, 
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nonrandom chemical environment. The sample could be stored for years without any 
measurable signs of deterioration or quality loss. 
 
Assignment and Gln0 cyclization 
 The next step of the NMR analysis requires the exact knowledge of the identity 
of the observed resonances. For such small proteins like RANTES it was sufficient to 
record a single CBCANH experiment, which correlates Cβ, Cα, N and HN chemical 
shifts. As N is coupled not only to its own Cα but also to the Cα of the preceding 
residue, CBCANH spectrum allows to “walk” along the sequence. 
 
 
Figure 5.3 15N-1H HSQC spectrum of 15N,13C-labeled 5P12-RANTES-E66S at pH 3.8 at 37°C with 
assigned backbone resonances. Due to the incomplete Gln0 cyclization two Gly1 peaks: big G1 and 
small G1’ are observed corresponding to the cyclic (dominant) and the free (residual) forms, 
respectively. 
 
 The quality of 5P12-RANTES-E66S CBCANH spectrum and very limited 
overlap permitted a complete assignment using only CBCANH information (Figure 
5.3). As 5P12-RANTES-E66S has an extra Gln0 at the very N-terminus, it was possible 
to assign Gly1, which normally would not be visible due to the protonated N-terminus. 
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Interestingly, the very N-terminal Gln0 peak can also be observed because of a 
spontaneously occurring irreversible glutamine cyclization (Figure 5.4A). A stable 
pentacyclic pyroglutamate ring is formed as a result of nucleophilic attack of the 
backbone nitrogen lone pair on the side chain carbonyl carbon with a release of NH3. 
The reaction requires a deprotonated nitrogen and therefore at low pH takes days to 
complete. When HSQC is recorded soon after sample preparation a second resonance 
of Gly1 (G1’) corresponding to the free N-terminus is also observed (Figure 5.3). The 
G1’/G1 peak intensity ratio decreases from ∼8 right after sample preparation to ∼2.5 
day after. After four days the reaction is nearly complete The approximate estimation of 
the reaction half life yields ∼2 days (Figure 5.4B). 
 
 
Figure 5.4 N-terminal Gln cyclization. Mechanism of the reaction relies on the nucleophilic attack of 
the backbone nitrogen on the side chain carbonyl carbon (A). Speed of the reaction was followed as 
a free/cyclic glutamine peak intensity ratio (B). 
 
Chemical shift table 
 HNCACB spectrum was also used to construct a table of 5P12-RANTES-E66S 
chemical shifts (Table 5.1). Such table constitutes a valuable data set since: 
- by calculating chemical shift differences for each residue structure of 5P12-
RANTES-E66S can be compared to the known structure of RANTES, 
Time (days)
R
at
io
 fr
ee
/c
yc
lic
H
2 N O
NH
2 O
HN N
HO
HN
O
days
B
A
R
at
io
 fr
ee
/c
yc
lic 8.15
2.48
0.13 0.13 0.08 0.05 0.03 0.02
0
2
4
6
8
10
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
5P12-RANTES-E66S
τ1/2 ~ 2 days
85 
 
- by subtracting random coil chemical shifts from the experimental shifts, the 
positions of secondary structure elements and unstructured regions can be 
mapped (see the secondary chemical shift analysis in Figure 5.6), 
- using a suitable software e.g. CS-ROSETTA (100, 101) a low resolution 5P12-
RANTES-E66S structure could be even calculated. 
 
Table 5.1 Chemical shift (HN, 15N, 13Cα, 13Cβ and 13C’) table of 5P12-RANTES-E66S (cyclized side 
chain of Gln0). N/AV (not available), N/AP (not applicable). 
No. HN (ppm) 15N (ppm) 13Cα (ppm) 13Cβ (ppm) 13C’ (ppm) 
Q0 7.893 125.229 59.896 28.008 178.165 
G1 8.334 109.399 44.372 N/AV N/AV 
P2 N/AP N/AV N/AV N/AV N/AV 
P3 N/AP N/AV 62.939 31.821 N/AV 
L4 8.196 122.127 55.359 42.553 177.569 
M5 8.283 120.699 55.477 33.061 175.979 
A6 8.201 124.955 52.791 19.369 178.097 
T7 7.959 111.865 62.103 69.709 174.815 
Q8 8.305 121.549 55.964 29.400 175.669 
S9 8.201 116.435 58.690 64.023 173.934 
C10 8.185 118.712 52.792 39.408 174.112 
C11 9.105 118.744 56.281 44.573 174.479 
F12 9.025 121.092 58.117 40.272 173.786 
A13 7.523 121.961 51.121 21.355 175.302 
Y14 8.400 117.730 55.496 41.503 177.142 
I15 8.863 121.347 61.520 38.969 175.934 
A16 8.632 126.849 53.810 20.409 177.762 
R17 7.562 117.712 52.732 31.143 N/AV 
P18 N/AP N/AV 62.373 31.503 176.707 
L19 5.583 122.092 52.683 42.451 N/AV 
P20 N/AP N/AV 63.088 31.359 177.830 
R21 8.516 127.209 58.918 29.444 178.766 
A22 8.590 118.762 53.760 18.529 178.592 
H23 7.963 112.856 54.835 29.393 174.320 
I24 7.731 120.183 62.119 38.871 174.699 
K25 9.413 125.520 57.029 35.571 175.765 
E26 8.017 114.655 55.012 31.663 172.973 
Y27 8.309 117.445 56.105 43.076 172.871 
F28 8.526 115.136 56.324 40.700 173.219 
Y29 8.965 119.491 57.989 39.881 177.748 
T30 8.138 110.574 61.945 70.875 174.923 
S31 8.806 115.140 58.483 64.127 176.894 
G32 8.916 114.359 46.434 N/AP 174.563 
K33 8.179 118.407 56.498 32.096 177.665 
C34 7.590 119.031 54.244 38.907 175.435 
S35 8.778 118.620 61.190 63.216 174.190 
N36 8.209 118.310 50.218 39.203 N/AV 
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P37 N/AP N/AV 62.970 32.287 176.602 
A38 8.158 122.311 52.488 24.539 175.724 
V39 8.273 119.852 60.353 34.472 172.460 
V40 8.839 126.735 60.251 32.175 176.040 
F41 8.987 122.877 56.600 41.138 174.817 
V42 8.826 122.692 60.931 33.175 177.725 
T43 9.366 118.479 60.893 71.591 177.023 
R44 8.480 118.582 59.019 29.624 177.143 
K45 7.670 117.356 55.819 31.383 175.225 
N46 8.359 114.885 54.723 36.762 174.687 
R47 7.468 117.735 55.520 31.166 175.436 
Q48 8.599 121.670 55.396 29.931 175.972 
V49 9.232 122.077 60.835 35.102 174.640 
C50 8.819 124.050 57.562 48.066 173.811 
A51 9.736 124.801 50.843 24.114 174.486 
N52 8.357 120.396 50.176 38.883 N/AV 
P53 N/AP N/AV 63.824 32.012 175.610 
E54 7.739 114.512 56.239 28.882 177.813 
K55 7.377 118.426 54.318 32.297 177.626 
K56 8.819 125.330 60.543 32.191 179.010 
W57 8.157 115.328 59.151 26.686 176.947 
V58 5.842 122.601 66.030 30.867 177.578 
R59 7.334 118.614 59.408 29.596 179.140 
E60 8.332 118.102 59.159 28.532 179.662 
Y61 8.545 122.199 60.227 37.423 179.035 
I62 8.461 119.465 65.913 37.673 178.509 
N63 7.999 118.361 55.959 38.350 177.139 
S64 7.952 114.265 60.212 63.821 175.655 
L65 7.926 122.808 56.044 43.383 177.715 
S66 8.060 114.663 59.004 64.035 174.268 
M67 8.075 121.761 55.662 33.328 175.736 
S68 8.061 120.917 59.403 64.748 N/AV 
 
Similarity and differences to the wild type RANTES 
 Last but not least it needs to be noticed that 5P12-RANTES-E66S HSQC 
spectrum to a large extent overlays well with the spectrum of RANTES-E66S (Figure 
5.5). This helped with the assignment of 5P12-RANTES-E66S but obviously not in the 
case of the N-terminus, which sequence has been modified (Figure 5.5, red resonances). 
Since RANTES-E66S similarly to the wild type RANTES readily forms dimers, two 
sets of HSQC peaks are observed even at such low concentrations as 25 µM. This is not 
the case of 5P12-RANTES-E66S, for which even at 0.6 mM only one set of peaks is 
observed and proves that at the tested conditions 5P12-RANTES-E66S does not form 
dimers. This seems logical, as the N-terminus, which vastly contributes to the 
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dimerization interface has been significantly modified. As a natural consequence of its 
monomerism, 5P12-RANTES-E66S resonances should also overlap better with the 
resonances of RANTES-E66S monomer than with the resonances of RANTES-E66S 
dimer. This is indeed the case, particularly obvious for Ser31 and Gly32, for which the 
difference between monomer and dimer RANTES-E66S resonances of is the most 
striking but also for many other residues e.g. Ala13, Leu19, Arg21, Phe28, Ala51, 
Tyr61, etc. (Figure 5.5). 
 
 
Figure 5.5 Similarity of 5P12-RANTES-E66S to RANTES-E66S. The 15N-1H HSQC spectra of 604 
µM 5P12-RANTES-E66S (black and red) and 25 µM RANTES-E66S (blue) were overlaid. As 
RANTES-E66S readily forms dimers, low concentration was used to increase monomer:dimer ratio. 
The exemplary nonoverlaping resonances of both RANTES variants were labeled with assignment 
information. 5P12-RANTES-E66S resonances overlap well with the resonances of monomeric 
RANTES-E66S (particularly clear for S31 and G32) with the exception of the N-terminus (red), for 
which the amino acid sequence has been mutated. 
 
 Similarity of 5P12-RANTES-E66S to the wild type RANTES is also visible 
from the secondary chemical shift analysis in Figure 5.6, where 13Cα, 13Cβ, 13C’, 15N 
shifts were plotted against 5P12-RANTES-E66S residue number. The secondary 
structure elements according to the PDB entry 1EQT were drawn on the top. Although, 
1EQT structure contains RANTES with a minor modification of the N-terminus 
(missing Ser1 and Pro2Gly mutation), it should be representative for the secondary 
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structure elements of the wild type RANTES. This is because the very N-terminus of 
RANTES is neither a part of any secondary structure element itself nor is involved in 
RANTES dimerization interface. Therefore is unlikely that such a modification could 
affect the overall RANTES structure in any major way. On the other hand 1EQT 
structure offers a high resolution of 1.6 Å, lacks other mutations or chemical 
modifications and was crystallized alone (without a disaccharide ligand). 
 The positive 13Cα and 13C’ and and negative 13Cβ shifts are an indication of 
helical secondary structure and are clearly observed for 310 (η1) and α-helix (α1). 
Amino acids participating in β-strands, on the other hand, often have negative 13Cα and 
13C’ and positive 13Cβ. With the exception of the oxidized Cys50 this is clearly the case 
for β1 and β3 strands. However, in the case of Cys50 the positive value of 13Cα in the 
middle of a β-strand and an extraordinary large 13C’ shifts (Figure 5.6, grey bars) may 
suggest that the used random coil values for oxidized cysteine (102) may not be 
adequate. For β2 strand, 13Cα and 13Cβ shifts predict the presence of a β-strand, whereas 
the information from 13C’ is more ambiguous. The chemical shift values of the N-
terminus do not deviate significantly towards any type of secondary structure, which is 
understandable as the intermolecular βN strand cannot be formed in monomeric 5P12-
RANTES-E66S. Therefore it is likely that the N-terminus is flexible and adopts random 
coil conformation. The outstanding very large 13Cα shift of the very N-terminal Gln0 
can be easily rationalized by the cyclization of the Gln0 side chain. Secondary shift 
analysis goes along with the similarity of HSQC spectra and suggests that 5P12-
RANTES-E66S structure is similar to the structure of the wild type RANTES 
monomer. 
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Figure 5.6 Secondary chemical shift analysis (13Cα, 13Cβ, 13C’, 15N) of 5P12-RANTES-E66S. 
Secondary structure elements according to PDB entry 1EQT (81) are drawn at the top. 
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Relaxation experiments 
 A complete protein biophysical characterization on a molecular level requires 
both solving its three dimensional structure and knowledge about its dynamics, that is 
about the flexibility/rigidity of its parts on various timescales. Although, due to the 
similarity of the 5P12-RANTES-E66S and the wild type RANTES HSQC spectra and 
due to the extensive workload (months), high resolution structure determination was 
not attempted, 5P12-RANTES-E66S dynamics has been characterized. For this purpose 
three following relaxation experiments were performed (Figure 5.7): 
- T1 called also spin-lattice or longitudinal relaxation, 
- T2 called also spin-spin or transverse relaxation and 
- {1H}-15N heteronuclear NOE cross-relaxation. 
For the vast majority of 5P12-RANTES-E66S resonances (residues 10-66) 1/T1, 1/T2 
and {1H}-15N NOE values remain on steady levels of 2.25±0.14 s-1 (SD), 6.36±1.84 s-1 
and 0.71±0.05, respectively. This means that the tumbling rate is relatively uniform 
along the protein’s amino acid sequence and that the protein behaves like a rigid 
particle. This situation is different for the C-terminus (residues 67-68) and for the N-
terminus especially (residues 0-9), for which all 1/T1, 1/T2 and {1H}-15N NOE values 
significantly deviate from the protein’s average. For the C-terminus the 1/T1, 1/T2 and 
{1H}-15N NOE values drop to 1.03 s-1, 1.55 s-1 and -0.63 (for Ser68), whereas for the N-
terminus even more up to 0.55 s-1, 1.06 s-1 and -2.59 (for Gln0), respectively. These low 
values of the N- and C-termini result from the ps-ns motions i.e. the enhanced 
flexibility of 5P12-RANTES-E66S backbone in these regions. The hump of 1/T2 
around residues 5-9 comes from the additional motions on the µs-ms timescale. Such 
an increased N-terminal flexibility goes along with the fact that, unlike for the wild 
type RANTES, the N-terminus on the 5P12-RANTES-E66S is not involved in a 
dimerization interface i.e. in the formation of the intermolecular β-sheet. 
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Figure 5.7 Relaxation of 5P12-RANTES-E66S measured on 600 MHz spectrometer at 37°C. The 
presented data is an average of two (1/T1 and {1H}-15N NOE) or three (1/T2) independent 
experiments. The error bars represent the standard deviation. Secondary structure elements 
according to PDB entry 1EQT (81) are drawn at the top. 
 
RANTES-CCR5/detergent interaction 
 
5.2.1.1 Introduction 
 CCR5 interaction with chemokines and with RANTES especially plays a key 
role in CCR5 biology. Since RANTES can compete HIV infection, revealing details of 
RANTES-CCR5 interaction became increasingly interesting as a door to understand an 
exact molecular mechanism of CCR5 involvement in the disease. RANTES-CCR5 
interaction was studied using SPR by Navratilova and coworkers (103) and also in our 
laboratory using ITC and NMR by Lydia Nisius (13, 82) and using SPR by Sébastien 
Morin (unpublished data). Since SPR setup relies on a selective (usually via an 
antibody) CCR5 capture on a chip, receptor pre-purification is usually not necessary. 
The situation changes when it comes to ITC or NMR, which do not provide an intrinsic 
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purification possibility and both require purified CCR5 and RANTES. Additionally, 
SPR is far more sensitive than ITC or NMR and therefore requires much smaller 
protein amounts, which becomes an asset when obtaining large receptor yields is 
challenging. 
 The RANTES-CCR5 interaction studies performed previously in our laboratory 
used insect cell-expressed CCR5 solubilized in FC-12 (13, 82). After comparing 
several detergents, FC-12 was selected because it solubilized CCR5 with the largest 
yield, gave the most homogenous electron micrograph of purified CCR5 and preserved 
CCR5 native conformation as judged by immunoprecipitation with 2D7 (see section 
Discussion of Chapter 3). With ITC it was observed that RANTES interacts with CCR5 
with a KD of ∼ 1 µM. However, when unlabeled CCR5 was titrated into 15N-labeled 
RANTES-E66S, no chemical shift perturbations could be observed, and what’s more, 
RANTES-E66S resonances weakened with the increasing amounts of the injected 
receptor and a set of new resonances appeared. 
 
5.2.1.2 NMR analysis 
 By that time, we have already found that 2D7 does not immunoprecipitate 
CCR5 in FC-12. This could indicate that the structure of the receptor is affected but 
another explanations e.g. perturbation of 2D7 structure by FC-12, electrostatic 
repulsion of 2D7 antigen-binding epitope by positively charged head groups of FC-
12/CCR5 micelle or a simple competition could not be completely excluded. However, 
besides a potential effect of FC-12 on CCR5, there was no other evidence suggesting 
that in FC-12, CCR5-RANTES interaction could not be studied. In addition, despite 
extensive detergent screening (see sections Detergent screening of Chapters 3 and 4) no 
better detergents could be found to replace FC-12 for CCR5 solubilization and 
purification. Those detergents that were showed to support CCR5 recognition by 2D7 
did not permit purification of the stable receptor at high yields. 
 Therefore, to compare with the previous results of Nisius (13), namely 
RANTES interaction with the FC-12-solubilized insect cell-expressed wild type CCR5, 
FC-12-solubilized E. coli-expressed m9CCR5306 monomer was stepwise titrated into a 
50 µM 15N,13C,2H-labeled RANTES-E66S solution. The RANTES-E66S resonances 
weakened with the increasing FC-12-solubilized m9CCR5306 concentration (Figure 
5.8). The effect was much greater than what could result from a moderate (∼10%) 
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sample dilution and was resonance-selective. A set of ∼15 pronounced resonances, all 
around 8.2 ppm (Figure 5.8C), distinguished itself from the previously intensity-
homogenous RANTES-E66S dimer spectrum (Figure 5.8A). These observations 
coincide with the previous findings of Nisius for the wild type CCR5 expressed in 
insect cells (13). 
 
 
Figure 5.8 HSQC spectra of RANTES-E66S at pH 3.8 at 25°C without detergent (A) and with 1:2 
(B) and 1:1 (C) molar ratio of CCR5. Negative peaks resulting from folding are colored red. The 
exemplary nonoverlaping resonances were labeled with the assignment information. The resonances 
below the threshold were surrounded by black dashed circles. 
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Figure 5.9 HSQC spectra of 50 µM RANTES-E66S at pH 3.8 at 25°C without detergent (A) and 
with 5% FC-8 (B) and 1% FC-12 (C). Negative peaks resulting from folding are colored red. The 
exemplary nonoverlaping resonances were labeled with the assignment information. 
 
 However, the very similar observation was made when Fos-Choline detergents 
solutions without CCR5 were injected. The intensity of RANTES-E66S resonances 
decreased upon addition of a detergent from the Fos-Choline family (Figure 5.9). The 
resonances of RANTES-E66S weakened up to a complete disappearance. Fos-Cholines 
with various hydrocarbon chain length from 8 to 16 were tested and with the exception 
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of FC-8 (CMC in H2O 3.4%) each of them at 1% concentration bleached the vast 
majority of the original RANTES-E66S resonances. FC-12 was additionally tested at 
0.5% (by diluting the sample at 1%) with the same effect. When FC-8 concentration 
was raised to 5%, RANTES-E66S resonance were largely but not completely gone 
(Figure 5.9B). 
 The remaining set of RANTES-E66S resonances (most of them) could be 
assigned solely based of the HNCACB data to the N- and C- RANTES-E66S termini. 
The visible residues until T7 (Y3-T7) and all the residues from I62 onwards could be 
unambiguously identified (Figure 5.9C). The secondary shift analysis of the assigned 
resonances suggests that within the very terminal regions the RANTES-E66S 
secondary structure was not severely perturbed (Figure 5.10). The N-terminus remained 
largely unstructured, whereas the C-terminus with large positive 13Cα shifts was still a 
part of α1 helix. 
 At pH 6.3 the effect of 1% FC-12 addition was milder than at pH 3.8 (data not 
shown). This indicates that the phenomenon of disappearing RANTES-E66S 
resonances is in some way also pH-modulated. 
 Unlike Fos-Choline detergents DHPC with a similar head group did not bleach 
RANTES-E66S resonances even at 5% concentration (Figure 5.11A). Similarly, when 
1% Cymal-5 or 2.2% DDM/CHAPS/CHS mixture (1/1/0.2) were injected no resonance 
bleaching occurred. Interestingly, detergents with a maltose head group shifted 
RANTES-E66S equilibrium towards its monomeric form (Figure 5.11A,B). Such effect 
was not observed for any other tested detergent. 
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Figure 5.10 Secondary chemical shift analysis (13Cα, 13Cβ, 15N) of RANTES-E66S in the presence of 
1% FC-12. For a convenient comparison to Figure 5.6 data was plotted to the same scale. Although 
HNCACB spectrum of RANTES-E66S was recorded at 25°C (5P12-RANTES-E66S at 37°C), the 
secondary chemical shift pattern closely resembles the patter of 5P12-RANTES-E66S. Secondary 
structure elements according to PDB entry 1EQT (81) are drawn at the top. 
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Figure 5.11 HSQC spectra of 50 µM RANTES-E66S at pH 3.8 at 25°C with 5% DHPC (A), with 
1% Cymal-5 and with 2.2% DDM/CHAPS/CHS (1/1/0.2) mixture. Negative peaks resulting from 
folding are colored red. The exemplary nonoverlaping resonances were labeled with the assignment 
information. The resonances below the threshold were surrounded by black dashed circles. 
 
 The impact of detergents on the HSQC spectrum turns out to be the same also 
for 5P12-RANTES-E66S (data not shown). Similarly to RANTES-E66S, FC-12 
cleared all of its original resonances leaving a set of new ones, again corresponding to 
both termini, whereas DDM/CHAPS/CHS did not have an effect. A summary of tested 
conditions can be found it Table 5.2. 
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Table 5.2 The effect of detergents on RANTES resonances – summary of tested conditions. 
No. RANTES pH Detergent CMC in H2O HSQC 
Intensity 
ratio (M:D) 
1 E66S 3.8 ------ ------ folded M<D 
2 E66S 3.8 1% FC-8 3.4% folded M<D 
3 E66S 3.8 5% FC-8 3.4% mixed M≈D 
4 E66S 3.8 1% FC-10 0.35% unfolded ------ 
5 E66S 3.8 0.5% FC-12 0.047% unfolded ------ 
6 E66S 3.8 1% FC-12 0.047% unfolded ------ 
7 E66S 6.3 1% FC-12 0.047% mixed M<D 
8 E66S 3.8 1% FC-16 0.00053% unfolded ------ 
9 E66S 3.8 1% DHPC 0.06742% folded M<D 
10 E66S 3.8 5% DHPC 0.06742% folded M<D 
11 E66S 3.8 1% Cymal-5 0.12% folded M≈D 
12 E66S 3.8 
1% DDM 
1% CHAPS 
0.2% CHS 
0.0087% 
0.49% 
------ 
folded M≈D 
13 E66S 3.8 0.26% FC-12 1:2 CCR5 ratio 0.047% folded M<D 
14 E66S 3.8 0.45% FC-12 1:1 CCR5 ratio 0.047% mixed M<D 
15 5P12-E66S 3.8 1% FC-12 0.047% unfolded ------ 
16 5P12-E66S 3.8 
1% DDM 
1% CHAPS 
0.2% CHS 
0.0087% 
0.49% 
------ 
folded M only 
 
5.2.1.3 Circular dichroism 
 The disappearance of RANTES HSQC resonances in the presence of some 
detergents implies that some kind of direct RANTES-detergent interaction takes place. 
The fact that the RANTES resonances become invisible upon contact with detergents 
but not with the other was not reported previously and has a strong impact on the 
selection of the detergent for RANTES-CCR5 interaction studies and on the 
interpretation of the results obtained by Nisius in FC-12 (82). 
 To investigate this phenomenon further CD of RANTES-E66S was measured 
without and with the presence of FC-12 (Figure 5.12). First, the spectra of plain buffer 
and of buffer with 0.5% FC-12 were measured to check for the contribution of 
detergent to the measured ellipticity. The spectra of both the plain buffer and the buffer 
with detergent did not show any differential absorbance of left and right circular 
polarized light (straight lines, data not shown). Subsequently, after collecting the 
spectrum of RANTES-E66S in the plain buffer, few microliters of concentrated FC-12 
stock was mixed into the cuvette to 0.5% final concentration. The overall shape of the 
RANTES-E66S spectrum changed dramatically after the addition of the detergent. The 
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positive hump at 230-235 nm disappeared and the negative amplitude of the signal 
increased. A minimum at ∼208 nm became very pronounced. These changes suggest 
that in the presence of FC-12 RANTES-E66S secondary structure may be severely 
perturbed. 
 
 
Figure 5.12 CD spectra of 50 µM RANTES-E66S after subtraction of the plain buffer (blue) and of 
50 µM RANTES-E66S with 0.5% FC-12 after subtraction of the buffer with 0.5% FC-12 (green). 
 
5.3 Discussion 
 Gaining insights into CCR5-RANTES interaction is an important step towards 
understanding RANTES-mediated CCR5 signal transduction as well as the mechanism 
of HIV-infection inhibition. Although CCR5-RANTES interaction have been studied in 
vivo and in vitro, no atomic resolution details could be elucidated. To facilitate CCR5-
RANTES interaction studies by NMR, in parallel to establishing an NMR-emendable 
system for CCR5, we have looked into RANTES itself and into a suitable system, in 
which its interaction with CCR5 could be studied. 
 For this purpose 5P12-RANTES-E66S, a clinically relevant, noninflammatory 
and highly-effective against HIV infection RANTES variant was cloned. Using the 
previously established protocols, 5P12-RANTES-E66S was expressed in 15N,13C-
labeled minimal medium as N-terminal fusion to GB1 domain of protein G and purified 
with milligram yields. The sample could be concentrated to mM concentration and 
could be stored for years without any signs of deterioration. 
 The HSQC spectrum of 5P12-RANTES was composed of 63 sharp backbone 
resonances (corresponding to 63 nonproline RANTES residues) spanning over 4 ppm 
of hydrogen dimension. Such large peak dispersion is characteristic for well folded 
proteins. The fact that no second set of resonances is observed even at 0.6 mM and that 
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HSQC spectrum overlaps better with RANTES-E66S monomer is an evidence that 
5P12-RANTES-E66S is purely monomeric. Differences with regards to the 
oligomerization behaviour between 5P12-RANTES-E66S and the wild type RANTES 
are expected as in the 5P12-RANTES-E66S the N-terminus providing a dimerization 
interface and E66 involved in tetramerization are mutated. The monomerizm of 5P12-
RANTES-E66S is a clear benefit for its anti-microbicide properties (aggregation of 
RANTES causes inflammation and enhances HIV infection) as well as an advantage for 
NMR studies. 
 As the N-terminus of 5P12-RANTES-E66S starts with a glutamine, a cyclic 
pyroglutamate is spontaneously formed. Right after sample preparation the N-terminus 
is mostly free. After one day at pH 3.8 ∼30% is already cyclic and after four days of 
incubation at mixed temperatures (37°C form NMR measurement and 4°C for storage) 
the reaction is complete in ∼90%. The half life is the reaction is approximately 2 days. 
 Based on the data obtained from CBCANH (13Cα, 13Cβ shifts) and HNCO (13C’, 
15N shifts) experiments a chemicals shift table of 5P12-RANTES-E66S was composed. 
By subtracting random coil values a secondary chemical shifts were calculated. The 
obtained secondary shift plot predicts the expected helical secondary structure elements 
present in the wild type RANTES, namely the short 310 helix (η1, residues 20-22) and 
the long C-terminal α-helix (α1, residues 55-67) as well as the three β1 (residues 24-
29), β2 (residues 39-43), and β3 (residues 48-51) strands but not the N-terminal βN 
(residues 8-10). The absence of the first β-strand is expected as for the wild type 
RANTES it was a part of the intermolecular β-sheet, which for the monomeric 5P12-
RANTES-E66S is not formed. In general, with the exception of the unstructured N-
terminus and the inability to dimerize, 5P12-RANTES-E66S secondary structure 
closely resembles the wild type RANTES. A remarkable overlap of the 5P12-
RANTES-E66S HSQC spectrum with the spectrum of the RANTES-E66S monomer 
supports this conclusion. 
 Performed T1, T2 and {1H}-15N NOE relaxation experiments showed that the 
tumbling rate of 5P12-RANTES-E66S is relatively uniform for residues 10-66 of the 
5P12-RANTES-E66S molecule. This means that the main body of 5P12-RANTES-
E66S behaves like a rigid particle. The relaxation of the residues 67-68 is slower and is 
a consequence of the increased flexibility of the C-terminus (C-terminal fraying). As 
the N-terminus of 5P12-RANTES-E66S in not involved in the intermolecular β-sheet, 
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large flexibility of the N-terminus is expected. The observed low 1/T1, 1/T2 {1H}-15N 
NOE values are the consequence of ps-ns motions (residues 0-9), whereas the 1/T2 
hump (residues 5-9) a result of the additional motions on the µs-ms time scale. 
 Both RANTES-E66S and 5P12-RANTES-E66S were shown to interact with 
Fos-Choline detergents. The interaction appeared as an intensity decrease of the 
majority of the HSQC peaks. Interestingly, it was not the case for a set of ~15 backbone 
(and few side chain) resonances, which remained visible even after a complete 
bleaching of all other signals. Most of these peaks (12 out of 15) could be assigned 
based on HNCACB experiment to the N- (residues 3-7) and C-termini (residues 62-68). 
From the secondary chemical shifts of the residues 62-68 it could be concluded that in 
the presence of FC-12 the C-terminal α-helix (or at least its second half) is present. 
 The RANTES-E66S resonance bleaching was observed for all tested Fos-
Cholines with C8, C10, C12 and C16 aliphatic chains. The effect was dependent on 
detergent concentration, the length of its aliphatic chain (directly related to CMC) and 
pH. Depending on the combination of these factors, unperturbed (e.g. 1% FC-8 pH 
3.8), mixed (e.g. 5% FC-8 pH 3.8 or 1% FC-12 pH 6.3) or completely bleached (e.g. 
1% FC-12 pH 3.8) RANTES-E66S spectra could be observed. 
 The very similar resonance bleaching was observed when FC-12-solubilzied 
unlabeled m9CCR5306 monomer was titrated into RANTES-E66S. The observation that 
0.45% FC-12 introduced with 1:1 molar ratio of m9CCR5306 did not bleach RANTES-
E66S spectrum completely, whereas 0.5% FC-12 with m9CCR5306 did, can be 
rationalized by the involvement of a part of FC-12 in the interaction with m9CCR5306 
(solubilization). If to assume that 165 FC-12 molecules (see section Characterization of 
CCR5 size distribution, stability and homogeneity of Chapter 4) solubilize one 
m9CCR5306 monomer, then the presence of 41 µM m9CCR5306 leaves ~0.24% less FC-
12 for the interaction with RANTES-E66S. Therefore, despite total 0.45% FC-12 
contents, the effective FC-12 concentration affecting RANTES-E66S resonances is 
only ~0.2%. 
 Extending the analysis on other detergents, we have tested the impact of DHPC 
(similar head group as Fos-Cholines but two short aliphatic chains), Cymal-5 
(maltoside head group) and DDM/CHAPS/CHS mixture (frequently used in functional 
CCR5 studies) on RANTES-E66S HSQC spectrum. DHPC up to 5% concentration did 
not affect RANTES-E66S in any major way. This suggests that the property of 
RANTES-E66S (and also 5P12-RANTES-E66S) resonance bleaching cannot be 
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attributed solely to the choline head group of Fos-Choline detergents but rather results 
from the interplay between the head group and the aliphatic chain. This is supported by 
the fact that Cymal-5, having the same aliphatic chain as FC-12 but different head 
group did not bleach the intensities of RANTES-E66S. On the other hand both Cymal-5 
and DDM/CHAPS/CHS mixture shifted the RANTES-E66S equilibrium towards 
monomer. 
 The impact of FC-12 on RANTES-E66S was further analyzed by CD. A 
dramatic change of the shape of the spectrum suggests that in the presence of FC-12 
RANTES-E66S secondary structure is affected. The appearance of a pronounced 
minimum at ~208 nm may suggest that RANTES-E66S adopted more α-helical 
structure. Although the disappearance of protein resonances is often cause be 
aggregation (the so-called “dark state”), this mechanism is less likely, as the resonance 
bleaching is observed also for the nondimerizing 5P12-RANTES-E66S at pH 3.8 
(conditions strongly promoting high solubility, where even heavily aggregating wild 
type RANTES can be studied). 
 Taken together, these findings show that careful detergent selection for 
CCR5-RANTES studies is absolutely crucial. The lack of 2D7 recognition may suggest 
that in the presence of FC-12 the native CCR5 structure is not maintained. The 
disappearance of the HSQC resonances upon the addition of FC-12 is a clear evidence 
of the RANTES-FC-12 interaction. The CD spectrum distortion indicates that FC-12 
perturbs RANTES secondary structure. These three observations suggest that the FC-12 
should be considered unsuitable for CCR5-RANTES interaction studies and that the 
previous observations by Nisius by NMR (13) and ITC (82) were erroneously 
interpreted as CCR5-RANTES binding. 
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Abstract
Currently no experimental 3D structure for the GPCR and HIV-1 coreceptor CCR5 are
available that would help understanding its diverse roles and allow the development of better
drugs, both against HIV-1 infection and inflammation diseases. Here, we present a
comprehensive SPR-based study of the interactions of CCR5 with different ligands, including
the small-molecule inhibitor Maraviroc, diverse variants of the chemokine RANTES, as well
as the conformation-dependent antibody 2D7. Our data suggest that the similar anti-HIV
potency for two RANTES variants differing in their N-terminus (5P12-RANTES and
PSC-RANTES) is due to two different mechanisms: to the higher affinity of 5P12-RANTES
for CCR5, while the lower affinity of PSC-RANTES for CCR5 is compensated by
internalization and sequestration of CCR5 in the cell. Hence, 5P12-RANTES efficiently
blocks CCR5 which still sits on the membrane, while PSC-RANTES hides CCR5 in the cell,
making it inaccessible to gp120 on HIV-1 particles. In addition to these observations, our
data show linear oligomerization of WT-RANTES and its modulation by variations in the
C-terminus of the chemokine.
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Introduction
The G protein-coupled receptor (GPCR) CC chemokine receptor 5 (CCR5) regulates immune-cell
trafficking upon activation by its endogenous ligands: macrophage inflammatory protein 1α (MIP-1α,
also known as CCL3, chemokine (C-C motif) ligand 3), MIP-1β (also known as CCL4), and RANTES
(Regulated on Activation, Normal T-cell Expressed and Secreted, also known as CCL5) (reviewed in
[1]). These agonists activate G protein signaling and regulate CCR5 by processes involving
phosphorylation by G protein coupled receptor kinases (GRK), desensitization by β-arrestin,
internalization in the cell, and either recycling to the cell surface or degradation.
The entry of the human immunodeficiency virus type 1 (HIV-1) into host cells requires the sequential
interaction of the viral envelope glycoprotein 120 (gp120) with the host-cell factor CD4 and with either
CCR5 or CXCR4 (CXC chemokine receptor 4, reviewed in [1–3]). This process is facilitated by the fact
that these three receptors cluster on microvilli of macrophages and T cells [4]. This encounter leads to
the fusion of viral and host cell membranes which results in the infection of the cell by HIV-1. In general,
CCR5 serves as the coreceptor during both the early stages and the asymptomatic phase of infection.
CXCR4 can serve this function in later stages: during progression of the disease to AIDS, possibly as
a result from pressure of the immune system against R5-tropic viruses (i.e. viruses using CCR5), thus
favoring X4-tropic viruses (i.e. viruses using CXCR4).
Since both, viral gp120 and the chemokines bind to overlapping extracellular parts of the receptor, the
presence of a chemokine prevents the interaction of CCR5 with the viral protein, thereby hindering HIV-1
infection [5, 6]. Indeed, RANTES, MIP-1α, and MIP-1β were identified as HIV-1 suppressive factors
in CD8+ T cells [5]. Blocking of CCR5 as a medical approach to prevent HIV-1 infection was further
encouraged by the observation that homozygous individuals with the ∆32 mutation (a 32 base-pair deletion
in the CCR5 gene which results in a frameshift and the expression of a truncated nonfunctional receptor)
are virtually resistant to HIV-1 infection, while not suffering from any major health issues [7, 8]. This
effect results from the absence of CCR5 on the surface of cells and thus the impossibility for gp120 to find
its coreceptor [9].
As the use of natural chemokines as drugs would induce undesirable effects (i.e. inflammation), different
approaches have been undertaken in order to develop noninflamatory chemokine variants (especially
RANTES variants) with high activity against HIV-1 infection. These include N-terminal truncations
[10–16], chemical modifications (among others, PSC-RANTES) [17–20], mutagenesis and elongation
(among others, 5P12-RANTES) [21–24], as well as fusion strategies [25, 26]. Other approaches have used
peptidic fragments of the chemokine such as the N-terminus [27–29] or the N-loop/β1-strand [30–32].
Some RANTES variants with N-terminal modifications showed promising characteristics as topical
microbicides. For example, PSC-RANTES protected from vaginal challenges for HIV-1 infection in
macaques [6]. Later, 5P12-RANTES and 6P4-RANTES were developed in order to lower the high
production cost for chemical synthesis of PSC-RANTES [24]. These fully-recombinant variants showed
similar anti-HIV effects as PSC-RANTES [24, 33], i.e. ∼20x anti-HIV potency over WT-RANTES [24].
Moreover, their stability indicated that they are suitable for use as topical microbicides [34].
5P12-RANTES is currently being tested in clinical trials. This variant was chosen over 6P4-RANTES
(and PSC-RANTES) because it is not an agonist, but an inverse agonist (also known as antagonist), and
thus elicits neither CCR5 signaling nor internalization (and subsequent recycling), but simply blocks the
binding site for chemokines and gp120 [24]. This is explained by the different N-terminus on these
variants, as shown in Figure 1 and discussed below.
Small-molecule antagonists have been developed by several pharmaceutical companies. These include
compounds such as TAK-779 [37], SCH-C [38], Aplaviroc [39], Vicriviroc [40], TAK-220 [41], and
Maraviroc [42]. These small molecules are CCR5 antagonists and bind to a common area: a groove on
the extracellular side of CCR5 which is formed by the transmembrane helical bundle ([43–47], see
below). Whereas small-molecule inhibitors listed above prevent the binding of gp120 by an allosteric
mechanism, Kang et al. [48] recently presented a sligthly larger small-molecule inhibitor which, in
addition to binding to the allosteric site, can protrude out of the transmembrane groove and sterically
block interactions involving the second extracellular loop of CCR5. This kind of dual-mechanism
inhibitor should be valuable for anti-HIV drugs. Maraviroc, however, is currently the only drug towards
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           1......... 11........ 21........
WT-R.      SPYSSDTTPC CFAYIARPLP RAHIKEYFYT
PSC-R.     XXXSSDTTPC CFAYIARPLP RAHIKEYFYT
5P12-R.  Q GPPLMATQSC CFAYIARPLP RAHIKEYFYT
           31........ 41........ 51........ 61....68
WT-R.      SGKCSNPAVV FVTRKNRQVC ANPEKKWVRE YINSLEMS
PSC-R.     SGKCSNPAVV FVTRKNRQVC ANPEKKWVRE YINSLEMS
5P12-R.    SGKCSNPAVV FVTRKNRQVC ANPEKKWVRE YINSLEMS
Figure 1: The RANTES variants PSC-RANTES and 5P12-RANTES differ from WT-RANTES by
their N-terminus sequence (underlined in the sequence and shown as spheres on the RANTES monomer
structure). The differences in PSC-RANTES and 5P12-RANTES compared to WT-RANTES are
highlighted in gray on the sequence. XXX stands for the n-nonanoyl-thioprolyl-cyclohexylglycyl moiety,
which replaces the first three amino acids in PSC-RANTES. The glutamine residue at the N-terminus of
5P12-RANTES undergoes spontaneous cyclization to pyroglutamate [35]. The figure with PDB 1RTO
[36] was prepared using PyMOL (Schrödinger).
CCR5 on the market. It reached the market after accelerated approval by the FDA in 2007. It is now
being used for treatment of R5-tropic HIV-1 infections under the commercial names of
Selzentry R©/Celsentri R©. Although Maraviroc has been administered to patients for the medical
treatment of HIV-1 for only a few years, cases of resistance to this drug and other entry inhibitor
candidates [49–52] indicate that new drugs will be needed, calling to a better understanding of CCR5
and its interactions with different ligands.
Whereas chemokines are expected to interact with the extracellular side of CCR5, the small-molecules,
as already discussed, bind to CCR5 in an extracellular groove present in the center of the transmembrane
helices [43–47]. This was shown indirectly through mutagenesis and modeling studies using Maraviroc,
Vicriviroc, Aplaviroc, TAK-779 and TAK-220 [43–46], and also directly using a cross-linking approach
[47]. This is consistent with the fact that both small-molecule inhibitors and antibodies recognizing
the N-terminus of CCR5 can bind simultaneously, as indicated by their apparent synergy against HIV-1
infection [53]. The binding mode for chemokines involves the use of different parts of the chemokine for
binding to the extracellular loops of CCR5 (core domain of the chemokine) and CCR5’s transmembrane
domain (N-terminus of the chemokine) [54–56]. These also have a different function. The core domain of
the chemokine allows tight binding to the various extracellular parts of CCR5 (including the N-terminus
[55]), while the N-terminus of the chemokine protrudes into the groove formed by the transmembrane
helices and elicits activation of the receptor [54]. This is the so-called two-site model [57]. The binding
site for small-molecule inhibitors is termed the allosteric site, as opposed to the extracellular chemokine
binding site which is termed the orthosteric site [46, 58].
For the characterization of CCR5 and its interactions with different ligands, several groups turned to
surface plasmon resonance (SPR) and used detergent-solubilized CCR5. Navratilova et al. [59] optimized
solubilization conditions for maximal stability of CCR5 and focused on improving the recognition of the
extracted receptor by the conformation-dependent antibody 2D7 [60]. It was shown that a detergent
mix (DDM/CHAPS/CHS) supplemented with lipids (DOPC and DOPS) could both extract properly
folded CCR5 and stabilize it, consistent with the fact that cholesterol (from which CHS is a derivative)
is essential for conformational integrity of CCR5 [61]. Later, Navratilova et al. [62] showed that CCR5 in
these conditions was able to bind both its natural ligand RANTES and several small-molecule inhibitors,
including TAK-779 [37]. Also, binding of nine HIV-1 gp120 variants with CCR5 was shown [63]. As a
follow-up on the detergent screen by Navratilova et al. [59], Rich et al. [64] published a method by which
high-throughout detergent screening could be performed using SPR. For this study, they used CCR5
as a model and probed the recognition by the conformation-dependent antibody 2D7 [60]. Although
details for each detergent were not made available, the authors noted the general trends that maltoside
detergents with a C9 to C13 alkyl tail were the ones which, while being able to solubilize CCR5, could
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also maintain the highest binding ability. Recently, Navratilova et al. [65] proposed an elegant approach
to probe binding of ligands to a specific binding site. Their approach consisted in using three different
channels for recording the SPR data. The first and second channels were as in a standard setup and
consisted of a reference channel without CCR5 and a channel with CCR5. A third channel consisted of
CCR5 saturated with the small-molecule inhibitor Maraviroc. That way, ligands could be discriminated
as whether their binding was affected by the presence of a small-molecule inhibitor in the allosteric site,
an important feature for anti-HIV small-molecule drug screening.
Contrary to the studies cited above which used detergent-solubilized CCR5, Silin et al. [66] directly
coupled CCR5-containing membrane vesicles to the SPR chip. Using this setup, they could show the
highly functional nature of CCR5 with the interaction of almost stoichiometric amounts of RANTES.
Yoshiura et al. [56] used SPR-based recognition of CCR5 by 2D7 to show the long term stability of CCR5
embedded in lipids of nanodiscs. The authors also showed MIP-1α binding to CCR5 using both SPR and
NMR (nuclear magnetic resonance) data.
Previously, we have described large-scale expression of CCR5 based on the baculovirus / insect cell system
[67]. This system, while still taking advantage of eukaryotic cells, provides an improvement in terms of
yield when compared to mammalian cell expression as pioneered by Mirzabekov et al. [68] for CCR5.
The yield is also higher than for expression in E. coli as demonstrated by Ren et al. [69]. In theory, an
advantage of using eukaryotic expression (e.g. with the insect cell system) over prokaryotic expression,
is the possibility of obtaining proteins including posttranslational modifications [70]. This is important
as CCR5 contains several posttranslational modifications (disulfide bridges, sulfated tyrosine residues,
O-glycosylation, palmitoylation of selected cysteine residues, and phosphorylation, discussed in [71]).
Here, we present an extensive set of SPR data showing the ligand binding competency of our
recombinant, insect cell-overexpressed CCR5 [67]. We show the binding of RANTES variants and the
interference by the presence of Maraviroc or the 2D7 antibody. These data give insights on the binding
modes of RANTES variants, in particular on the different mechanisms by which both PSC-RANTES
and 5P12-RANTES (which differ in their N-terminus) reach similar anti-HIV potencies, despite
displaying different phenotypes and affinities for CCR5. Moreover, we observe linear oligomerization of
WT-RANTES through a mechanism related to aggregation, a process speculated to serve for
pre-concentration of chemokines near their target receptors [72–74].
Materials and Methods
Materials
Detergents were purchased from Anatrace (High Wycombe, UK) and lipids from Avanti Polar Lipids
(Alabaster, USA), while other reagents were either from Applichem (Darmstadt, Germany), Roth
(Arlesheim, Switzerland), or Sigma-Aldrich (Buchs, Switzerland). The 2D7 and anti-His antibodies were
from BD Pharmingen (Allschwil, Switzerland) and Qiagen (Hombrechtikon, Switzerland), respectively.
5P12-RANTES-E66S and RANTES E66S were overexpressed as described previously for RANTES-E66S
by Duma et al. [55]. Importantly, we ensured that the N-terminal glutamate residue in
5P12-RANTES-E66S was cyclized to pyroglutamate [35] using both mass spectrometry and nuclear
magnetic resonance (NMR, data now shown). WT-RANTES, WT-RANTES-biotin, PSC-RANTES,
5P12-RANTES-biotin, as well as MIP-1β were prepared by total chemical synthesis as described before
[20, 75]. The variants used in this study differed in the presence or absence of the mutation E66S, which
prevents aggregation of RANTES at pH >4.
CCR5 was overexpressed in the baculovirus / insect cell system as described before [67]. It contained a
C-terminal 6-His tag followed by a Strep-tag. Insect cell membranes containing the β1 adrenergic receptor
mutant m23 (β1AR-m23) were prepared as in [76] and used as a control.
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SPR
SPR experiments were performed with a T100 instrument from GE Healthcare (Zürich, Switzerland)
running at 20◦C (with samples kept at 8◦C) with a flow rate of 50 µL/min. In general, injections were
performed for 360 s (6 min) with dissociation recorded for 1200 s (20 min). Between injections, one
or more additional 1000 s (∼17 min) waiting periods were generally inserted for proper dissociation of
accumulated ligands in order for the captured receptor to return to the apo state. Data were analyzed
using the Biacore T100 Evaluation Software (GE Healthcare, Zürich, Switzerland). Curve fitting was
performed using a 1:1 interaction model and took into account both refractive index contributions [77]
and mass transport effects [78]. In order to allow comparison of signal amplitudes, sensorgrams were also
normalized for the amount of CCR5 on the chip. Indeed, capture of CCR5 on the chip varied from 2000
to 6000 RU (resonance units) and was normalized between different experiments to the same amount (i.e.
5000 RU). The variation in the noise, especially visible for Maraviroc, is a consequence of the normalization
procedure based on the effective level of receptor captured on the chip. For β1AR-m23 (control), only low
amounts of the receptor mutant (known to overexpress poorly [76]) were captured on the chip surface.
The SPR setup consisted of a sensor chip CM5 (i.e. gold surface modified with carboxymethylated
dextran, purchased from Biacore, Zürich, Switzerland) on which an amine-coupled (using EDC,
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride, and NHS, N-hydroxysuccinimide,
purchased from Biacore, Zürich, Switzerland) anti-His antibody (Qiagen, Hombrechtikon, Switzerland)
was immobilized and used for the capture of CCR5 through its C-terminal His-tag. The capture was
used as an on-chip affinity purification for the isolation of CCR5 from clarified detergent-solubilized
crude membrane solutions. This allowed fast immobilization of CCR5 and, consequently, retention of
activity, as CCR5, like other GPCRs, is known to lose activity as a function of time when in solution
with detergents [56, 59]. After capture of CCR5 on the chip, it was important to wait sufficiently long
(from 5 to 10 hours) such that the initial decay from the antibody surface became negligible. This
ensured a stable baseline and did not affect the quality of captured CCR5. Indeed, no noticeable loss of
activity was observed as a function of time (up to several days) when CCR5 was captured on the SPR
chip (data not shown). The reference channel was used to subtract background signal due to, for
example, changes in refractive index during injection of analytes. The reference channel also contained
the anti-His antibody and served as a control for binding to either the chip dextran matrix surface or the
anti-His antibody. Subtraction of blank injections was used in addition to the use of the reference
channel (i.e. double-referencing, [79]).
For SPR experiments, insect cell membranes containing baculovirus-overexpressed CCR5 were prepared
according to Nisius et al. [67], except that the buffer consisted of 10 mM HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) pH 7.5, 150 mM NaCl, 50 µM EDTA
(ethylenediaminetetraacetic acid), 10% (v/v) glycerol (buffer A) and contained no protease inhibitors.
The membrane preparations were frozen at -70◦C in 200 µL aliquots (equivalent to 15 mL of CCR5
culture, i.e. ∼30 µg of CCR5). CCR5 was solubilized from these aliquots for 2 h at 4-8◦C. The aliquots
were first thawed and mixed with 133 µL of 6% (w/v) DDM (n-Dodecyl-β-D-maltopyranoside) in buffer
A, 200 µL of 4% (w/v) CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) + 0.8%
(w/v) CHS (cholesteryl hemisuccinate) + 0.3144% DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) in
buffer A: for final detergents and lipids concentrations as follows: 1% (w/v) DDM, 1% (w/v) CHAPS,
0.2% (w/v) CHS, and 0.0786% (w/v) DOPC. For the control with FC-12 (n-dodecylphosphocholine),
the final concentration was 1% (w/v). After solubilization, soluble material was separated from insoluble
material by centrifugation at 17000 g for 60 min at 4-8◦C. The SPR running buffer consisted of 20 mM
HEPES pH 7.0, 150 mM NaCl, 0.1 mg/mL BSA (bovine serum albumin), 0.02% (w/v) CHS, 0.1% (w/v)
CHAPS, 0.1% (w/v) DDM, and 50 nM DOPC (buffer B). For the control with FC-12, the final
concentration was 0.1% (w/v).
Non-E66S RANTES variants (WT-RANTES and PSC-RANTES) displayed high-amplitude non-specific
binding to the dextran matrix of the CM5 sensor chip at concentrations equal or above 108 nM (data not
shown). Hence, experiments with these variants were performed with concentrations up to 36 nM (where
no such unspecific interaction to the chip was observed). The ability of E66S RANTES variants to form
higher order oligomers (or to interact with the dextran matrix) was reduced [80–82] and no unspecific
binding to the CM5 chip was observed for concentrations up to 1 µM.
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Figure 2: Interaction of different ligands with CCR5. Interactions with a CCR5 surface in
DDM/CHAPS/CHS (the detergent mix used for subsequent experiments, left). Controls include surfaces
without any receptor, with CCR5 solubilized in FC-12, as well as with a different GPCR (β1AR-m23).
Fits for data in DDM/CHAPS/CHS are shown in light gray (with fitted values available in Table 1).
RANTES variants were injected at 36 nM, Maraviroc at 108 nM, and 2D7 at 5 nM. For each case, both
solubilization and the SPR experiment were performed using the corresponding detergent mix.
Results and Discussion
Interaction of different ligands with CCR5
In order to study interactions of CCR5 with its ligands, we turned to SPR, as it allows direct, real-time,
and label-free observation of molecular interactions [83]. SPR was already successfully used to study
CCR5 and other GPCRs (reviewed in [84]). Immunoprecipitation and SPR experiments using the
conformation-dependent 2D7 antibody (which recognizes the natively folded first half of the second
extracellular loop of CCR5, ECL2, [60, 85]) showed that maltoside detergents are best suited for
recognition of CCR5 [59, 62, 64, 68]. Using SPR and CCR5 solubilized using a detergent mix including
the maltoside detergent DDM (DDM/CHAPS/CHS), we could observe binding of all the ligands tested:
the 2D7 antibody, RANTES variants WT-RANTES, PSC-RANTES, and 5P12-RANTES-E66S, as well
as Maraviroc (see Figure 2). As all ligands tested (including MIP-1β, see Supplementary Figure S1 and
accompanying text) showed interaction with CCR5 solubilized in DDM/CHAPS/CHS, this mix was
used for subsequent experiments. A very similar mixture was previously shown to be optimal for the
stabilization of GPCRs [86, 87] and was also used for CCR5 in a previous SPR study [62].
Interaction with the conformation-dependent antibody 2D7 [60, 85], was clearly observed in this detergent
mix. This interaction, with a KD on the sub-nM range, confirmed the quality of our protein (see Figure 2
and Table 1). A similar approach was used by Myszka and coworkers to assess the quality and quantity
of solubilized CCR5 in their SPR experiments [59, 63, 64].
The observed KD values for each RANTES variant were in the nM to sub-nM range, with
5P12-RANTES-E66S displaying a higher (∼20-25x) affinity than the other ligands: ∼2.6 nM for
WT-RANTES, ∼2.1 nM for PSC-RANTES, and ∼0.1 nM for 5P12-RANTES-E66S (see Figure 2 and
Table 1). Previously, the affinity of RANTES for CCR5 was characterized and yielded an IC50 of ∼7 nM
in a competition experiment with MIP-1β [88] and KD values from 0.2 to 6.2 nM in different setups
[22, 45, 89] including SPR [62].
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Table 1: Fitted parameters for 1:1 interaction with CCR5.
Variant MW Detergents kon koff KD Rmax χ2
(kDa) (s−1M−1) (s−1) (nM) (RU) (RU2)
2D7 ∼150 DDM/CHAPS/CHS 5 x 105 5 x 10−5 0.1 638 0.156
WT-RANTES 7.851 FC-12 6 x 104 3 x 10−4 4.7 83 0.0804
WT-RANTES 7.851 DDM/CHAPS/CHS 1 x 105 3 x 10−4 2.6 60 0.0589
PSC-RANTES 7.894 DDM/CHAPS/CHS 3 x 106 7 x 10−3 2.1 96 1.38
5P12-RANTES-E66S 7.884 DDM/CHAPS/CHS 3 x 105 2 x 10−5 0.1 78 0.183
5P12-RANTES-biotin 8.434 DDM/CHAPS/CHS 5 x 105 2 x 10−4 0.4 70 0.0750
Maraviroc 0.514 DDM/CHAPS/CHS 4 x 104 6 x 10−5 1.4 19 0.0657
MW: Molecular weight.
Rmax: Maximal amplitude extracted from fit. Fitted parameters were rounded for presentation purposes.
Although the fitted KD values were in a similar range for the different RANTES variants, the binding
profiles displayed significant differences with regards to both association (kon) and dissociation (koff)
rates. Indeed, PSC-RANTES associated with a fast kon of ∼3 x 106 s−1M−1, whereas WT-RANTES
and 5P12-RANTES-E66S had very similar kon values of ∼1 x 105 and 2 x 105 s−1M−1, respectively.
For the koff , all RANTES variants behaved differently with PSC-RANTES dissociating relatively fast
(koff = 7 x 10−3 M−1), WT-RANTES dissociating on an intermediate timescale (koff = 3 x 10−4 M−1)
and 5P12-RANTES-E66S dissociating more slowly (koff = 2 x 10−5 M−1). The fitted association and
dissociation parameters for WT-RANTES are discussed in light of data previously reported by Navratilova
et al. [62] in the Supporting Material (see Supplementary Figure S2 and accompanying text).
To probe whether the E66S mutation affected the interaction of 5P12-RANTES-E66S with CCR5, we
used 5P12-RANTES without the E66S mutation (5P12-RANTES-biotin, a 5P12-RANTES variant
C-terminally coupled to biotin). As shown in Supplementary Figure S3 the binding profiles for both
5P12-RANTES variants were analogous, yielding similar affinities (see Table 1). As the E66S mutation
in 5P12-RANTES-E66S allowed working at higher concentration (see further below), we worked with
5P12-RANTES-E66S for most experiments.
Although of very low amplitude due to the low molecular weight (514 Da), the signal for the binding of
Maraviroc could be observed with 1.4 nM affinity (see Figure 2 and Table 1). This is in agreement with
KD values of ∼0.07-0.86 nM reported by Napier et al. [90].
Several control experiments showed the specificity of observed signals to the captured CCR5 (see Figure 2).
In a first control, insect cell membranes in which CCR5 was absent were solubilized in DDM/CHAPS/CHS
(see Figure 2). In this case, no binding was observed, confirming the absence of interaction to other proteins
from in insect cell membranes that could have been captured on the chip, either by adsorption on the
dextran matrix or recognition by the anti-His antibody.
A second control was performed with CCR5 solubilized using the detergent FC-12 (see Figure 2), from
the fos-choline series of detergents in which the absence of recognition by 2D7 was previously shown
[59, 68]. In agreement with these results, 2D7 did not bind to CCR5 in FC-12, similarly to most ligands
tested. However, surprisingly, WT-RANTES could also bind CCR5 in FC-12, where no other ligands
(except PSC-RANTES to a very low amplitude) could interact with the receptor. These results could
indicate unspecific binding of the wild type chemokine to the protein/detergent mixed micelle. This topic
is discussed in more detail below.
In a third control, we immobilized a different GPCR on the chip, namely the m23 mutant of the
β1 adrenergic receptor (β1AR-m23) [76]. As shown in Figure 2, no interaction was observed for 2D7,
5P12-RANTES-E66S and Maraviroc on β1AR-m23. For WT-RANTES, a clear binding signal was
observed. This could be fitted to a KD of 2.2 nM, in the same range as for WT-RANTES with CCR5 in
DDM/CHAPS/CHS and FC-12 (i.e. 2.6 and 4.7 nM, respectively, see Table 1). However, both the
association and dissociation phases appeared faster. The normalized amplitude was also very similar
with a fitted Rmax of 65 RU compared to 60 RU for interaction with CCR5 in DDM/CHAPS/CHS. This
result indicates that WT-RANTES is likely interacting with the mixed micelle formed by a GPCR and a
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Figure 3: Effect of Maraviroc on binding of RANTES variants in DDM/CHAPS/CHS. RANTES variants
were injected at 36 nM. Maraviroc was included in the running buffer, which allowed constant saturation.
The binding profiles in absence of both 2D7 and 5P12-RANTES-E66S are shown as references on the left.
detergent. Alternatively, WT-RANTES might simply interact with the many charges on both receptors.
However, the details of this interaction are probably slightly different on the two receptors, as based on
the faster association and dissociation phases for WT-RANTES with β1AR-m23 compared to
interaction with CCR5. For PSC-RANTES, some binding to β1AR-m23 was observed, although to a low
amplitude (similarly to the control with CCR5 in FC-12).
Effect of Maraviroc on RANTES binding
In cell assays Maraviroc inhibits binding of RANTES (and other chemokines) to CCR5, with an IC50 of
∼5 nM [42]. The effect of Maraviroc on the binding of the different RANTES variants was assessed (see
Figure 3). At a concentration of 1 µM, which should be sufficient for total saturation of CCR5 based on
the IC50 and the fitted KD for Maraviroc binding (1.4 nM, see Table 1), binding of 5P12-RANTES-E66S
was completely inhibited, although WT-RANTES bound with the same amplitude and the same
interaction profile as in the absence of Maraviroc. Up to a concentration of 30 µM Maraviroc,
WT-RANTES bound without changes in the profile (although interaction in the presence of 30 µM
Maraviroc was with lower amplitude). However, above 150 µM Maraviroc, the interaction was
abrogated. This could indicate a second Maraviroc binding site on CCR5, or the presence of different
populations of CCR5 with different affinities for Maraviroc. Alternatively, this observation might simply
arise because of unspecific interactions of Maraviroc to any of the components at the very high
concentration used (0.15 mM).
The interaction of PSC-RANTES was affected already by 1 µM Maraviroc, but in a different manner
compared to 5P12-RANTES-E66S. Indeed, at 1 µM Maraviroc, PSC-RANTES interacted with a fast
dissociation rate and with a total amplitude of binding reduced by ∼60%. At all higher Maraviroc
concentrations tested, this profile was identical to the situation at 1 µM Maraviroc. This contrasts with
the case of WT-RANTES where virtually no binding was observed at Maraviroc concentrations equal
or higher than 150 µM. PSC-RANTES in the presence of Maraviroc might simply yield unproductive
binding to CCR5. This is indicated by a very fast dissociation rate (and thus low affinity), and could
result from partial interaction of PSC-RANTES with CCR5 allowing its docking on CCR5, but preventing
the interaction to lock in.
Importantly, the inhibition observed for 5P12-RANTES-E66S and PSC-RANTES above 1 µM Maraviroc,
and for WT-RANTES above 150 µM Maraviroc, were both reversible after long enough dissociation
(consistent with the fitted koff , see Table 1) of Maraviroc from CCR5 (data not shown). Effects of
Maraviroc on the binding of RANTES variants were also observed in other detergent systems (data not
shown), qualitatively consistent with results from in cell assays showing inhibition of RANTES binding
in the presence of Maraviroc [42].
111
Not saturated
W
T-
R.
            Saturated
(5P12-RANTES-E66S)
Saturated
   (2D7)
0
50
100
0
50
100
R
el
at
iv
e 
re
so
na
nc
e 
un
its
 (R
U,
 no
rm
ali
ze
d)
0 500
5P
12
-R
.-E
66
S
0 500
Time (s)
0 500
0
50
100
PS
C-
R.
Figure 4: Competition experiments with 5P12-RANTES-E66S or the 2D7 antibody in
DDM/CHAPS/CHS. RANTES variants were injected at 36 nM, while the saturating injection of
5P12-RANTES-E66S (before each individual RANTES variant tested) was performed at 1 µM (middle).
For 2D7 (right), saturation was achieved by multiple 10 nM injections prior to measurement of the different
RANTES variants. The binding profiles in absence of both 2D7 and 5P12-RANTES-E66S are shown as
references on the left.
RANTES competition assay
In order to test whether RANTES variants bind to a common location, an experiment was designed in
which CCR5 was saturated with a 1 µM injection of the slow-dissociating variant 5P12-RANTES-E66S
prior to injection of the different RANTES variants (see Figure 4). After this saturating injection, the
binding of 5P12-RANTES-E66S was considerably reduced (positive control). The effect was intermediate
for PSC-RANTES, similar to the effect of Maraviroc. There was no effect on binding of WT-RANTES.
These data show a clear separation of binding sites for WT-RANTES and 5P12-RANTES-E66S, and are
in agreement with data from the Maraviroc competition assay.
An equivalent, but reversed, experiment using WT-RANTES would have been interesting, but proved
impossible since, at concentrations equal or above 108 nM, WT-RANTES interacts with the dextran
matrix of the CM5 chip used in the SPR setup (data not shown). Moreover, as shown below, binding
sites for WT-RANTES are not saturable. However, the same experiment was possible with the 2D7
antibody (see Figure 4). This 2D7 competition experiment gave very similar results to the
5P12-RANTES-E66S competition assay (see Figure 4). WT-RANTES was not competed by 2D7,
although the dissociation rate became faster. This could indicate that 2D7 covers a small portion of the
binding site for WT-RANTES or that some allosteric effects destabilize the interaction. The 2D7
competition results for 5P12-RANTES-E66S and PSC-RANTES were consistent with previously
published data where 2D7 blocked binding of RANTES, MIP-1α, and MIP-1β to CCR5 [85, 91]. Indeed,
2D7 recognizes the second extracellular loop of CCR5 [85] which is also a major determinant of
chemokine binding specificity [60, 92].
In summary, these competition experiments indicate that binding sites for PSC-RANTES and
5P12-RANTES-E66S partially overlap together and with the binding site for 2D7, while WT-RANTES
appears not to share its binding site with 5P12-RANTES-E66S, but slightly with 2D7.
RANTES saturation assay
A saturation experiment was performed during which WT-RANTES was injected several times (i.e. 40-50
times). WT-RANTES accumulated on CCR5 upon the first injection. However, contrary to what would
happen for a saturable and stoichiometric interaction, the amplitude of WT-RANTES association to
CCR5 did not decrease for subsequent injections. Overall, WT-RANTES accumulated in similar amounts
after each injection on the chip surface with captured CCR5/DDM/CHAPS/CHS mixed micelles (see
Figure 5). The same phenomenon was observed for CCR5 solubilized in FC-12 (data not shown), where
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Figure 5: Saturation experiments with WT-RANTES (circles), 5P12-RANTES-E66S (diamonds) or the
2D7 antibody (triangles). Shown is the binding amplitude of each successive injection (normalized to
the amplitude of the first injection, top) and the baseline level for subsequent injections (which reports
on total accumulation on the chip, bottom). The dashed/dotted line on the top represents 100%, while
dashed and dotted lines on the bottom represent theoretical exponential curves for aggregation with two
or three binding sites, respectively. The different molecular weights for RANTES variants (∼8 kDa) and
2D7 (∼150 kDa) scale the respective saturation profiles.
WT-RANTES is the only ligand showing clear interaction (see Figure 2), as well as with β1AR-m23.
Accumulation of WT-RANTES was constant: each new injection increased the signal with the same
amplitude. This indicates that the phenomenon observed is not unspecific aggregation of WT-RANTES
to multiple sites (see Figure 5), as the signal buildup would then get higher after each injection. Indeed,
this is more consistent with molecules injected in each round having access to a constant number of binding
sites (not less, not more). This is reminiscent of the WT-RANTES linear oligomers discussed in the work
of Wang et al. [82] (see further below).
On the contrary, binding of 5P12-RANTES-E66S reached saturation after only a few injections (see
Figure 5), consistent with 5P12-RANTES-E66S competition assay results (see Figure 4) Similarly, binding
of the 2D7 antibody saturated after only a few injections (see Figure 5).
Effect of salt
As shown by the absence of interaction in the presence of 500 mM NaCl in the running buffer (see
Figure 6), WT-RANTES binds in a mostly electrostatic manner. Also, high salt concentrations (i.e. 500
mM NaCl) completely remove bound protein (data not shown). On the contrary, 5P12-RANTES-E66S,
which interacts on the orthosteric site of CCR5 (as shown above, by the Maraviroc competition assay), can
still bind to CCR5 (with similar affinity, but lower amplitude) in the presence of 500 mM NaCl (see Figure
6), and is not removed by 500 mM NaCl (data not shown). The relative protection of 5P12-RANTES-E66S
binding to CCR5 from the effect of salt is probably related to its uncharged N-terminal pyroglutamate
residue [35] and generally hydrophobic N-terminal residues. Similarly, PSC-RANTES, which contains a
very hydrophobic N-terminus modification (N -nonanoyl, des-Ser1 [6-thioproline2, l-cyclohexylglycine3]
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Figure 6: Effect of salt on binding of RANTES variants to CCR5 in DDM/CHAPS/CHS. Interaction
of the different variants was probed with 500 mM NaCl, after which a control injection was performed at
150 mM NaCl. RANTES variants were injected at 36 nM. The binding profiles in absence of both 2D7
and 5P12-RANTES-E66S are shown as references on the left.
RANTES(2-68)) which could anchor it to CCR5, can still bind with a similar affinity, although to a
slightly lower amplitude, in the presence of 500 mM NaCl (see Figure 6).
With 500 mM NaCl in the running buffer, we could not detect the low-amplitude signal from Maraviroc.
However, when including 1 µM Maraviroc in the high salt buffer, the interaction with
5P12-RANTES-E66S, 5P12-RANTES-biotin, and PSC-RANTES was affected in a similar manner as in
the low salt (150 mM) buffer (data not shown). This indicates that, although not directly detected,
binding of Maraviroc in the presence of 500 mM NaCl is possible. This is similar to binding of
5P12-RANTES-E66S and PSC-RANTES, and consistent with Maraviroc interaction with CCR5 being
mainly driven by hydrophobic interactions (except for the interaction with Glu-283) through contacts
with the aromatic rings and aliphatic chains of residues Trp-86, Tyr-108, Tyr-251, Phe-109, and Ile-198
in the transmembrane helical groove of CCR5 [45, 47].
Mechanism of interaction by WT-RANTES
As discussed above, different competition experiments were performed with either Maraviroc,
5P12-RANTES-E66S, or 2D7 as the blocking agent. These assays proved the specificity of interaction
for most ligands, except for WT-RANTES. Indeed, WT-RANTES could bind CCR5 in both
DDM/CHAPS/CHS and FC-12, as well as β1AR-m23 in DDM/CHAPS/CHS. In addition, its binding
was only slightly affected by the presence of other ligands such as Maraviroc, 5P12-RANTES-E66S, or
2D7. Finally, its binding site could not be saturated. These data, taken together with the salt sensitivity
of the interaction, indicate the possibility for binding of WT-RANTES to either a different site on
CCR5, e.g. the highly charged intracellular part, or to the protein/detergent mixed micelles.
In order to probe the mechanism by which WT-RANTES interacts in a non-saturable manner with both
CCR5 and β1AR-m23, the behavior of additional RANTES variants was tested. The variants used for
this purpose varied in their C-terminus, but not in their core and N-terminus, the parts assumed to be
involved in binding to CCR5 [54–56]. As observed in Figure 7, the binding profile of WT-RANTES,
WT-RANTES-biotin, and RANTES-E66S varied considerably. Indeed, the dissociation rate was faster
for WT-RANTES-biotin compared to WT-RANTES. It was even faster for RANTES-E66S. The apparent
faster association phase for these two variants, as seen on Figure 7, is a consequence of faster dissociation
as the effective association phase (kobs) is governed both by the association and dissociation rates: kobs =
(kon x concentration) + koff . These results, together with the results from the saturation assay (see
Figure 5), indicate that binding of WT-RANTES to CCR5 may share some similarity with the linear
oligomerization of RANTES, a process involving the charged residue E66 (located in the C-terminus) [80–
82]. This hypothesis fits with the dramatic effect of salt on the interaction of WT-RANTES. Indeed, the
dimer-dimer interaction involved in the formation of the linear oligomers involves several salt bridges with
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Figure 7: Effect of C-terminal modifications in the binding profile of RANTES. RANTES variants were
injected at 36 nM.
K25, E26, R44, and E66 [82]. This hypothesis also reconciles assays where the binding of WT-RANTES
was shown not to saturate (see Figure 5). Indeed, a linear oligomerization process through the C-terminus
yields linear chains, which means that molecules accumulate with a fixed rate [82], contrary to unspecific
aggregation which yields higher rates as the randomly- and multiply-branched aggregate grows in size.
Such oligomerization is not observed for 5P12-RANTES-E66S because of its C-terminus (E66S). For
PSC-RANTES, in principle, there should be oligomerization by this mechanism. However, due to the
faster dissociation rate of PSC-RANTES (precluding accumulation of the chemokine on the chip), we
could not clearly observe it.
Conclusions
The kinetics data presented here complement the study by Escola et al. [93] who explained the mechanism
by which PSC-RANTES displays its high anti-HIV potency. These data suggest that for 5P12-RANTES
(as for Maraviroc) the HIV-1 entry inhibition mechanism relies on tight interaction with CCR5 and
long-term blockade of the binding site for gp120, whereas for PSC-RANTES, this activity is based on CCR5
sequestration inside the cell as shown previously [93]. Indeed, PSC-RANTES and 5P12-RANTES display
different phenotypes [20, 24, 93] and their anti-HIV activity is modulated differently by mutations in CCR5
[94]. PSC-RANTES (and WT-RANTES) are both able to activate CCR5 and cause its internalization
[26]. However, when CCR5 is bound to PSC-RANTES, it is sequestered in the cell and does not recycle
to the cell surface [93]. On the contrary, 5P12-RANTES neither activates nor internalizes CCR5 [24].
Here, we explain the very similar anti-HIV potency of 5P12-RANTES and PSC-RANTES (respectively
28 and 25 pM) [24] as a result of higher affinity (mainly because of a slower dissociation rate) in the
case of 5P12-RANTES (see Table 1) and CCR5 sequestration in the cell for PSC-RANTES [93]. The
KD for 5P12-RANTES-E66S and 5P12-RANTES-biotin is ∼5-20x lower (∼5-20x higher affinity) than
for PSC-RANTES (see Table 1). The effect is even more pronounced for the dissociation rate which is
∼35-350x slower for 5P12-RANTES variants compared to PSC-RANTES. Thus, association of CCR5 with
5P12-RANTES is longer-lived than with PSC-RANTES. However, PSC-RANTES does not only interact
with CCR5 on the cell surface, but induces internalization and sequesters CCR5 in the cell with more
potency than WT-RANTES [93]. Once CCR5 is sequestered in the cell, it is not available for interaction
with gp120.
In Figure 8, we show a model explaining the phenotypes of Maraviroc and the different RANTES
variants. In this model, Maraviroc and 5P12-RANTES-E66S bind to the orthosteric binding site on
CCR5, which either partially overlaps with the binding site for Maraviroc or is under control of an
allosteric mechanism triggered by the presence of Maraviroc (as observed here for 5P12-RANTES-E66S
and PSC-RANTES, and by others for WT-RANTES [42, 45, 95, 96]). Indeed, as proposed by many
before, the chemokines interact with both the extracellular loops and transmembrane groove using their
core and N-terminus, respectively [54–56]. Overall, our results for 5P12-RANTES-E66S and
PSC-RANTES agree with the two-site model [54, 57]. However, WT-RANTES behaves differently in our
setup. Indeed, WT-RANTES binds not on the orthosteric site, but on a different location. One
possibility is that WT-RANTES binds on either the highly charged intracellular side of the receptor, on
the detergent-stabilized transmembrane surface of CCR5 (and β1AR-m23), or on the detergents forming
the GPCR/detergent mixed micelle, or using a combination of these mechanisms. This behavior of
WT-RANTES, however, might be related to its propensity to form linear oligomers at high
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Figure 8: Schematic model for the anti-HIV mechanisms of Maraviroc and different RANTES variants.
Although 5P12-RANTES and PSC-RANTES display similar anti-HIV potencies, their dissociation rates
from CCR5 are very different. This fits with the fact that, whereas 5P12-RANTES causes neither CCR5
signaling nor internalization, PSC-RANTES internalizes CCR5 and sequesters it in the cell. Thus, the
high anti-HIV potency of 5P12-RANTES is obtained, as for Maraviroc, through long-term blockade of
CCR5, while PSC-RANTES prevents gp120 from interacting with CCR5 by hiding it in the cell [93]. In
addition, in our SPR setup, although the exact binding site for WT-RANTES on CCR5 is undefined, linear
oligomerization of WT-RANTES following its initial attachment is clearly observed. The inset shows the
arrangement of two dimers (yellow and orange, as well as green and blue pairs) of WT-RANTES in a
linear oligomer. Residue E66 is shown as spheres. The figure with PDB 2L9H [82] was prepared using
PyMOL (Schrödinger).
concentrations [82]. Indeed, the C-terminus mutants RANTES-E66S and WT-RANTES-biotin have
considerably different binding profiles both displaying faster dissociation. This could therefore be related
to the capacity of RANTES to bind to and linearly oligomerize on glycosaminoglycans through its
C-terminus [80–82], a process important for preconcentration of the chemokines in the vicinity of their
receptors [72–74]. As already discussed earlier, this linear oligomerization process is not observed for
5P12-RANTES-E66S as its modified C-terminus (with the E66S mutation) precludes the formation of
chains of dimers. For PSC-RANTES, the fast dissociation precludes additive accumulation of the
chemokine during following injections, preventing observation of this phenomenon.
We believe the SPR setup discussed here which uses our insect cell-overexpressed CCR5 can be useful as
a complement to in vivo data, as was recently shown for Visfatin/NAMPT [97]. In the current study, we
could complement previously published data and show the different mechanisms by which PSC-RANTES
and 5P12-RANTES reach very similar anti-HIV potency. We could also observe linear oligomerization of
WT-RANTES.
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Interaction with MIP-1β
In addition to observing the interaction of 2D7, several RANTES variants, and Maraviroc, we could
observe the interaction of CCR5 with an additional, MIP-1β. The fitted KD was ∼180 nM (see Figure 9).
The affinity was lower compared to the KD in COS-7 cells (∼2 nM) [88] and HEK-293 cells (∼0.2 nM) [90]
or the IC50 measured in COS-7 cells (∼7 nM) [88] and CHO-K1 cells (∼10 nM) [98]. High concentration
of MIP-1β (1 µM) was necessary for observation of a clear binding signal.
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Figure 9: Binding profile of MIP-1β in DDM/CHAPS/CHS. MIP-1β was injected at 1 µM.
Comparison with previous studies
Although the KD for WT-RANTES is very similar to the value previously published by Navratilova et al.
[62] (i.e. 2.6 nM vs 3.9 nM), both the association and dissociation rates are very different, with the
kon and koff values from Navratilova et al. [62] being both two orders of magnitude faster. There is no
obvious reason for this, except maybe the source of CCR5 (insect cells vs Cf2Th mammalian cells) or
the lipids used as additives in the detergent mix (50 nM DOPC vs 35 nM DOPC + 15 nM DOPS for
Navratilova et al. [62]), although the latter does not affect 2D7 binding as shown by Navratilova et al.
[59]. Nevertheless, it cannot be excluded that specific binding of DOPS to CCR5 (with nM affinity) could
have a noticeable impact on its RANTES binding properties. One additional factor which could affect
the binding of RANTES is the source of CCR5. While Navratilova et al. [62] used CCR5 overexpressed
at low yield in Cf2Th canine thymocyte cells, our CCR5 was overexpressed in the baculovirus/insect cell
system. It is well known that glycosylation is different in these two systems [99].
Finally, the flow rate could cause the observed differences. Indeed, whereas our experiments were
performed with a flow rate of 50 µL/min, Navratilova et al. [62] used a faster flow rate of 100 µL/min.
With a too slow flow rate, artifacts can arise. For example, mass transport (also called mass transfer)
effects can slow down the effective association rate, thereby increasing the apparent KD (resulting in an
apparent lower affinity) [78]. On the other hand, if the flow rate is too slow, rebinding can occur during
the dissociation phase. In this case, as the molecule rebinds to the surface before exiting the flow cell,
the apparent dissociation rate is slowed down, thereby reducing the apparent KD (resulting in an
apparent higher affinity) [100]. We tested this possibility by running our samples at 100 µL/min. Figure
10 shows a comparison of binding profiles for RANTES variants using different flow rates. As shown in
Figure 10, data for both PSC-RANTES and 5P12-RANTES-E66S are neither affected by mass transport
effects nor by rebinding of the ligands during the dissociation phase. Indeed, both the kon and koff rates
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recorded with a flow rate of 100 µL/min are very similar to those measured with a flow rate of 50
µL/min (with both association and dissociation phases being almost exactly superposable). However, for
WT-RANTES, the situation is different. Indeed, both the association and dissociation rates are
increased by a factor of ∼10 with a clearly visible change in the binding profile (see Figure 10). The KD,
however, is not affected as both changes are compensated. These accelerated rates for WT-RANTES,
however, are more consistent with data from Navratilova et al. [62] with which they nevertheless still
differ by one order of magnitude.
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Figure 10: Effect of the flow rate on the binding profiles for RANTES variants. RANTES variants were
injected at 36 nM for 360 s at 50 µL/min (left) and for 210 s at 100 µL/min (right).
Different 5P12-RANTES variants
To probe whether the E66S mutation affected the interaction of 5P12-RANTES-E66S with CCR5, we used
5P12-RANTES without the E66S mutation (5P12-RANTES-biotin, a 5P12-RANTES variant C-terminally
coupled to biotin). Figure 11 shows that the E66S mutation in 5P12-RANTES-E66S does not significantly
affect the binding profile. Except for the faster dissociation rate observed for 5P12-RANTES-biotin, other
fitted parameters are similar for both 5P12-RANTES variants (see Table 1 in the main document).
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Figure 11: Comparison of binding profiles for 5P12-RANTES-E66S and 5P12-RANTES C-terminally
coupled to biotin. Both RANTES variants were injected at 36 nM.
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Abstract 
Proteins denature not only at high, but also at low temperature as well as high pressure. These 
denatured states are not easily accessible for experiment, since usually heat denaturation 
causes aggregation, whereas cold or pressure denaturation occur at temperatures well below 
the freezing point of water or pressures above 5 kbar, respectively. Here we have obtained 
atomic details of the pressure-assisted, cold-denatured state of ubiquitin at 2500 bar and 
258 K by high-resolution NMR techniques. Under these conditions, a folded, native-like and 
a disordered state exist in slow exchange. Secondary chemical shifts show that the disordered 
state has structural propensities for a native-like N-terminal b-hairpin and a-helix and a non-
native C-terminal a-helix. These propensities are very similar to the previously described 
alcohol-denatured (A-) state. Similar to the A-state, 15N relaxation data indicate that the 
secondary structure elements move as independent segments. The close similarity of 
pressure-assisted, cold-denatured and alcohol-denatured state with native- and non-native 
secondary elements supports a hierarchical mechanism of folding and indicates that similar to 
alcohol, pressure and cold reduce the hydrophobic effect. Indeed, at non-denaturing 
concentrations of methanol, a complete transition from the native to the A-state can be 
achieved at ambient temperature by varying the pressure from 1 to 2500 bar. The methanol-
assisted pressure transition is completely reversible and can also be induced in protein G. 
This method should allow detailed studies of the hydrophobic contribution to protein stability 
by tuning the strength of the hydrophobic effect in a continuous and completely reversible 
manner. 
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\body 
Introduction 
It has long been known that proteins unfold not only at high temperatures, but also at 
high pressures (1) as well as low temperatures (2). The so-called heat, pressure and cold 
denaturations can be described in a unified way by Hawley’s theory (1, 3). This theory 
assumes a simplified two-state model of protein unfolding, where the free energy difference 
between folded and unfolded states is a general parabolic function of temperature and 
pressure: 
! 
"G = "#2 (p $ p0)
2 + "%(p $ p0)(T $T0) $
"Cp
2T0
(T $T0)2 +
"V0(p $ p0) $"S0(T $T0) + "G0
   (1) 
In Eq. (1) D indicates the difference of the respective value between denatured and 
native state, b is the compressibility factor 
! 
("V /"p)T , a the thermal expansivity factor 
! 
("V /"T)p , Cp  the heat capacity 
! 
T("S /"T)p  and p0, T0 an arbitrarily chosen reference point. 
Since usually Db < 0 and DCp > 0, DG has a maximum, but tends to -∞ for very large and 
very small values of both T and p. The phase boundary between denatured and native states is 
then given by the condition DG = 0, which corresponds to a tilted ellipse within the pT plane. 
The two-state model is clearly an oversimplification, since both folded and unfolded 
states can be heterogeneous and due to the paucity of data it is also unclear whether the heat-, 
cold- or pressure-denatured states are identical. Nevertheless the model presents a very 
valuable general framework to pinpoint the main contributing thermodynamic entities, which 
are intimately linked to protein hydration and the hydrophobic effect (4, 5). Thus DCp is 
positive and proportional to the number of hydrophobic residues (6, 7), which may be 
attributed to the increase of water order around exposed hydrophobic groups. Similarly, the 
negative sign of Db can be explained from the fact that water in the vicinity of exposed 
hydrophobic groups such as those of an unfolded protein has a much higher compressibility 
than that of hydrophilic surface water, bulk water or the protein interior (8, 9). Therefore, at 
high pressures the exposure of the hydrophobic core leads to a decrease in the volume of the 
system and unfolding is favored, i.e. the hydrophobic effect is reduced (10-12). 
The cold-denatured state of proteins is usually not easily accessible since cold 
denaturation temperatures are almost always below the freezing point of water. An exception 
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has been reported for the protein L9, where the reduction of hydrophobic interactions by a 
destabilizing leucine to alanine point mutation lead to a heterogeneous cold-denatured state 
above 273 K with native and non-native structural elements (13). Supercooled solutions of 
native proteins have been investigated by NMR by Szyperski and colleagues in small 
capillaries that prevent water freezing (14). However, only in the case of the cold shock 
protein of Bacillus caldolyticus, cold denaturation could be observed, but no structural data 
were presented (15). For ubiquitin, cold denaturation under normal pressure has not been 
observed down to temperatures of 238 K (16). A reverse micelle system has been proposed to 
overcome the limitation from water freezing (17). In this system, the progressive 
heterogeneous disappearance of native state ubiquitin NMR resonances at temperatures 
below 253 K and the lack of appearance of new resonances was interpreted as evidence for a 
heterogeneous cold-denatured state and the presence of a more stable core around ubiquitin’s 
a-helix in the remaining native state (17). 
The freezing point of water is lowered by high pressure, since liquid water has the 
unusual property of higher density than ice. Thus water can be kept liquid down to 251 K at a 
pressure of 2.07 kbar (3). This fact together with the pressure-induced destabilization of 
proteins makes cold denaturation at higher pressures more easily observable than at ambient 
pressure. Pressure-assisted cold denaturation has been followed for ubiquitin (18-20) using 
high-pressure quartz NMR tubes. The analysis of chemical shift data, resonance intensities 
and 15N relaxation (18-20) showed that the pressure-assisted cold unfolding of ubiquitin is not 
a simple two-state process, but that several intermediates exist at 3 kbar and pH 4.6. At 273 K 
one intermediate is locally unfolded in the segments of residues 33-42 and 70–76. At a 
pressure of 2 kbar and temperatures below 273 K (21), a further set of resonances is observed 
that was identified with a floppy unfolded state. However, due to the small sample volume of 
about 15 ml of the conventional pressure cells used, sensitivity was severely limited and no 
structural information on the pressure-assisted cold-denatured state was derived. 
Here, we have characterized the pressure-assisted cold denaturation of ubiquitin using a 
newly developed high-pressure NMR cell (Daedalus Innovations LLC, PA, USA) with a 
significantly larger sample volume of ~120 ml. The obtained high sensitivity provided 
sequence-specific backbone and side chain 13Cβ assignments at pressures from 1 to 2500 bar. 
The sequence-specific information on chemical shifts and 15N relaxation data indicates that 
the cold-denatured state is an unfolded ensemble with a high propensity for a first b-hairpin 
and a-helix that are similar to the native state. In contrast, the C-terminal has high propensity 
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for a non-native second a-helix. These structural propensities are very similar to the 
conformational ensemble of ubiquitin’s A-state (22, 23), which is induced by 60 % methanol 
at pH 2 (24) at ambient temperature, as well as of ubiquitin’s urea-denatured state (25, 26). 
The close similarity between pressure-assisted cold-denatured state and A-state is further 
proven by the fact that the transition from a native- to an A-state-like NMR spectrum can be 
induced at pH 4.5 and 45 % methanol at 308 K by the application of pressure. All the 
described forms of destabilization of ubiquitin’s native state seem to lead to a similar 
unfolded state ensemble suggesting a robust folding pathway via ubiquitin’s first b-hairpin 
and a-helix. 
The high similarity of methanol- and pressure-destabilized states further suggests that the 
main mechanism of pressure unfolding is the reduction of the hydrophobic effect. A similar 
transition from the native to a partially unfolded state can be induced for protein G in the 
presence of methanol at a pressure of 2500 bar and ambient temperatures. 
Results and Discussion 
Resonance assignments 
When ubiquitin is cooled from ambient to low temperatures at 2500 bar (pH 6.5), the 
onset of cold denaturation becomes visible in 15N-HSQC spectra at about 278 K by the 
appearance of a new set of resonances in a narrow spectral region typical for the expected 
disordered polypeptide of the cold-denatured state. At 258 K both native and cold-denatured 
state show a maximum number of cross peaks at about equal intensities (Fig. 1). The spectral 
changes induced by pressure and cold temperature are completely reversible. Apparently at 
258 K and 2500 bar cold-denatured and native state coexist in an approximate 1:1 
equilibrium in slow exchange on the chemical shift scale. No cross peaks could be detected in 
an EXSY experiment (not shown) with a mixing time of 3.2 s, which sets a lower limit to the 
exchange time of about 20 s. 
Assignments of the folded state at 258 K and 2500 bar were obtained by following the 
15N-HSQC spectra from ambient conditions through a combined pressure and temperature 
path (298 K/1 bar → 298 K/2500 bar → 258 K/2500 bar). As the temperature is decreased, 
the folded state cross peaks broaden to some extent in a heterogeneous way with 
disappearance of a few resonances, indicating varied disorder of these residues. In total 61 
backbone resonances could be assigned (Fig. 1). Differential broadening of the folded state 
by pressure has been observed before at room temperature (pH 4.6, 3000 bar) using 15N 
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transverse relaxation measurements (20). At ambient and at low temperature, the affected 
residues are located mainly in the region D21-I44, indicating the destabilization of ubiquitin’s 
a-helix and of the irregular region connecting to strand b3 by high pressure. 
Resonances of the cold-denatured state were assigned from a combination of triple 
resonance 3D experiments. The quality of these spectra at 258 K and 2500 bar is very good 
and allowed the unambiguous backbone resonance assignment for 57 residues in the cold-
denatured state and also confirmed the assignment of the folded state. These data cover 80 % 
of all non-proline residues. Unassigned residues in the denatured state include the N-terminal 
methionine and several residues in the C-terminal tail (Fig. 1). 
Secondary structure information from 13Ca, 13C’, and 15N chemical shifts 
The deviations of observed chemical shifts for backbone nuclei from their random coil 
values, known as secondary chemical shifts (Δδ = δobs − δrc), can be used as a fast and 
accurate measure of polypeptide secondary structure (27, 28). Not surprisingly, the secondary 
shifts ΔδCa, ΔδC’ and ΔδN for the folded state at 258 K, 2500 bar and at 298 K, 1 bar are 
almost identical (Fig. 2) indicating that the native state backbone conformation is almost 
completely preserved even at the low temperature and high pressure. It is noted that 
referencing of the chemical shifts was achieved indirectly via the resonance frequency of 
water (29), which was calibrated to TSP in a separate experiment yielding a temperature and 
pressure dependence of the form δH2O(p, T)/ppm = 7.866 –1.612·10-4 bar-1·p –1.025·10-2 K-1·T 
+ 5.945·10-7 bar-1K-1·p·T (SI Appendix Fig. S1). The good agreement of the native state 
secondary shifts under both conditions indicates that this method is also adequate for 
obtaining secondary structure information at 258 K and 2500 bar. 
Fig. 3 shows the secondary shifts ΔδCa, ΔδC’ and ΔδN for the pressure-assisted cold- 
denatured state at 258 K, 2500 bar. The negative secondary shifts for 13Ca and 13C’ in the 
region of residues 1 to 18 indicate a propensity for an extended b-type structure reminiscent 
of the native first b-hairpin. This is also supported by the 15N secondary shifts, which are 
positive in this region and show a dip for residues 9 to 11, indicative of a b-turn. It is 
revealing to compare these secondary shifts to respective secondary shifts of the A-state (22, 
23) and the urea-denatured state (25) (Fig. 3). Both A-state and urea-denatured state have a 
very similar pattern as the cold-denatured state in this part of the sequence, albeit the size of 
ΔδCa and ΔδC’ values of the cold-denatured state and the urea-denatured state is about 25-
50% of the A-state values. Since A-state and native state secondary shifts are of very similar 
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size in this region, it may be concluded that the first b-hairpin is populated to about 25-50 % 
in the cold-denatured state. 
Compared to the A-state and the urea-denatured state, 15N secondary shifts of the cold-
denatured state show a distinct positive offset (Fig. 3), which was not noticed for the folded 
state at 258 K (Fig. 2, see above). To characterize this effect we have also determined the 
chemical shifts of a 15N-labeled nonapeptide as a function of pressure in the range from 1 to 
2500 bar and temperature from 258 to 298 K (SI Appendix Fig. S2). The 15N chemical shifts 
have an approximate linear dependence on pressure and temperature, which on average 
corresponds to coefficients of (2.93 +/- 0.53)·10-4 ppm/bar and (-17.0 +/- 9.3)·10-3 ppm/K. 
This indicates that the 15N chemical shift of an exposed amide is much more influenced by 
pressure and temperature than that of a buried amide or the chemical shift of 13Ca and 13C’ 
nuclei. Presumably, the compression of the hydrogen bonds between the exposed amide and 
water is responsible for this behavior. To correct for this effect relative to ambient conditions 
(298 K, 1 bar), the 15N secondary shift of the cold-denatured state at 258 K, 2500 bar was 
adjusted by -1.41 ppm (Fig. 3, red bars), which brings the secondary shift pattern in closer 
agreement to A-state and urea-denatured states. 
The similarity between cold-denatured and A-state continues beyond the first b-hairpin. 
Residues 23 to 32 show similar positive ΔδCa and ΔδC’ shifts for cold-denatured and A-
state, indicative of an a-helix, which is located at the same position as the native a-helix. 
Their absolute size is about 20 % (cold-denatured) or 50 % (A-state) of the native secondary 
shifts, which indicates that both states contain respective fractional populations of native state 
in this region. Also the ΔδN shifts of cold-denatured and A-state have a similar sequence 
pattern. However, the rather small ΔδN values of the cold-denatured state may be affected by 
an overall offset resulting from inaccurate compensation of the non-specific pressure effect 
on 15N shifts of exposed amides (see above). It is also noted that the urea-denatured state has 
close to zero or even negative ΔδCa and ΔδC’ shifts in the region of residues 23 to 32, which 
are not indicative of an a-helical conformation. In contrast, a-helical Ca-Ca contacts on the 
order of 10-20 % of the native state have been found in structural ensembles calculated from 
extensive RDC, PRE and SAXS data (26). This may not necessarily be a contradiction since 
binding of urea apparently leads to backbone conformations, which are more extended than 
the typical random coil (30). This in turn would bias the observed chemical shift, which is 
averaged over the small fraction of a-helical and the large fraction of unfolded 
conformations, towards the extended values, i.e. to negative ΔδCa and ΔδC’ shifts. 
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A high similarity between cold-denatured and A-state is also found in the second half of 
the protein for residues 38 to 76. In native state ubiquitin, this part largely consists of the anti-
parallel b-sheet b4/b3/b5 that closes the structure by its connection to strand b1. However, in 
the A-state, this part is switched to the long a-helix a’ (22, 23) (Fig. 4). The pattern of 
positive ΔδCa and ΔδC’ as well as mixed positive/negative ΔδN secondary shifts of the 
cold-denatured state is highly similar to the A-state (Fig. 3). It is noted that the center part of 
helix a’ has somewhat reduced secondary shifts both in the cold-denatured and A-state, 
indicative of a weakening of helix propensity - a feature which had been overlooked 
previously (22, 23). Again the absolute size of the secondary shifts is about 50 % of the A-
state values in this region. Thus along the entire sequence the cold-denatured state has 
deviations from ‘pure random coil’ behavior which correspond to approximately 50 % of the 
secondary structure propensities of the A-state. 
Backbone dynamics 
The backbone dynamics of the two states at 258 K and 2500 bar has been characterized 
by 15N T1, T2 and {1H}-15N NOE relaxation experiments. With the exception of the flexible 
C-terminus beyond residue V70, rather uniform T1, T2, and {1H}-15N NOE values are 
observed for the folded state resonances (Fig. 5A), indicative of a mostly homogeneous, well 
folded structure. Excluding residues with obvious exchange contributions to T2 (31) or fast 
backbone motions (NOE < 0.6), the average T2/T1 ratio (0.035) corresponds to a rotational 
correlation time τc of 16.9 ns. Thus τc is increased 4.1 fold compared to folded ubiquitin at 
300 K and 1 bar (4.1 ns) (31). This is in good agreement with a ratio of 3.64 for the water 
self-diffusion coefficients (D300K/1bar = 2.41 10-5 cm2/s, D258K/2500bar = 6.60 10-6 cm2/s) (32). 
Apparently the Stokes-Einstein relation is approximately fulfilled, albeit at 258 K, 2500 bar 
τc is about 11 % larger than expected from the value at 300 K. This increase may be caused 
by an increase in the hydration shell of ubiquitin at low temperature and high pressure or by 
genuine differences in the pressure and temperature dependence of water rotational and 
translation diffusion (32). As noted before, a number of folded state residues in the region 
D21-I44 showed signs of pressure-induced exchange broadening consistent with 15N T2 data 
at room temperature (20). These were excluded from the estimate of τc. Due to the low 
intensity of the resonances at 258 K no quantitative analysis of the exchange was attempted. 
In contrast to the folded state, the 15N backbone resonances of the denatured state at 258 
K, 2500 bar show strong variations in their relaxation behavior (Fig. 5B). Thus the {1H}-15N 
NOE values are reduced from an average of 0.74 to 0.4 indicative of larger amplitude local 
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backbone motions on the subnanosecond time scale. The NOE values are rather uniform and 
very similar to data (average 0.4) for the A-state at 300 K (22). Furthermore, T1 increases and 
T2 decreases along the sequence from residue Q2 to about Q40 indicating slower overall 
motions in the C-terminal part. An identical behavior is found for the A-state. 
In the absence of exchange broadening, the 15N T2/T1 ratio is to good approximation 
independent of rapid internal motions and of the magnitude of the chemical shift anisotropy 
and depends only on the overall rotational diffusion tensor (31). Brutscher et al. have used 
this property to estimate effective tumbling times along the sequence of the A-state (22). Fig. 
6 shows the 15N T2/T1 ratio for the denatured and folded state at 258 K, 2500 bar in 
comparison to the A-state at 300 K. In addition, also the expected T2/T1 ratio of an isotropic 
rotator is given as a function of the isotropic τc. For the cold-denatured state, the T2/T1 ratio 
decreases from about 0.4 at residue Q2 to about 0.06 in the region between residues Q40 to 
V70, corresponding to an increase in the effective rotational correlation time from about 4 ns 
to 13 ns. This profile is very similar to the A-state, albeit the A-state ratios are shifted to 
higher values due to the faster tumbling at 300 K. It has been noted previously (22) that the 
A-state T2/T1 ratios form plateaus with different values along the sequence, which roughly 
correspond to the first b-hairpin as well as helices a and a’. It was thus concluded that these 
secondary structure elements move independently from each other. Similar plateaus are 
observed for the cold-denatured state, although the difference between helix a and a’ is not as 
pronounced, which may also be expected from the decreased slope of the T2/T1 curve at 
larger rotational correlation times. For both conditions, a similar increase in T2/T1 is observed 
around residue I35, which indicates increased mobility of the linker between helix a and a’. It 
is also evident that the N-terminal residues Q2 to F4 of the cold-denatured state are more 
flexible than the rest of the b-hairpin, whereas no such N-terminal fraying is observed in the 
A-state. With the exception of this minor difference, the overall 15N relaxation behavior of 
both cold-denatured and A-state is very similar. It may thus be concluded that also the cold-
denatured state consists of the three independently moving secondary structure elements b-
hairpin, helix a and helix a’. 
Pressure-induced unfolding in methanol 
Both cold and pressure denaturation are linked to a reduction in the energetic cost of 
exposing hydrophobic groups to water in the cold or under pressure, i.e. to a reduction of the 
hydrophobic effect. Since methanol also reduces the strength of the hydrophobic effect, it 
seems not surprising that the A-state at 60 % methanol and pH 2 has strong similarities to the 
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pressure-assisted cold-denatured state. This observation prompted us to test whether a 
combination of methanol and pressure would also induce an A-state like structural ensemble 
of ubiquitin. 
This is indeed the case. At pH 4.6, 45 % methanol and 308 K, predominantly native state 
resonances are observed in the 1H-15N HSQC at 1 bar (Fig. 7A). However, also a second set 
of very weak resonances is visible, which according to their intensities corresponds to about 
14 % population. When pressure is increased gradually towards 2500 bar, the native state 
resonances become weaker at the expense of the second set of resonances. The transition is 
almost complete at 2500 bar (Fig. 7A), where the second state has a population of about 
93 %. An assignment of the backbone resonances shows that the 13Ca, 13C’ and 15N secondary 
shifts of this pressure-induced state (Fig. 7C) are almost identical to the A-state at 298 K 
(Fig. 3). These results clearly show that pressure has a very similar effect on the 
conformation of ubiquitin as methanol. 
A few general conclusions follow from a closer look at the behavior of individual 
resonances during the pressure variation from 1 to 2500 bar (Fig. 7B): (i) since distinct sets of 
resonances are observed for native and A-state, the exchange time between both states is 
significantly longer than the inverse of their chemical shift separation, i.e. tens of 
milliseconds. (ii) From the intensity-derived population ratios it follows that the free energy 
of the native state is about 4.5 kJ/mol lower than that of the A-state at 1 bar, whereas at 2500 
bar, it is about 6.7 kJ/mol higher. (iii) The chemical shift change of resonances for both states 
during the pressure variation shows that their conformations vary to some extent with 
pressure. Thus pressure not only changes the depth of the free energy wells for both states, 
but also their shape. 
The pressure-induced transition is completely reversible and will allow a detailed 
analysis of the transition from ubiquitin’s native to its A-state. Such an analysis is currently 
in progress. The methanol/pressure transition can also be induced in other proteins. SI 
Appendix Fig. S3 shows the continuous pressure-induced unfolding for protein G at 60 % 
methanol and 303 K, pH 2.5. Again a second distinct set of resonances becomes visible at 
high pressure, which is populated to about 45 % at 2500 bar. Such an A-state of protein G has 
not been observed before under normal pressure conditions. The backbone assignment (SI 
Appendix Fig. S4) and analysis of secondary shifts (Fig. 8A) reveals that the A-state of 
protein G mainly consists of one central helix that is in a similar position as the native state 
helix (Fig. 8B). However, its N-terminal end is extended by about one helical turn to residue 
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17 and its population is reduced to about 50 % as indicated by a respective reduction in the 
size of secondary shifts. In addition small propensities for b-conformations are observed in 
the A-state at the positions of the native state N-terminal and C-terminal b-strands 1-4. 
Conclusion 
Here we have presented a detailed structural characterization of ubiquitin under pressure-
assisted cold denaturing conditions, which is based on extensive assignments of the backbone 
resonances at 258 K and 2500 bar and the analysis of secondary chemical shifts and 15N 
relaxation data. Under these conditions, ubiquitin exists in slow exchange equilibrium 
between a folded and a disordered state. The folded state closely resembles the native state 
structure of ubiquitin as determined in crystal or in solution, although as shown previously 
for high pressure at room temperature (20) enhanced mobility of many residues, in particular 
in the C-terminal part, is evident from the 15N relaxation data. 
The disordered state is not purely random coil, but has propensities for a native-like N-
terminal b-hairpin and a-helix as well as a non-native C-terminal a-helix that are very similar 
to those described previously for the A-state (22). These structural propensities are on the 
order of 20 % of fully formed secondary structure elements. Similar to the A-state, 15N 
relaxation data indicate an independent segmental motion of these three secondary structure 
elements with limited mobility of the backbone N-H vectors on the subnanosecond time 
scale. It is noted that the propensities for residual structure do not contradict earlier findings 
of high solvent exchange rates under cold denaturing conditions (33), since the residual 
structural populations are in fast exchange with other conformations on the chemical shift 
scale of milliseconds. A certain similarity also exists to ubiquitin’s urea-denatured state 
where propensities for a native-like N-terminal b-hairpin and a-helix have been reported (25, 
26). However, the latter state is considerably more flexible on the nanosecond time scale as 
evident from its strongly reduced {1H}-15N NOE values (34). 
The residual native-like structure in the cold-denatured state of ubiquitin is consistent 
with a hierarchical order of protein folding where larger entities of native structure form from 
smaller native-like pieces (35). Evidence for hierarchical folding has been given in certain 
cases, e.g. for cytochrome c from the heterogeneity of hydrogen exchange rates under mild 
unfolding conditions (36) and for a destabilized mutant of L9 that allowed observation of a 
cold-denatured state containing native and non-native structural elements at ambient 
temperatures (13). For ubiquitin, intermediates in folding have been identified in kinetic 
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experiments (37) and have previously been postulated from heterogeneous line broadening of 
the cold-denatured state in a reverse micelle system (17). Our analysis reveals the following 
complex folding landscape: the structural propensities in the N-terminal part of the cold-
denatured state are native-like, but they are non-native in the C-terminal part. Thus the 
formation of the C-terminal a-helix is off-pathway. This off-pathway structure first needs to 
unfold before the native C-terminal b-sheet can form and close the structure via the parallel 
connection from the C-terminal strand b5 to the N-terminal strand b1. The latter connection 
has the largest sequence separation, i.e. contact order in ubiquitin. Its formation is thus the 
most entropically disfavored of all. Since average contact order and folding speed of single 
domain proteins are inversely correlated (38), it is expected that the formation of the 
antiparallel sheet b1/b5 is the rate-limiting final step in the folding of ubiquitin. The 
concomitant presence of the on-pathway N-terminal b-hairpin and a-helix and the off-
pathway C-terminal a-helix in the cold-denatured state is consistent with such an order of 
folding events. Furthermore also the inverse process of unfolding has been shown to start by 
breaking sheet b1/b5 in the case of thermal (39) and pressure (40) denaturation. We conclude 
therefore that an A-state-like conformational ensemble is the major thermodynamic and 
presumably also kinetic intermediate nearest to the native state in the ubiquitin folding 
pathway. 
The observation of cold or pressure denaturation is severely limited by the low 
temperatures and high pressures required. The cold denaturation temperature of ubiquitin at 
ambient pressure is below 238 K (16), whereas at room temperature pressure denaturation 
occurs at 5.4 kbar (41). Similar cold denaturation temperatures at ambient pressure and 
unfolding pressures at ambient temperature are required for many other proteins (3). The 
simultaneous application of low temperature and pressure allowed us to observe about 50 % 
of denatured ubiquitin at 258 K and the current maximal pressure of 2500 bar suitable for 
high-sensitivity NMR experiments. The close similarity of the pressure-assisted cold-
denatured state and the methanol-denatured state is consistent with the notion that in both 
cases the destabilization results from the weakening of the hydrophobic effect. We could 
show here that the combination with methanol shifts the unfolding transition further into the 
easily observable pressure and temperature range. Indeed a complete transition from native 
state to unfolded ensemble occurs at 308 K, 45 % methanol in the pressure range from 1 to 
2500 bar. The unfolded ensemble under these conditions is highly similar to both the 
pressure-assisted cold and the methanol-denatured state of ubiquitin. A similar transition is 
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observable for protein G. The methanol-assisted pressure transitions are completely 
reversible. This opens the way to follow the unfolding of proteins via a tunable weakening of 
the hydrophobic effect in a continuous manner by atomic-resolution NMR experiments. 
Experimental procedures 
Sample preparation 
15N/13C-labeled human ubiquitin was prepared as described (42). NMR samples for the 
pressure-assisted cold-denatured state contained 1.0 mM 15N/13C-labeled protein in 10 mM 
potassium phosphate buffer, 0.02 % NaN3, 90/10% H2O/D2O, pH 6.5. For measurements 
under methanol-destabilizing conditions, a further ubiquitin sample contained 0.6 mM 
15N/13C-labeled protein 30 mM sodium acetate, 45 % methanol, 45 % H2O, 10 % D2O, pH 
4.6. 
15N/13C-labeled protein G was prepared as described (43). For measurements under 
methanol-destabilizing conditions, the sample contained 0.25 mM 15N/13C-labeled protein G, 
25 mM potassium phosphate, 50 % methanol, 40 % H2O, 10 % D2O, pH 2.5. 
High-pressure measurements 
All experiments were carried out using a commercial high-pressure NMR cell (Daedalus 
Innovations LLC, PA, USA) with an inner diameter of 3 mm and an active volume of 120 mL. 
The tube was rated to 2500 bar and used in an aluminum alloy static pressure cell connected 
to a high pressure generator (High Pressure Equipment Company) via a pressure line. Both 
line and pressure generator were filled with extra-low viscosity paraffin wax (Sigma-Aldrich 
id 95369). 
NMR experiments 
All NMR spectra were recorded on Bruker Avance DRX800 or DRX600 spectrometers 
equipped with a triple resonance pulsed field gradient TXI probes. Backbone assignments 
were achieved using standard three-dimensional CBCA(CO)NH, HNCA, HNCO and 15N-
edited 1H-1H nuclear Overhauser effect spectroscopy (NOESY) experiments. 15N relaxation 
measurements (T1, T2, {1H}-15N NOE) for the cold-denatured state of ubiquitin were recorded 
at 600 MHz. All spectra were processed with NMRPipe (44) and evaluated with NMRView 
(45) or PIPP (46). 
Analysis of relaxation data 
Resonance intensities of NMR relaxation spectra were extracted using the program 
nlinLS contained in NMRPipe (44). T1 and T2 decay curves were then fitted to the intensities 
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by an in-house written routine implemented in Matlab (MathWorks, Inc.) using Monte Carlo 
estimation of errors. 
Determination of secondary shifts 
Chemical shifts for native state ubiquitin  (293 K, 1 bar, pH 6.6) are from BMRB entry 
6457 and for urea-denatured ubiquitin (8 M urea, 10 mM glycine 90 %/10 % H2O/D2O, pH 
2.5, 298 K) from BMRB entry 16626. For the latter, an offset of 0.2 ppm was added to 
account for an uncorrected shift of the water line used for indirect referencing in the presence 
of urea. Chemical shifts of the ubiquitin’s A-state (60 % methanol, 30 % H2O, 10 % D2O, pH 
2, 298 K) were obtained as described (23). 
Secondary chemical shifts were obtained by subtracting random coil shifts generated by 
the University of Kopenhagen web server 
http://www1.bio.ku.dk/english/research/pv/sbin_lab/staff/MAK/randomcoil/script/), which uses 
protein sequence, pH and temperature corrections (47-49). 
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Figure Legends 
Fig. 1: (A) 1H-15N HSQC spectrum of uniformly 15N,13C-labeled ubiquitin at 258 K and 2500 
bar (pH 6.5). Peaks are labeled with assignment information for the folded state (green) and 
the cold-denatured state (blue). Negative contour lines are shown in red. The amino acid 
sequence of ubiquitin is indicated at the top with assigned residues underlined for both states. 
The spectrum was acquired for 1.5 hrs at a sample concentration of 1 mM on an 800 MHz 
spectrometer. (B) enlarged region of the box shown in A. 
 
Fig. 2: Secondary chemical shifts analysis (13Cα, 13C’, 15N) of the native state of ubiquitin at 
low temperature and high pressure (258 K, 2500 bar) and at ambient conditions (293 K, 1 
bar, pH 6.6). Secondary structure elements of the native state are drawn at the top. 
 
Fig. 3: Secondary chemical shift analysis (13Cα, 13C’, 15N) of the cold-denatured state (258 K, 
2500 bar), the urea-denatured state (298 K, 1 bar), and (C) the A-state (298 K, 1 bar) of 
ubiquitin. Secondary structure elements of the A-state are drawn at the top. The red bars for 
the 15N secondary shift of the cold-denatured state (D258K) are shifted relative to standard 
referencing (black bars) by -1.41 ppm to account for the uniform pressure effect on solvent 
exposed amide groups (see text). 
 
Fig. 4: Structural switch from native state (left) to A-state (right). Corresponding structural 
elements are coded by identical colors: N-terminal b-hairpin (orange), central a-helix 
(magenta), C-terminal half (green). The C-terminal half switches from a b-sheet structure in 
the native state to the long a-helix a’ in the A-state. The structural scheme of the A-state is 
adapted from Brutscher et al. (22). 
 
Fig. 5: 15N relaxation data of ubiquitin at 258 K and 2500 bar recorded at 600 MHz. T1 (top), 
T2 (middle), and {1H}-15N NOE (bottom) values for the folded (A) and the denatured (B) 
state are shown along the primary sequence. Secondary structure elements of the folded state 
(left) and the A-state (right) are drawn at the top of each panel. 
 
Fig. 6: T2/T1 ratios calculated from 600 MHz 15N relaxation data for ubiquitin. Black curve: 
folded state (258 K, 2500 bar) T2/T1 ratios as a function of residue number (bottom horizontal 
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axis). Blue curve: cold-denatured state (258 K, 2500 bar). Red curve: A-state (300 K, 1 bar) 
replotted from Brutscher et al. (22). The dashed green curve shows the T2/T1 ratio for an 
isotropic rotator at 600 MHz as a function of tc (top horizontal axis). Secondary structure 
elements of the A-state are drawn at the bottom. 
 
Fig. 7: Pressure-induced unfolding of ubiquitin in 45 % methanol at 308 K (A)  1H-15N HSQC 
recorded on a 600 MHz spectrometer at pressures of 1 (dark blue), 500 (blue), 1000 (green), 
1500 (magenta), 2000 (orange), and 2500 bar (red), respectively. (B) expanded region of (A) 
showing the transition in the glycine region. Resonances are labeled with assignment 
information corresponding to the native state (dark blue) or the pressure-induced A-state 
(red). (C) Secondary chemical shift analysis (13Cα, 13C’, 15N) of the pressure-induced unfolded 
state of ubiquitin in 45 % methanol (308 K, 2500 bar). The secondary shifts are almost 
identical to the A-state (see Fig. 3). Secondary structure elements of the A-state are drawn at 
the top. 
 
Fig. 8: Secondary chemical shift analysis (13Cα, 13C’, 15N) of the two observable states of 
protein G in 50 % methanol, pH 2.5, 303 K, 2500 bar. See SI Appendix Fig. S3 and S4 for 
respective 1H-15N HSQC spectra. (A) Secondary shifts of the unfolded A-state. (B) Secondary 
shifts of the folded, native state. Respective secondary structure elements are drawn at the top 
of each panel. 
  
146 
 
 
 
 
 
 
 
 
 
 
  
 7.0 7.6 8.2 8.8 9.4  8.2 8.4 8.6 8.8
105
115
125
122
124
126
ppm1HN
15 N
MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG
10 20 30 40 50 60 70
Q2
A B
Figure 1: Vajpai et al.
N258K
V70
L73
L69
E16
V26
Q49
R74 L71
L50
F45
D52
D32K63
D21
R72
I23
Q31
A46
E64
G47 S20
T9
G10T22
T55
S57
G35
G75
E34 I3
K33 Y59
K11
R54
Q41K29
Q40
S65
N60
G76
E18
L56
K27
T12
L15
I13
L67 K6
Q62
A28
D58
K48
N25
D39
V5
T14
I44
F4
V17
T66
H68
T7
D258K
K6
L15F4
E18
A28
V5
K27
L56I3E24
Q31
I23
I30
L50
L69
R54
K48
Y59
Q40
N60
E51
V17
N25
D52
T14
D32
D21
E16
V26
K11
Q41
I36
E34
K33
K29
I13
L8
Q2
G10
G47
G75G35
G53
A46
D39
T12T7
H68
S57T55S20
T22
T9
V70
147 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
N
2 5
8 K
N
2 9
8 K
Δ
δ N
Δ
δ C
'
Δ
δ C
α
N
2 5
8 K
N
2 9
8 K
N
2 5
8 K
N
2 9
8 K
Figure 2: Vajpai et al.
[ppm]
residue number
-4
0
4
-4
0
4
-4
0
4
-4
0
4
-15
-10
-5
0
5
0 10 20 30 40 50 60 70
-15
-10
-5
0
5
B1 B2 B3 B4 B5A
148 
 
 
 
 
 
  
-1
0
1
-2
0
2
-1
0
1
-1
0
1
-2
0
2
-1
0
1
-2
0
2
-5
0
5
0 10 20 30 40 50 60 70
-2
0
2
residue number
Figure 3 Vajpai et al.
D
25
8K
A-
st
at
e
D
u
re
a
D
25
8K
A-
st
at
e
D
u
re
a
D
25
8K
A-
st
at
e
D
u
re
a
Δ
δN
Δ
δC
'
Δ
δC
α
[ppm]
B1 B2 A A’
149 
 
 
 
 
 
 
 
 
 
 
  
native state
A-state
Figure 4 Vajpai et al.
N
17
17
N
34 23
23
34
39
39
72
72
C
C
150 
 
 
 
 
 
  
native 258 K
0 20 40 60 0 20 40 60
0.5
1.0
1.5
2.0
T 1
 
[s]
0
0.04
0.08
T 2
 
[s]
0
0.5
1.0
0.50
0.75
1.0
0.1
0.2
0
0.4
0.8
A B
{1 H
}-1
5 N
 N
O
E
denatured 258 K
Figure 5 Vajpai et al.
residue number
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
0 5 10 15 20 25
Tc [ns]
0 10 20 30 40 50 60 70
0
0.1
0.2
0.3
0.4
0.5
T 2
/ T
1
residue number
Figure 6 Vajpai et al.
A-state
D258
N258
T2/T1(Tc)
152 
 
 
 
 
 
 
 
  
104
106
108
110
8.4 8.2 7.8 7.6 7.48.0 ppm
B
15
Figure 7 Vajpai et al.
N
G53
G35
G75
G10
G47
G9
T55
G35
G9
G10
T22
G75
8.0 7.09.0
110
115
120
125
A
1HN
residue number
C
-2
0
2
-2
0
2
0 10 20 30 40 50 60 70
-10
0
Δ
δN
Δ
δC
'
Δ
δC
α
ppm
153 
 
 
 
 
 
 
residue number
residue number
Figure 8 Vajpai et al.
A
B
Δ
δN
Δ
δC
'
Δ
δC
α
Δ
δN
Δ
δC
'
Δ
δC
α
-2
0
2
-2
0
2
0 10 20 30 40 50-10
-5
0
-4
0
4
-4
0
4
0 10 20 30 40 50
-10
0
154 
 
High pressure NMR reveals close similarity 
between cold and alcohol protein denaturation due 
to a reduction of the hydrophobic effect 
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Table S1: Pressure and temperature dependence of water chemical shift relative to TSP. The 
chemical shift of the water 1H resonance relative to TSP was determined on a sample of 5 
mM TSP, 95% H2O/5 % D2O, 10 mM phosphate, pH 6.5 on a Bruker Avance DRX600 
spectrometer using the Daedalus 3 mm pressure cell rated to 2500 bar. Reproducibility of the 
chemical shift was better than 3 ppb as estimated from duplicate measurements. 
 
T [K] p [bar] 1H [ppm] T [K] p [bar] 1H [ppm] 
255 2500 5.233 313 1 4.653 
258 2500 5.205 313 625 4.669 
261 2500 5.177 313 1250 4.685 
264 2500 5.149 313 1875 4.702 
267 2500 5.122 313 2500 4.719 
270 2500 5.095 323 1 4.551 
273 1 5.081 323 625 4.572 
273 625 5.069 323 1250 4.592 
273 1250 5.065 323 1875 4.612 
273 1875 5.068 323 2500 4.631 
273 2500 5.071 333 1 4.454 
283 1 4.968 333 625 4.479 
283 625 4.966 333 1250 4.502 
283 1250 4.969 333 1875 4.524 
283 1875 4.974 333 2500 4.547 
283 2500 4.982 343 1 4.349 
293 1 4.862 343 625 4.380 
293 625 4.867 343 1250 4.406 
293 1250 4.873 343 1875 4.430 
293 1875 4.883 343 2500 4.455 
293 2500 4.894 313 1 4.653 
303 1 4.756 313 625 4.669 
303 625 4.766 313 1250 4.685 
303 1250 4.778 313 1875 4.702 
303 1875 4.791 313 2500 4.719 
303 2500 4.805    
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Figure S1: Pressure and temperature dependence of water chemical shift relative to TSP 
The pressure and temperature dependence of the water chemical shift according to Table S1 
is shown. The solid lines present a global fit against p and T according to 
δH2O(p, T) = (a0 + a1·p + a2·T  +  a3·p*T)  
with 
 a0 [ppm] a1 [ppm/bar] a2 [ppm/K] a3 [ppm/(bar*K)] 
ai 7.866E+00 -1.612E-04 -1.025E-02 5.945E-07 
Dai* 7.137E-03 3.751E-06 2.316E-05 1.240E-08 
*error in the parameters ai derived from the linear fit using an experimental error of 2 ppb for 
the chemical shift of water. The mean deviation of the measured points from the fit is 3.6 
ppb. 
It is noted that the final functional form 
δH2O(p, T)/ppm = 7.866 –1.612·10-4 bar-1·p –1.025·10-2 K-1·T + 5.945·10-7 bar-1K-1·p·T 
 is in very good agreement with literature values (1) for the temperature dependence of the 
water chemical shift at ambient pressure 
 δH2O(1 bar, T)/ppm = 5.051 - 0.0111 K-1 (T+273.15 K). 
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Figure S2: Temperature and pressure dependence of amide 15N chemical shift of the 
nonapeptide EGAAWAASS 
 
 
15N chemical shifts [ppm] are shown as a function of residue number r, temperature T [K] and 
pressure p [bar]. Uniformly 15N-labeled peptide (~1 mM) was dissolved in 10 mM sodium 
acetate-d5, pH 4.5, 95/5% H2O/D2O. Chemical shift referencing was achieved by indirect 
referencing to water, whose chemical shift had been temperature- and pressure-adjusted 
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according to Figure S1. The 15N chemical shifts are fitted (straight line) to a linear function of 
the form δ15N(p, T)/ppm = a0 + a1·p + a2·T using the following parameters: 
 
Residue Nr a1 [10-4 ppm/bar] a2 [10-3 ppm/K] 
2 3.40 -12.3 
3 2.52 -7.5 
4 2.81 -14.8 
5 3.70 -33.3 
6 2.88 -28.4 
7 2.72 -11.9 
8 3.37 -18.5 
9 2.07 -9.4 
Average 2.93 -17.0 
Std 0.53 9.3 
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Figure S3: Pressure-induced unfolding of protein G in 50 % methanol at 303 K, pH 2.5 
 
1H-15N HSQC recorded on a 800 MHz spectrometer at pressures of 1 (dark blue), 1500 
(green), and 2500 bar (red), respectively. 
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Figure S4: Assignment of native and unfolded state of protein G in 50 % methanol at 303 K, 
2500 bar, pH 2.5 
 
1H-15N HSQC spectrum of protein G. Peaks are labeled with assignment information for the 
folded state (green) and the pressure/methanol-denatured state (blue). The amino acid 
sequence of protein G is indicated at the top with assigned residues underlined for both states. 
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8 Conclusions and perspectives 
 
 In this thesis we sought to study CCR5 and its interaction with RANTES by 
NMR. We started with the CCR5 expressed in insect cells, however, to obtain an access 
to a cost-efficient uniform isotope labeling a CCR5-tailored E. coli expression system 
was additionally established. The receptor produced in both systems was analyzed in 
detail with regards to the secondary structure contents, oligomeric state, particle size, 
stability and functionality. 
 Carefully performed immunoprecipitation assay revealed that in the presence of 
Fos-Choline-12, a detergent used for high-yield purification, CCR5 is not recognized 
by the conformation dependent antibody 2D7. This finding corrected the previous 
observations made in the group and at the same time lead to a better SPR setup, where 
CCR5 interactions with numerous ligands could be studied. 
 Large-scale detergent screening revealed that CCR5 is readily solubilized by 
ionic and zwitterionic detergents but not by the milder maltosides. This fact is 
consistent for the receptor produced in both insect cells and in E. coli but comes as a 
surprise, since the maltosides are indisputably the most successful detergent family in 
GPCR structure determination. This observation, together with the high aggregation 
tendency and very low thermal stability, again observed for the receptor from both 
sources, may be an indication that CCR5 is intrinsically very unstable. Hence, some 
kind of significant stabilization e.g. thermostabilizing mutations yielding a better-
behaved receptor may be an important step towards CCR5 structure determination. 
 The established E. coli expression system enables to obtain milligram quantities 
of 15N,13C,2H-labeled CCR5. Using this material a set of 3D experiments was 
recorded and we have currently attempted the assignment. Unfortunately, the quality of 
the spectrum suffers from overlap and line broadening and needs further improvements. 
The fact that the majority of the resonances remain invisible is most likely either a 
consequence of a nonoptimal detergent system or, again, a symptom of the receptor 
intrinsic instability. 
 Using SPR we studied CCR5 interactions with 2D7, MIP-1β and various 
RANTES variants. It was shown that wild type RANTES aggregates on the surface of 
the receptor micelle via a mechanism compatible with a linear oligomerization, which 
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can be abolished by a E66S mutation, the same one that renders RANTES unable to 
form tetramers. The higher CCR5 binding affinity of 5P12-RANTES, explains why 
5P12-RANTES, which does not cause CCR5 internalization is similarly potent anti-
HIV microbicide as PSC-RANTES, which upon binding causes CCR5 endocytosis. 
 It was shown by NMR that 5P12-RANTES-E66S even at high concentration is 
purely monomeric and with the exception of the flexible N-terminus its structure is 
similar to the structure of the wild type RANTES. Using the example of RANTES-
E66S perturbation by Fos-Choline-12 it was demonstrated that the selection of 
detergent is crucial not only for the receptor (which is usually the only criterion) but 
also for the ligand.  
 By applying high-pressure NMR techniques cold denaturation of ubiquitin was 
studied. The secondary shift analysis revealed that the cold-denatured state closely 
resembles the alcohol-denatured state. This indicates a common mechanism of 
pressure, cold and alcohol denaturation via a reduction of the hydrophobic effect. The 
presented method should be a useful tool to study the hydrophobic component of the 
protein stability. 
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